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ABSTRACT
The primary aim of this thesis was to test the hypothesis that there is a lower 
prevalence of breast cancer among blind women with no perception of light 
(NPL) compared to those with light perception (LP). Secondary aims included 
examination of reproductive outcomes and quantification of the 24 h 
production of the urinary metabolites oestrone-3-glucuronide (e1g) and 6- 
sulfatoxymelatonin (aMT6s) among women with LP and NPL. A final aim was 
to determine the prevalence of circadian rhythm disorders using physiological 
parameters for classification.
A survey (n = 1392) and field study (n = 130, NPL n = 40, LP n = 90) were 
conducted in blind women. Among survey participants, NPL women reported 
an earlier age at menarche (age 12.2 ± 1.5 versus 12.5 ± 1.6 years, p < 0.01), 
which appeared to be related to age at loss of LP (trend p < 0.01). Breast 
cancer risk was lower among women with NPL compared to women with LP 
(confounder-adjusted OR = 0.42, 95% Cl = 0.21-0.85). The 24 h output of 
urinary metabolites e l g and aMT6s did not appear to be related to differences 
in light perception (confounder-adjusted p = 0.42), menopausal status 
(confounder-adjusted p = 0.86), or circadian type (confounder-adjusted p = 
0.34).
Among field study subjects with LP 49% were classified as normally 
entrained, 17% were abnormally entrained, 28% were non-entrained and 6% 
were unclassifiable. Of those with NPL, 40% were classified as non-entrained
IV
33% were classified as normally entrained 25% were classified as abnormally 
phased and 3% were unclassified.
The results of this of this thesis demonstrate that blind women with NPL have 
a lower risk of breast cancer, an earlier menarche and are more likely to have 
an abnormal circadian rhythm compared to those with LP. These differences 
do not appear to be related to differences in e1g or aMT6s.
SUMMARY
The primary aim of this thesis was to test the hypothesis that there is a lower 
prevalence of breast cancer among those women with no perception of light 
(NPL) compared to those with light perception (LP). Secondary aims of this 
thesis, included examination of reproductive outcomes in blind women to 
identify differences related to light perception status and quantification of the 
24 h production of the urinary metabolites of oestrogen and melatonin among 
women with LP and NPL. An additional aim of this thesis was to determine the 
prevalence of circadian rhythm disorders using physiological parameters for 
classification.
In order to investigate these aims, a survey and field study was conducted in 
blind women. The first part of the study included an extensive survey of blind 
women (n = 1392), which included medical history, breast cancer risk factors, 
reproductive outcomes, sleep history, general demographics and other 
outcomes of interest. The survey portion of the study was used to assess 
prevalence of breast cancer and reproductive outcomes among LP and NPL 
women.
The field study portion of the study was conducted to determine the 
prevalence of circadian rhythm disturbance among a subset of women (n = 
130, NPL n = 40, LP n = 90) who also completed the survey and to assess 
urinary production of oestrogen and melatonin metabolites in LP versus NPL 
women. For this portion of the study, subjects were asked to keep sleep and
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nap logs and to wear wrist-borne actigraphy for eight weeks. On two or three 
occasions during this time they were asked to collect urine samples over a 48 
h period in 4-hour collection bins during the day and 8-hour collection bins 
overnight. These collections were then assessed for 6-sulphatoxymelatonin 
(aMT6s), for determination of circadian phase, and oestrone-3-glucuronide 
(E1G), for comparison in LP versus NPL subjects.
NPL differed from LP women on several demographic and reproductive 
outcomes. NPL women were slightly younger, had a higher BMI, and tended 
to use oral contraceptives more often than women with LP. NPL women were 
less likely to be parous than LP women. They also reported an earlier age at 
menarche, which appeared to be related to age at loss of light perception, as 
those who reported an earlier loss of light perception also reported a 
significantly earlier menarche. There was, however, no difference in age at 
natural menopause between LP and NPL women.
Women with NPL accounted for 30% of the survey cohort but only 17% of 
breast cancer cases. Breast cancer risk was lower among women with NPL 
compared to women with LP (age-adjusted OR = 0.52, 95% Cl = 0.27 to 
1.01), a finding which became statistically significant after additional 
adjustment for breast cancer risk factors (OR = 0.42, 95% 01 = 0.21-0.85). 
When restricting to postmenopausal women and non-night shift workers the 
results remained unchanged. The level of vision categories associated with 
severe visual impairment (light perception only, shadows and hand 
movement) were associated with an increased risk of breast cancer compared
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to NPL, while the categories comprising those with the best vision (counting 
fingers, top letter on the vision chart), were not associated with an increased 
risk of breast cancer.
There were 118 field study subjects with complete data sets available for 
circadian classification (LP n = 78, NPL n = 40). A large proportion of subjects 
with LP were classified as normally entrained (n = 38, 49%). Of the 13 
subjects (17%) determined to be abnormally entrained, eight were at an 
advanced phase and five were delayed. There were 22 LP subjects (28%) 
who were classified as non-entrained and five (6%) who were unclassifiable. 
A large proportion (40%) of subjects with NPL were classified as non- 
entrained (n = 16). There were 13 subjects who were classified as normally 
entrained (33%) and 10 subjects (25%) classified as abnormally phased. Of 
the abnormally phased subjects, seven were classified at an advanced phase 
and three were classified as delayed. One subject was unclassified (3%). The 
proportion of subjects classified as non-entrained, entrained and abnormally 
entrained was the same for those with two eyes present as it was for those 
with no eyes present. The conditions most associated with abnormal 
entrainment and/or non-entrained type were enucleation of any cause (63%), 
retinopathy of prematurity (57%) and glaucoma (71%). By contrast, 59% of 
subjects with retinitis pigmentosa were classified as normally entrained.
The prevalence of sleep disorders as assessed using the PSQI was 76% for 
subjects with NPL and 66% for subjects with LP, although all categories of 
blindness except for amblyopia and retinoblastoma had mean PSQI scores
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indicative of a sleep disorder.
In order to determine whether hormonal differences might relate to the 
differences in breast cancer risk among those with LP and NPL, the urine 
samples collected during the field study were assayed for aMT6s and elg. 
There were no differences in 24 h aMT6s production when stratified by light 
perception status (confounder-adjusted p = 0.42). In addition, there were no 
differences in 24 h production of aMT6s in pre- compared to post-menopausal 
subjects (confounder-adjusted p = 0.86). Finally, there were no significant 
differences in 24 h aMT6s production by circadian type (confounder-adjusted 
p = 0.34).
As expected, post-menopausal women produced significantly less e1g over 
24 h than pre-menopausal women (post-menopausal mean = 7.86 ± 5.07 
pg/24 h; pre-menopausal mean = 29.67 ± 17.17 pg/24 h; p < 0.001). There 
was a non-significant elevation in elg among LP compared to NPL subjects, 
(LP mean = 21.11 ± 17.55; NPL mean = 15.63 ± 14.49; age-adjusted p = 
0.08). There were no significant differences in 24 h e lg  production by 
circadian type (age-adjusted p = 0.32).
There were no correlations in aMT6s or e lg  production among all subjects 
combined (age-adjusted p = 0.63) or when stratified by light perception status 
or menopausal status. There was, however, a significant positive correlation 
among normally entrained subjects (age-adjusted p = 0.02) and a trend 
towards a negative correlation among non-entrained subjects (age-adjusted p
IX
0 .18).
In summary, the results of this thesis demonstrate that blind women with NPL 
have a lower risk of breast cancer compared to those with LP. These results 
also suggest that an earlier age at NPL is associated with an earlier 
menarche, although other reproductive milestones do not appear to be 
different among NPL compared to LP women. Subjects with NPL are more 
likely to experience circadian rhythm disturbance compared to those with LP, 
though disturbed sleep is apparent across many types of blindness regardless 
of LP status. Finally, there is some evidence for a relationship between e lg 
and aMT6s among normally entrained subjects, though it is unclear how such 
a relationship might relate to breast cancer risk.
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INTRODUCTION
CHAPTER 1 - INTRODUCTION
1.1 Preface
Breast cancer is the most prevalent cancer among women and the second 
leading cause of cancer death in women in the United States (American 
Cancer Society 2007). While there has been a recent decline in the incidence 
of breast cancer cases, the reason for the decline and the underlying causes 
of the disease are largely unknown (American Cancer Society 2007). Family 
history is strongly linked to breast cancer risk, but only accounts for about 5- 
10% of total breast cancer cases (Dumitrescu & Cotarla 2005). High levels of 
circulating oestrogens are also strongly associated with breast cancer risk 
(Key et al. 2002), while factors leading to decreased levels of circulating 
oestrogen are consistently associated with a lower risk of breast cancer 
(Hankinson et al. 2004). Timing of exposures, for example the duration of time 
between menarche and menopause or the age at a woman’s first birth, seem 
to be key factors in whether a woman will eventually develop breast cancer 
(Colditz & Frazier 1995).
Migration studies have shown that breast cancer rates rise in parallel with 
movement from Asian countries to the United States (US) and that risk 
increases with successive generations residing in the US (Leung et al. 2002). 
Rates of breast cancer within Asia are significantly higher among women 
residing in westernised cities (Ziegler et al. 1993). These findings strongly 
suggest that lifestyle differences in eastern and western societies contribute to
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this increased risk.
Exposure to electromagnetic fields (Stevens 1987), pesticides (Teitelbaum et 
a/. 2007) and dietary factors (Boyd et a/. 1993) have all been suggested as
contributing factors to the difference in risk. One environmental exposure that 
has rapidly been gaining support as a breast cancer risk factor has been 
termed the “melatonin hypothesis.”
The melatonin hypothesis suggests that there is an inverse relationship 
between melatonin and oestrogen. Melatonin has been shown to exhibit 
oncostatic properties in vitro and in some animal models (Blask et al. 2002), 
but in humans evidence for the melatonin hypothesis comes from studies in 
female night shift workers who have a higher breast cancer risk (Pukkala et al. 
1995, Tynes et al. 1996, Pukkala et al. 1999, Schernhammer et al. 2001 ) and 
reportedly lower levels of circulating melatonin (Schernhammer & Hankinson 
2005) due to repeated exposure to light at night, which is known to suppress 
pineal melatonin production.
Studies in blind women, who are hypothesised to have a lower exposure to 
light at night, have also provided support for the hypothesis implicating 
melatonin as having a protective effect against breast cancer (Hahn 1991, 
Feychting et al. 1998, Pukkala et a i 1999, Kliukiene et al. 2001). Largely 
missing from these epidemiological findings are controlled studies of 
melatonin and oestrogen endocrinology in relation to shift work and cancer. 
The timing of measurement of melatonin and other circadian driven hormones
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is essential for uncovering the potential relationship between these hormones.
Despite the epidemiological evidence implicating a relationship between 
melatonin, oestrogen and breast cancer (Section 1.8), there are other 
plausible explanations for these findings. Night shift workers experience 
persistent circadian desynchrony which may also play a role in breast cancer 
risk. In order to understand and interpret the results of these studies it is 
essential to consider circadian organisation and the relationship of oestrogen 
and melatonin to circadian rhythms.
1.2 Characteristics of circadian rhythms
Circadian rhythms are internally generated by a self-sustaining oscillator that 
is common to almost all living organisms. The term ‘circadian’ comes from the 
Latin ‘circa’ meaning ‘about/around’ and ‘dies or diem’ meaning day’, to 
describe the coordination of biological rhythms to about a day’. The duration 
of time it takes to complete one oscillation is known as the endogenous period 
or tau (%). Circadian rhythms are organised around the 24-hour solar day and 
oscillate with a period near, but not exactly 24 h (Czeisler etal. 1999). The 
circadian oscillator, located within the hypothalamic suprachiasmatic nucleus 
(SCN; Section 1.3.1) receives input from both external and internal stimuli and 
its period may be entrained or synchronised by these time cues (zeitgebers). 
When entrainment of the circadian oscillator occurs, the downstream systems 
that the circadian clock controls (for example hormone production) are 
synchronised in turn.
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Circadian rhythms are distinct from other biochemical processes and have 
three key features; they persist under constant conditions in the absence of 
time cues, they are temperature compensated (i.e. the oscillators cycle at the 
same rate under different ambient temperatures within the physiological 
range, so the Q10 is set to approximately 1), and they are able to be reset by 
exposure to periodic external or internal stimuli (Hastings et al. 1961, Jacklet 
1980, Menaker & Wisner 1983). These features may be observed through 
measurement of the output rhythms of the circadian oscillator.
In humans, the core body temperature and melatonin rhythms are often used 
as proxy markers of the central SCN clock for assessment of circadian phase, 
amplitude and period (Jewett et ai. 1991, Czeisler et al. 1999), because they 
are the least susceptible to temporary changes in the environment, a 
phenomenon known as masking (Mrosovsky 1999). In normal circumstances 
the temperature rhythm is characterised by a peak during the day and trough 
at night. Conversely, the melatonin rhythm peaks at night. The phase is a 
measure of the position of the rhythm at a given point in time and generally 
the acrophase (peak), nadir (trough) or onset of the rhythm are used as daily 
markers of the rhythm. The amplitude of the rhythm is the size of the wave 
measured as the distance from the peak to the mesor.
1.2.1 Entrainment
One of the fundamental features of circadian rhythms is the ability of the
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rhythm to be reset or entrained by a stimulus to a new rhythm. The term 
ze/fgeber (German, meaning time giver ) is used to describe stimuli that can 
reset the clock. Entrainment occurs when the endogenous period (x) is equal 
to the period of the zeitgeber cycle (T-cycle) with a stable phase relationship 
or angle (e.g. measured as the relationship between the peak of the melatonin 
rhythm and the wake time).
Entrainment can sometimes be mistaken for masking. Masking is a 
phenomenon where stimuli have a forced expression on behaviour without 
entraining the pacemaker (Mrosovsky 1999). It is possible to determine 
whether a stimulus has evoked entrainment or masking by placing an 
organism in constant conditions following exposure to a stimulus. If the x 
resumes from a phase determined by the stimulus, entrainment has occurred 
and the stimulus may be classified as a zeitgeber. If the x resumes from a 
different phase, the stimulus produced a masking effect.
1.2.2 The phase response curve
In order for resetting to occur, the circadian oscillator needs to respond to a 
ze/fgeber differently at different phases in the cycle. This response does not 
need to be symmetric and a given stimulus may elicit phase advances, delays 
or both advances and delays at different points in the circadian cycle. The 
difference in the direction and magnitude of the response to a stimulus can be 
plotted as a function of the phase at which the stimulus is given. This plot is 
known as a phase response curve (PRC). A PRC can be plotted for any
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stimulus that is capable of phase shifting the clock (e.g. melatonin 
administration, light). For example, the circadian system is organised such 
that light administered in the subjective morning produces a phase shift to 
advance the system and light in the early subjective night delays the system 
(Section 1.2.3.1; Daan & Pittendrigh 1976).
There are two types of PRCs, Type 0 or ‘strong’ resetting and Type 1 or 
weak’ resetting (Winfree 1970). Type 1 resetting involves small phase shifts 
of less than 12 hours. Type 0 resetting involves large phase shifts equal to 12 
hours. The type of resetting that occurs depends on the strength of the 
zeitgeber and its ability to suppress amplitude in addition to shifting phase. 
Most zeitgebers are not able to produce immediate maximal phase shifting 
effects and it may take several cycles for a zeitgeber’s influence to be fully 
achieved. These cycles of disequilibrium are known as transients.
1.2.3 Photic zeitgebers
There are many zeitgebers that influence the mammalian clock, but the most 
important and strongest zeitgeber is light (Czeisler et ai. 1986, Czeisler et ai.
1995). Most species’ endogenous rhythms are slightly longer or slightly 
shorter than 24 h and in humans the endogenous circadian rhythm is 
approximately 24.2 hours, ranging from approximately 23.81 hours to 24.31 
hours (Middleton et ai. 1996, Hiddinga et ai. 1997, Czeisler et ai. 1999, Wright 
Jr. et ai. 2001). It is therefore necessary for the circadian clock to shift each 
day in order to remain in phase with the solar 24-hour light-dark cycle.
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Synchronisation to the 24-hour light-dark cycle occurs primarily through daily 
resetting via environmental light exposure (Pittendrigh 1981, Czeisler et al.
1989, Czeisler & Wright Jr. 1999, Jewett et ai. 2000). The effect that light will 
have on the circadian oscillator is dependent on properties of the organism 
(for example nocturnal vs. diurnal) as well as the properties of the light. 
Important features of light include the timing of the light pulse, as well as the 
intensity, duration, pattern and wavelength of the light.
1.2.3.1 Characteristics of light
1.2.3.1.1 Exposure to constant light
Aschoff described the influence of light on animal circadian rhythms in what 
Pittendrigh dubbed “Aschoffs Rule” at the Cold Spring Harbour Symposium in 
1960. Aschoffs Rule states that the period of an animal held in constant light 
(LL) is a function of the intensity of the light. This phenomenon is expressed 
differently in nocturnal and diurnal animals. For example, when most 
nocturnal animals are held in LL, circadian period lengthens with brighter light 
intensity. In most diurnal animals the opposite is true; the period shortens with 
brighter light intensity (Pittendrigh 1960). Aschoffs rule has several 
exceptions and may not apply quite so simply to human circadian physiology.
Another feature of maintaining vertebrate animals in LL is a phenomenon 
known as splitting. In mammals such as hamsters, splitting may be observed 
in the rest activity pattern of the animal. The activity pattern emerges with
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bouts of activity occurring approximately 12 hours out of phase. The two out 
of phase activity patterns may initially free run, but will eventually stabilise into
an antiphase relationship (Pittendrigh & Daan 1976). Splitting during LL is not 
limited to activity and has been observed in the output rhythms of temperature 
(Pickard et al. 1984) and luteinising hormone (LH) secretion (Swann & Turek 
1985). These observations led to neurophysiologic explorations in the SCN. 
Lesions of the entire SCN were found to abolish all observable rhythms, while 
partial SCN lesions abolished only one half of the split rhythm in golden 
hamsters (Pickard et al. 1984). Later studies revealed that the splitting 
phenomena originated from the left and right portions of the SCN cycling out 
of phase after exposure to LL (de la Iglesia et al. 2000). This finding 
demonstrated that the two sides of the SCN are capable of independent 
rhythm generation and that the observed period is a property of the SCN 
network of cells.
1.2.3.1.2 Timing and duration of light
Light exposure at different times of day will produce different phase shifting 
effects. A PRC to light was created to demonstrate the average phase shifts 
to light given at different times. The first mammalian PRC to light was 
described in flying squirrels, where carefully controlled 10-minute light pulses 
were administered across multiple circadian phases in individual animals 
(DeCoursey 1960). This study found that light timed at or near the onset of the 
dark phase elicited phase delays, while light timed at or near the onset of the 
light phase resulted in phase advances. This study further reported that light
during a squirrel’s inactive period had no effect on phase shifting. In humans 
and other diurnal mammals, the PRC to light is similar, with phase delays 
occurring with light timed just before the circadian temperature minimum and 
phase advances occurring just after the temperature minimum (Lewy et al.
1985, Honma & Honma 1988, Minors et al. 1991, Khalsa et al. 2003).
It has also been demonstrated that appropriately timed short pulses of light 
are sufficient to entrain some organisms. The distribution of these light pulses 
form what is known as a skeleton photoperiod. Skeleton photoperiods require 
at least two pulses light pulses timed so that one serves as a “dawn” signal 
and one serves as a “dusk” signal. Skeleton photoperiods have been well 
characterised in the pupil eclosion rhythm of Drosophila (Pittendrigh & Minis 
1964). When 15 minute light pulses are given between one and 11 hours 
apart, entrainment to the photoperiods happens as it would for a complete 
photoperiod during the same time. When light pulses are given more than 14 
hours apart. Drosophila interprets the shorter time between pulses as the 
subjective day (Pittendrigh & Minis 1964). There are species specific limits to 
entrainment by skeleton photoperiods and the initial phase of an organism 
prior to exposure to a skeleton photoperiod will also influence the 
interpretation of the pulses. Recently a PRC to two pulse skeleton 
photoperiods of varying durations was reported in mice (Comas et al. 2007). 
This study found that in mice, only skeleton photoperiods using a one hour 
light pulse of up to six hours apart elicit a PRC similar to the continuous light 
PRC. These findings suggest that there may be a saturation response to light 
pulses of longer durations and/or with longer durations of darkness in
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between.
Intermittent exposure to bright light at different times on the PRC has also 
been shown to be effective in phase shifting mammals. A series of two 
second pulses given over five minutes are sufficient to both phase delay and 
advance mice relative to the PRC (van den Pol et al. 1998). In addition, 
pulses of 10 microseconds given once per second over 50 microseconds are 
able to phase shift rats (Arvanitogiannis & Amir 1999).
In humans, intermittent pulses of light have been shown to elicit effects similar 
to continuous light pulses. Pulses of 5000 lux of light for 40 minutes, 
alternating with pulses of 20 minutes in 500 lux are sufficient to phase delay 
shift workers (Baehr et al. 1999). Intermittent pulses of light centred at the 
core body temperature minimum alternating with darkness and given for five 
minutes every 25 minutes or given for 45 minutes every 90 minutes over 6.5 
hours produce almost the same magnitude of phase shift as a single 
continuous 6.5 hour light pulse (Rimmer et al. 2000). Similarly, six pulses of 
15 minutes of intermittent bright light given every 90 minutes, centred three 
hours before the core body temperature minimum, were found to be sufficient 
to phase delay human subjects nearly as much as single continuous pulses of 
6.5 hours of bright light (Gronfier et al. 2004). Together, these studies suggest 
that the human response to light is similar to the animal response to light and 
that intermittent light exposure has a non-linear relationship with continuous 
light exposure.
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The duration of a light pulse is also important in the circadian response to 
light. In golden hamsters, pulses of bright light of only three seconds are 
sufficient to produce phase shifts (Nelson & Takahashi 1991). When these 
pulses were followed by a second pulse within one hour, the response was 
diminished. Subsequent studies found that the response to light stimuli has a 
saturating effect (Nelson & Takahashi 1999) and therefore the initial portion of 
a light pulse may be more important than longer duration pulses.
1.2.3.1.3 Intensity of light
The intensity of light affects melatonin suppression and phase shifting in a 
dose-dependent manner. Early studies suggested that high intensities of light 
were required in order to have a circadian effect (Aschoff ef a/. 1975). Later 
studies found that light of much lower intensities could both phase shift the 
clock and suppress melatonin. Two studies reported the existence of a dose 
response relationship between light intensity and magnitude of phase shift 
and melatonin suppression, with light as low as 100 lux producing a 
measurable effect (McIntyre et al. 1989, Boivin et al. 1996, Zeitzer et al. 
2000b). Subsequently, a carefully controlled laboratory protocol found that five 
of six subjects were able to entrain to a 24 hour day with exposure to only 1.5 
lux of light (Wright Jr. et al. 2001). These data suggest that very low levels of 
light are able to entrain the circadian clock to cycles within the limits of 
entrainment for a given stimulus.
It has also been reported that photoperiodic history is an important
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determinant on the effect of a given light stimulus. One study found that 500 
lux of light at night administered to subjects who remained in dim lighting 
conditions for a week was more potent than 500 lux of light administered to 
subjects following a week in bright lighting conditions (Hébert et al. 2002). 
Another report found that dim light for several hours prior to a 200 lux light 
stimulus had a stronger phase shifting effect than continuous exposure to 200 
lux of light at night (Smith et al. 2004). Together these data suggest that prior 
lighting conditions should be considered when measuring the effects of 
exposure to light at night.
1.2.3.1.4 Spectral composition of light
Another important property of light in relation to circadian response is 
wavelength. Short wavelength blue light has the most potent effect on 
circadian phase shifting and neuroendocrine effects in humans. Two groups 
constructed action spectra to identify physiological changes induced by 
varying wavelengths of narrow bandwidth light (Thapan et al. 2001, Brainard 
et al. 2001a). These groups each exposed human volunteers to 
monochromatic light of different wavelengths at night and measured the 
degree of melatonin suppression in each light condition. The short wavelength 
blue range of light (446-477 nm) identified by these studies does not match 
the action spectra for the absorption of the individual cones or for the photopic 
or scotopic visual systems (Thapan et al. 2001, Brainard et al. 2001 a,
Brainard et al. 2001b). Further studies demonstrated that light at wavelengths 
above (Lockley et al. 2003) and below (Brainard et al. 2008) the blue range
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have a lesser physiological impact on circadian outcomes when controlled for 
photon density and corrected for lens transmission. The potency of blue light 
is approximately the same as polychromatic white light with a photon density 
185 times blue light according to its effects on phase shifting (Warman et al. 
2003).
Early studies suggested that the cones did not account for circadian 
responses to light, while recent studies suggest that the cones may contribute 
to the circadian response to light in certain lighting conditions (e.g. dim light). 
In a comparison of polychromatic white to monochromatic blue light matched 
for photon density one group found that there is an enhanced response to 
polychromatic light, suggesting that there may be some influence from the 
cones on the circadian response to light (Revell & Skene 2007). Another 
recent study found that filtering blue light out of polychromatic light reduced 
the ability of the light to cause melatonin suppression (Kozaki et al. 2008). 
Additional evidence supporting the role of cones in some light responses 
comes from studies in the blind. Case studies in a few blind people lacking 
functional rods and cones, but retaining retinal ganglion cells required for 
circadian responses to light, have positive melatonin suppression in response 
to 460 nm of light, but no response to 555 nm of light (Zaidi et al. 2007). 
Furthermore, the action spectra derived from one such individual resulted in 
peak sensitivity to light at 480 nm. This demonstrates that a mechanism other 
than stimulation of melanopsin-containing retinal ganglion cells (presumably 
cones and/or rods) plays a role in circadian responses to light outside the 
peak sensitivity range.
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1.2.4 Non-photic ze/fgebers
While light is the most potent zeitgeber, there are non-photic zeitgebers that 
can both entrain and phase shift the clock. Social interactions were once 
thought to be the dominant synchroniser of the circadian system, but have 
since been shown to exhibit much weaker effects (Middleton et al. 1996, 
Middleton et al. 2002). Maternal social interactions are the dominant social 
zeitgeber in many animals prior to weaning and are sufficient to establish 
entrainment (Viswanathan & Chandrashekaran 1985, Shimoda et al. 1986). 
Social interactions in adult animal groups have also been shown to elicit 
entrainment (Mrosovsky 1988). Arousing activity, such as scheduled wheel 
running activity and handling appear to have a stronger influence on the 
circadian clock and have been shown to entrain mice (Edgar & Dement 1991, 
Mead etal. 1992, Marchant & Mistlberger 1996). Feeding is also an important 
non-photic synchroniser in animals and food anticipatory activity can phase 
shift the circadian system in some circumstances (Richter 1922, Mistlberger et 
al. 1996, Castillo et al. 2004). The food entrainable oscillator is distinct from 
the SCN and it may be located in the dorso-medial hypothalamus (DMH) 
(Gooley et al. 2006). Similarly, the olfactory bulb has been identified as a 
separate circadian pacemaker in mice (Granados-Fuentes et al. 2006) and in 
octagon degus olfactory cues have been shown to enhance entrainment to 
light induced phase shifts (Governale & Lee 2001).
Some drugs have been shown to elicit phase shifts in animal models, but the 
results of these experiments are variable and appear to be dependent on the
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animal and compound used. In rats, caffeine has been shown to elicit phase 
advances when given mid-day (Diaz-Munoz eta/. 1999) and phase delays
when given in the early subjective night in rats (Ding et al. 1998). The 
benzodiazepine triazolam has been shown to have phase shifting effects in 
golden hamsters with a PRC to administration at different times of day (Turek 
et al. 1986). Similarly, administration of exogenous melatonin is an 
established non-photic zeitgeber \n rodents. Melatonin is capable of causing 
phase shifts and entrainment in rats according to a PRC (Redman et al. 1983, 
Armstrong etal. 1986).
In humans, social stimuli such as knowledge of clock time have no influence 
on entrainment or phase shifting (Middleton etal. 1996, Lockley etal. 1997, 
Middleton et al. 2002). However, studies in totally blind individuals confirm 
that some social non-photic zeitgebers exist, but it is unclear what social 
zeitgebers cause entrainment (Sack et al. 1992, Lockley et al. 1997, Arendt et 
al. 1997, Klerman et al. 1998). Isolated bouts of high intensity exercise are 
able to elicit phase shifts (Van Reeth et al. 1994, Buxton et al. 1997, Baehr et 
al. 2003, Barger et al. 2004) and a human PRC to exercise has been reported 
(Buxton et al. 2003). Consumption of carbohydrate rich meals in the morning 
or evening does not appear to have an effect on the circadian system as 
measured by melatonin, but morning carbohydrate rich meals have been 
reported to cause phase advances in body temperature and heart rhythms 
(Krauchi et al. 2002), suggesting timed feeding may influence a peripheral 
oscillator system in humans.
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Studies examining the phase shifting effects of benzodiazepines on human 
circadian rhythms have been mixed. One study found no phase shifting effect 
of triazolam given at bedtime (Copinschi et al. 1990), while another study 
found a modest phase shifting effect when triazolam was given 3 h before 
bedtime in a jet-lag model (Buxton et al. 2000).
Melatonin administration in humans is capable of eliciting both phase shifts 
and entrainment. The human melatonin PRC demonstrates that exogenous 
melatonin causes advances when administered in the late subjective day and 
phase delays when administered in the early subjective day (Arendt et al. 
1985a, Lewy et al. 1992, Zaidan et al. 1994). However, one report suggests 
that single doses of melatonin are not sufficient to elicit phase delays (Wirz- 
Justice et al. 2002). The dose of melatonin used is an important factor in 
determining the magnitude of the phase advances, with phase shifts occurring 
with daily doses in the range of 0.05 to 5 mg and single doses of 5 mg 
sufficient to cause a phase advance of 1.5h (Deacon & Arendt 1995). 
Melatonin also facilitates entrainment. Daily timed doses of 0.5, 5 and 10 mg 
have been shown to entrain blind individuals with non-24-hour sleep wake 
disorder (Lockley et al. 2000, Sack et al. 2000, Lewy et al. 2001, Hack et al. 
2003) and daily doses of 5 mg have been shown to entrain sighted individuals 
living in dim light free running conditions (Middleton et al. 1997).
1.2.5 Limits of entrainment
Entrainment is dependent on three factors, the endogenous period of an
1 - 1 6
individual, the duration of the environmental T-cycle and the strength of the 
ze/fgeber mediating the entrainment. Entrainment to any environmental T- 
cycle, including the 24-hour solar day, must be within the range of 
entrainment for a given individual. The natural variation in human circadian 
period for sighted individuals measured in forced desynchrony protocols 
ranges from 23.81 to 24.31 with approximately 25% of people having a period 
shorter than 24 h (Czeisler et al. 1999, Wyatt et al. 1999, Wright Jr. et al.
2001). The natural solar light-dark cycle is sufficient to entrain most sighted 
individuals to the solar day. Recently, it has been shown that a modulated 
light exposure protocol, using 100 lux of light is sufficient to entrain individuals 
to T-cycles of longer than 24 h, where lighting schemes of lower intensity are 
not able to elicit stable entrainment (Gronfier et al. 2007).
Blind people lacking circadian light perception are unable to entrain via light 
exposure. Blind people have been shown to have an average period of 
approximately 24.5, which is longer than that observed for sighted people 
(Skene and Arendt 2008). Despite this, some blind people without circadian 
photoreception do appear to remain synchronised to the 24-hour day (Sack et 
al. 1992, Lockley et al. 1997, Klerman et al. 1998, Skene etal. 1999). It is 
unknown how these individuals remain in synchrony with the 24-hour day; 
however, one theory suggests that they have endogenous periods within the 
limits of entrainment for non-photic zeitgebers to cause entrainment (Klerman 
et al. 1998). Other totally blind people have endogenous periods outside the 
range of entrainment for non-photic zeitgebers and free-run with a period 
different from 24 h or partially entrain to a weak zeitgeber (Lewy & Newsome
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1983, Sack ef a/. 1992, Lockley ef a/. 1997, Klerman ef a/. 1998, Skene ef a/.
1999). In some cases the non-photic zeitgeber{s) is too weak to fully entrain a 
totally blind individual and the phenomenon of relative coordination is 
observed, whereby the individual becomes phase locked to the zeitgeber for a 
short period of time, but is unable to fully entrain and is released from the 
temporary entrainment after several cycles (Folkard et ai. 1990, Emens et al.
2005).
1.3 Circadian signal processing
1.3.1 SCN structure and function
In mammals, the SCN in the hypothalamus is the location of the central 
circadian pacemaker (Moore & Eichler 1972, Moore & Lenn 1972, Stephan & 
Zucker 1972). The SCN is a pair of nuclei located at the base of the third 
ventricle, directly above the optic chiasm and is comprised of 20,000-60,000 
neurons (Hofman et al. 1996, Kuhlman 2007). Each SCN cell receives input 
from 4-8 RHT axons (Jiang et al. 1997). The neurons that make up the SCN 
have soma approximately 10-15 pm in diameter and contain between one 
and three dendrites. Each dendrite is able to extend nearly the length of the 
SCN (van den Pol 1980, Jiang etal. 1997).
The SCN is structurally organised as a “core” (ventral, ventrolateral portions) 
and “shell” (rostral, dorsomedial, and ventromedial portions; Moore et al.
2002). Endogenously rhythmic neurons that do not respond directly to photic
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input are primarily found in the shell, while the majority of nonrhythmic 
photoreceptive cells are located in the core region (Antle et al. 2005).
Lesions of the SCN abolish many behavioural and hormonal rhythms, 
demonstrating that the SCN are necessary for most circadian rhythms in 
mammals (Moore & Eichler 1972, Stephan & Zucker 1972). SCN ablation, 
followed by transplantation of foetal SCN can restore some observable 
circadian function (Lehman et al. 1987, Ralph et al. 1990). Partial ablation of 
the SCN, followed by transplantation of mutant donor tissue results in 
expression of both the host and mutant rhythms (Vogelbaum & Menaker
1992). Further, SCN ablation followed by transplantation of mutant foetal SCN 
results in the restoration of circadian function, but with a rhythm determined 
by the mutant donor (Sawaki et al. 1984). Histological analysis of these 
transplants suggests that the restoration of rhythms is due to an ingrowth of 
the grafts into the paraventricular zone. However, transplants of cell 
suspensions (Silver et al. 1990) and encapsulated SCN tissue (Silver et al.
1996) suggest that humoural connections are sufficient to restore some output 
rhythms in SCN ablated animals. Finally, restoration of function may be 
dependent on the phase of the SCN cells used in the transplant as one study 
found that during “splitting” behaviour in hamsters the split rhythms 
correspond to the left and right sides of the SCN cycling in antiphase (de la 
Iglesia et al. 2000).
The SCN is an autonomous circadian pacemaker. Circadian firing activity has 
been measured in vivo and has demonstrated that the SCN control rhythmic
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firing in other brain regions (Inouye & Kawamura 1979). Spontaneous 
generation of metabolic (Schwartz & Gainer 1977) and electrical activity
(Groos & Hendriks 1982, Green & Gillette 1982) rhythms have also been 
measured in vivo, and later in vitro. The rhythms of SCN cells may be 
maintained in vitro and are capable of being phase shifted (e.g. through cyclic 
adenosine monophosphate (cAMP)) (Prosser & Gillette 1989).
1.3.2 Afferent projections to the SCN
1.3.2.1 Photic signal transduction
Light is the most potent synchroniser of the circadian system (Section 1.2.3). 
Light information reaches the SCN exclusively through the eyes in humans 
(Hollwich 1964, Czeisler ef a/. 1995, Lockley et al. 1998) and in other 
mammals (Snyder ef a/. 1965, Nelson & Zucker 1981, Yamazaki etal. 1999, 
Meijer ef al. 1999). The visual rod and cone system is not required for the 
majority of circadian photosensitivity. Functionally blind (rodless/coneless) 
mice retain the ability to entrain to an imposed light/dark cycle (Freedman ef 
al. 1999, Lucas et al. 1999) and some functionally blind humans have intact 
circadian responses to light (Czeisler et al. 1995, Klerman etal. 2002). 
Circadian photoreception is primarily mediated by intrinsically photosensitive 
melanopsin containing retinal ganglion cells (ipRGCs) distributed in a network 
across the inner retina (Provencio et al. 2000, Hannibal etal. 2001, Gooley ef 
al. 2001, Berson ef al. 2002). ipRGCs have inputs from the rods, cones, 
bipolar and amacrine cells and approximately 70% of RGCs that project to the
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SCN contain melanopsin (Berson et al. 2002, Hannibal & Fahrenkrug 2003, 
Gooley ef a/. 2003, Figure 1.1).
While melanopsin is clearly the primary circadian photoreceptor, rods and 
cones can contribute to the circadian light response, as melanopsin deficient 
mice are still able to entrain to a light-dark cycle, though with attenuated 
phase resetting responses to short light pulses (Panda ef al. 2002). Further, 
recent research has shown that rod-cone and melanopsin deficient mice are 
unable to entrain, have no masking reflex and have no pupillary light reflex, 
suggesting that these two systems are all that is required for circadian 
photoreception (Hattar ef al. 2003, Panda ef al. 2003). It has been 
hypothesised that melanopsin is responsible for bright light detection and rods 
and cones are responsible for light detection at lower intensities (Lucas ef al. 
2003, Mrosovsky & Hattar 2003, Dacey ef al. 2005) or that some wavelengths 
of light have a stronger effect on either cones or melanopsin (Mure ef al.
2007, Zaidi ef a/. 2007, Revell & Skene 2007).
Melanopsin is a vitamin A-based photopigment that is directly sensitive to light 
in vitro, with maximum sensitivity at 480 nm (Provencio ef al. 2000, Hattar ef 
al. 2002, Berson ef al. 2002, Provencio ef al. 2002). Most RGCs that contain 
melanopsin project to the SCN via the retinohypothalamic tract (RHT) (Gooley 
ef al. 2001, Hannibal ef al. 2002). The RHT projects primarily to the ventral
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parts of the SCN, but in some species also projects to dorsal regions (Moore 
& Lenn 1972, Card & Moore 1984). In addition to the SCN, melanopsin 
containing RGCs also project to areas that have been implicated in the 
processing of other non-visual light responses. These areas include; the 
ventral subparaventricular zone, the ventrolateral preoptic nucleus, the 
pretectal area, the intergeniculate leaflet (Gooley et al. 2003) and the lateral 
geniculate nucleus (Dacey et al. 2005). ipRGCs release pituitary adenylate 
cyclase activating peptide (PACAP) and the excitatory neurotransmitter 
glutamate (Hannibal et al. 2002). PACAP and glutamate are released together 
in the SCN and modulate synaptic transmission (Hannibal et al. 2004, Michel 
ef a/. 2006).
1.3.2.2 The IGLand GHT
The SCN receives indirect retinal input from intergeniculate leaflet (IGL) of the 
thalamus via the geniculohypothalamic tract (GHT) (Hickey & Spear 1976). 
The IGL is a thin layer of cells between the ventral lateral and dorsal 
geniculate nuclei of the thalamus (Ribak & Peters 1975, Pickard 1985). The 
IGL is the only area of the lateral geniculate complex that contains 
neuropeptide Y (NPY) (Card & Moore 1982, Harrington et al. 1985). The NPY 
producing neurons project via the GHT to the ventrolateral region of the SCN 
(Harrington et al. 1985, Card & Moore 1988). Lesions of the IGL have 
demonstrated that it is not required for circadian entrainment; however, the 
IGL appears to modulate some circadian responses to light. For example, in 
hamsters, loss of the IGL leads to decreased amplitude in phase advance
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responses to light (Pickard ef a/. 1987, Harrington & Rusak 1988). In addition,
the GHT appears to have an important role in the photic response to dawn 
and dusk, as response to a skeleton photoperiod is abolished when this area 
is lesioned (Edelstein & Amir 1999, Freeman et al. 2004). The action of the 
IGL on the SCN appears to be dependent on a functional retinal signal (Kaur 
& Rusak 2007).
It has also been hypothesised that the IGL plays a role in the differential 
response to light observed in diurnal and nocturnal species as the timing of 
the peak of NPY in SCN neurons occurs during the night in a diurnal rodent 
(Vidal & Lugo 2006) as opposed to just prior to the onset of darkness in rats 
(Shinohara ef al. 1993). It has also been shown that mice lacking NPY have 
an impaired response to gradual lighting changes, suggesting the IGL may 
play a role in conferring day length information to the SCN (Kim & Harrington 
2008).
The IGL may also play an important role in circadian response to non-photic 
zeitgebers as lesions in this area block phase-shift responses to 
benzodiazepines (Johnson et al. 1988) and activity induced phase shifts in 
hamsters (Wickland & Turek 1994). In addition, it has recently been 
demonstrated that these non-photic responses likely communicate with the 
SCN via a glutamate signal (Cain et al. 2007, Blasiak ef al. 2007, Pekala ef al. 
2007). The role of the IGL in humans and their response to light is not yet 
known.
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1.3.2.3 The raphe nuclei and serotonergic input
The median raphe nucleus is the origin of the third major projection to the 
SCN. Like the RHT and IGL, the raphe also projects to the ventrolateral core 
region of the SCN, where it overlaps with both the RHT and GHT projections 
(Moore et al. 1978). The raphe receives projections from the retina and the 
dorsal raphe projects to the IGL, suggesting that some photic information may 
be processed by both the IGL and raphe before reaching the SCN (Moga & 
Moore 1997, Hay-Schmidt etal. 2003).
The neurotransmitter associated with the raphe projection is serotonin. 
Between 40-50% of the projections from the raphe to the SCN contain 
serotonin (Leander et al. 1998, Hay-Schmidt et al. 2003). Serotonin 
modulates SCN clock activity and is thought to be involved in the circadian 
response to non-photic zeitgebers. Lesions of the median raphe projection to 
the SCN result in an altered onset of activity in response to light (Meyer- 
Bernstein et al. 1997). Application of serotonin agonists results in phase shifts 
similar to those observed following non-photic stimuli (Edgar et al. 1993, 
Mistlberger & Holmes 2000, Horikawa & Shibata 2004). Further, the 
interaction between light resetting and behavioural arousal appears to be 
dependent on serotonergic input (Mistlberger & Antle 1998). In addition, 
serotonin modulates light-induced phase shifts during the subjective night. 
Stimulating the raphe in hamsters results in serotonin release in the SCN and 
also blocks light-induced phase shifts during the subjective night (Dudley et al. 
1999, Rea & Pickard 2000).
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There are many serotonin receptors present in the SCN, but the SHTsa 
receptor appears to be the primary circadian receptor and its activation 
modulates light signalling in the SCN (Rea etal. 1994, Pickard et a i 1999, 
Duncan et a/. 2000).
Recent studies have demonstrated that selectively blocking serotonin from the 
raphe (Sterniczuk et a i 2008) in addition to blocking NPY from the IGL results 
in massive changes in the phase shifting response to light, suggesting both 
neurotransmitters can alter the light response (Lall & Harrington 2006).
1.3.3 Efferent projections from the SCN
The SCN signal is transmitted throughout the brain via humoural signals and 
action potentials. Both types of signalling are required for complete circadian 
rhythmicity. When SCN tissue is grafted into donor animals that have 
undergone SCN ablation, some motor behaviour is restored despite the loss 
of neural projections demonstrating the potency of humoural mechanisms 
(Silver et a i 1990, Silver et a i 1996). However, other rhythms such as that of 
melatonin and corticosteroid are not restored demonstrating that humoural 
mechanisms alone are not sufficient for complete control of circadian 
rhythmicity (Vogelbaum & Menaker 1992). There are several factors that are 
thought to be involved in this humoural regulation and they include, TGFa 
(Kramer ef a/. 2001), prokineticin-2 (Cheng et a i 2002), cardiotrophin-like 
cytokine (Kraves & Weitz 2006) and neuromedin S (Mori et a i 2005).
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Neuronal connections appear to play a dominant role in the communication of 
SCN signals. SCN projections are largely internal, with projections extending 
within the SCN that are thought to amplify the circadian signals which later 
project to relay targets in the brain. There are three major anatomical 
projections from the SCN; one to the preoptic area, one to the base of the 
third ventricle (to the retrochiasmatic area and ventromedial nucleus), and one 
that arcs through the ventral subparaventricular zone (vSPZ), dorsal 
subparaventricular zone (dSPZ) and the DMH (Swanson & Cowan 1975,
Watts et a i 1987, Watts & Swanson 1987, Gooley et a i 2006, Figure 1.2). 
Other projections with fewer neurons extend to the paraventricular nucleus 
(PVN), IGL and the orexin neurons of the lateral hypothalamus.
The projection to the PVN is the first step in the pathway to the pineal gland 
and melatonin production (Section 1.4). In addition, the PVN also projects to 
the anterior and posterior pituitary and is thought to be involved in the 
regulation of the photoperiodic control of reproduction. Lesion studies have 
demonstrated that projections to the vSPZ are responsible for sleep-wake 
rhythms, while the dSPZ projections are responsible for the body temperature 
rhythm (Lu et a i 2001). In addition, a further projection from the vSPZ to the 
DMH has shown that the DMH plays an important role in feeding (Gooley et 
a i 2006), the sleep-wake cycle, locomotor activity and corticosteroid secretion 
(Chou ef a/. 2003).
1.4 Melatonin
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Figure 1.2 SCN output projections. (Reproduced from Kuhlman 2007)
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1.4.1 Synthesis
The mammalian pineal gland is a small secretory organ located rostro-dorsal 
to the superior colliculus and beneath the stria medullaris. In mammals the 
pineal gland is the main site of melatonin production, though it is produced in 
lesser amounts in the Harderian gland (Buzzell et al. 1990), gut, retina and 
blood platelets (Arendt 1995). Melatonin was isolated by Aaron Lerner in 
1958. It was given the name melatonin because it was found to be “the factor 
that lightens melanocytes” due to its effect at lightening the pigment in frog 
skin cells (Lerner ef a/. 1958, Lerner & Case 1960).
Melatonin is ubiquitous; versions of it are found in animals, plants and 
bacteria (Hardeland 1999). In mammals, melatonin is primarily synthesised 
within the pinealocytes of the pineal gland (Figure 1.3). Pinealocytes take up 
circulating dietary tryptophan from the blood. The mitochondrial enzyme 
tryptophan-5-hydroxylase hydroxylates tryptophan to 5-hydroxytryptophan (5 
HTP). 5 HTP is decarboxylated by the aromatic amino acid decarboxylase to 
form 5-hydroxytryptamine (5-FIT, serotonin). The rate limiting enzyme is 
serotonin-N-acetyItransferase (AA-NAT), which acetylates serotonin to form 
N-acetylserotonin. Finally, N-acetylserotonin is 0-methylated by 
hydroxyindole-O-methyl transferase (HIOMT) to form N-acetyl-5- 
methoxytryptamine (melatonin). The circadian rhythm of AA-NAT is parallel to 
the circadian rhythm of melatonin with peak activity for each occurring during 
the dark phase (Klein & Weller 1970).
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Figure 1.3 Synthesis of melatonin. (Reproduced from Koch 2009) 
5-HTP = 5-hydroxytrptophan
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The melatonin rhythm is controlled exclusively by the SCN as demonstrated 
by SCN lesions which abolish the rhythmicity of melatonin synthesis (Moore & 
Klein 1974). The neural pathway leading to the production of melatonin 
includes the spinal cord (Yamashita et al. 1984, Cechetto & Saper 1988, 
Larsen 1999, Teclemariam-Mesbah et al. 1999, Zeitzerefa/. 2000a, Figure 
1.4). Ze/fgeber signals are processed in the SCN. The SCN sends GABA- 
ergic inhibitory signals to the paraventricular nuclei (PVN) which control the 
daily rhythmic reduction in melatonin production (Kalsbeek et ai. 2000) as well 
as light-induced melatonin suppression (Kalsbeek et al. 1999). The SCN also 
sends glutaminergic signals to the PVN which stimulate melatonin production 
(Perreau-Lenz et al. 2004). The PVN projects to the superior cervical ganglia 
(SCO) where neural cells project to the pineal (Klein et al. 1983a).
Noradrenaline is the primary regulatory neurotransmitter that initiates the 
synthesis of melatonin. Noradrenaline is released into the pineal perivascular 
space at night where it binds to a l and pi-adrenergic receptors. The o1- 
adrenergic receptors increase Ca2+ and protein kinase C which potentiates 
the stimulation of the pi-adrenergic receptors (Klein et al. 1983b). This in turn 
activates pineal adenylate cyclase and cyclic AMP (cAMP). cAMP activation 
stimulates production of AA-NAT in complex with the protein 14-3-3. The 
cAMP-induced gene transcription repressor (ICER) is activated in parallel with 
AA-NAT. Activation of ICER limits the nocturnal production of melatonin 
(Stehle et al. 1993). There is a time delay between the time cAMP is activated 
and AA-NAT production begins. Further, AA-NAT only remains active while
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Figure 1.4 The melatonin production/suppression pathway.
SCN = suprachiasmatic nucleus; PVN = paraventricular nucleus; NE = Norepinephrine 
(noradrenaline)
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the p1-adrenergic receptors are activated. When the p1-adrenergic receptors 
become deactivated, AA-NAT production ceases and melatonin is no longer 
produced (Vanecek & lllnerova 1980). Light at night also acutely halts 
melatonin production, but this process is different than it is for the daily 
entrainment “o ff’ response. Exposure to light at night results in the 
dephosphorylation and proteasomal proteolysis of AA-NAT with removal of a 
protective 14-3-3 protein in the retina (Klein et al. 2003, Pozdeyev at al.
2006). This response is immediate and the melaonin rhythm recovers if the 
light stimulus is removed.
1.4.2 Metabolism
The liver is the primary site of melatonin metabolism. It is hydroxylated by 
P450 into 6-hydroxymelatonin and then conjugated with either sulphate to 
form 6-sulphatoxymelatonin (aMTBs) or glucuronic acid to form 6- 
hydroxymelatonin glucuronide (Kopin at al. 1961, Arendt at al. 1985b, Arendt 
1995). The specific P450 enzyme metabolising exogenous melatonin to 6- 
hydroxymelatonin in animals and humans has been identified as CYP1A2 
(Skene at al 2001, Facciola at al. 2001). The metabolite aMT6s is the most 
prevalent melatonin metabolite in humans and it accounts for 50-80% of the 
melatonin produced, making it a reliable approximation of circulating 
melatonin levels (Bojkowski at al. 1987).
1.4.3 Receptors
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Melatonin receptors are high-affinity 7-trans-membrane guanine nucleotide 
binding protein (G-protein) coupled receptors. Three subtypes have been 
cloned, MT1 (formerly Mel1a), MT2 (formerly Mel1b) and MeHc (Reppert et 
al. 1995a, Reppert et al. 1996). There is large variability in the presence and 
distribution of receptor types among species. For example, birds express both 
MT1 and Mellc, but do not express MT2 receptors, while mammals express 
MT1 and MT2 subtypes (Reppert ef a/. 1995b).
There are two well-studied areas that contain melatonin receptors, the SCN 
(Weaver & Reppert 1996, Rivera-Bermudez at al. 2004) and the pars tuberalis 
(Williams & Morgan 1988). In the SCN, melatonin provides internal feedback 
and modulates circadian coordination (McArthur ef a/. 1991, Hunt at al. 2001). 
Both melatonin receptor types are present in the mammalian SCN where 
evidence suggests MT1 receptors are responsible for acute suppression of 
SCN firing and MT2 receptors appear to mediate phase advances and 
entrainment (Dubocovich at al. 1996).
MT1 receptors in the pars tuberalis (PT) have been well characterised in rats 
(Williams & Morgan 1988) and sheep (de Reviers at al. 1989, Williams at al.
1997), however, melatonin receptors do not appear to be prevalent in the 
human PT (Weaver at al. 1993, Williams at al. 1997). Melatonin is critical for 
rhythmic gene expression in the PT (von Gall at al. 2005) and binding to 
melatonin receptors in the PT conveys day length information for appropriate 
coordination of seasonal breeding, though receptors in the mediobasal 
hypothalamus may mediate the effect of melatonin on the gonadal axis of
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seasonal breeders (Maywood & Hastings 1995). In addition, melatonin via 
binding to melatonin receptors modulates the expression of clock genes in the 
PT, but not in the SCN (Johnston ef a/. 2006).
Melatonin receptors have also been described in numerous other tissues 
throughout the body. Other brain regions containing melatonin receptors 
include the zona incerta, anterior hypothalamus, pituitary stalk, arcuate 
nucleus, PVN, reunions nucleus and xiphoid nucleus (Song & Bartness 2001). 
In addition, melatonin receptors are prevalent throughout the body and MT1 
and MT2 receptors are located in the inner and outer plexiform layers, 
ganglion, amacrine and horizontal cells of the retina, where they may 
modulate effects on retinal physiology (Fujieda ef al. 1999, Dubocovich & 
Markowska 2005). Melatonin receptors may also be found in the cerebral and 
caudal arteries, where they are reported to play a role in thermoregulation 
(Viswanathan etal. 1990).
Melatonin receptors have also been identified in rat ovaries using 2- 
[^^^Ijiodomlatonin binding and RT-PCR cDNA amplification (Soares Jr. ef al.
2003). In addition, during the proestrus phase when oestrogen levels are high, 
melatonin binding is higher than in metestrus when oestrogen levels are low 
(Soares Jr. et al. 2003). Both MT1 and MT2 receptors have also been 
identified in human granulosa-luteal cells where melatonin administration 
modulates other steroids including an increase in LH receptors and a 
decrease in circulating GnRH and GnRH receptor levels (Woo ef al. 2001). 
Melatonin receptors have also been identified in human normal and
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cancerous breast tissue using histologic evaluation and immunoreactivity 
staining (Dillon et al. 2002). According to the same report, melatonin receptors 
are more abundant in invasive carcinoma and ductal carcinoma in situ (DCIS) 
compared to non-cancerous breast tissue.
1.4.4 Factors affecting melatonin production and metabolism
There are many external and internal factors that influence the amount, 
duration, timing and metabolism of melatonin produced during one circadian 
oscillation. Of the external factors, light has the most potent effect on 
melatonin production. The degree of melatonin suppression is dependent on 
the intensity and spectral composition of the light as well as the history of light 
exposure prior to the suppressing stimulus (Zeitzer et al. 2000b, Brainard et 
al. 2001, Thapan et al. 2001, Hebert et al. 2002, Lockley et al. 2003, Wright et 
al. 2004). Seasonal lighting changes are sufficient to shift the human 
melatonin rhythm to an earlier phase in the summer compared to winter 
(Broadway et al. 1987, Bojkowski & Arendt 1988). In addition, melatonin has 
been reported to increase in both duration and secretion in high latitude 
locations such as Finland (Kauppila et al. 1987). The duration of melatonin 
secretion has also been shown to lengthen in as short as four weeks of 
exposure to long nights (14 h) compared to short nights (8 h) (Wehr et al.
1993).
Many dietary and lifestyle choices may influence melatonin production. As 
tryptophan is required for the production of melatonin, dietary availability is
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necessary for normal melatonin production (Zimmermann et al. 1993).
Another dietary factor that may influence melatonin production is vitamin B6.
Vitamin B6 is a co-enzyme in tryptophan decarboxylation and administration 
of vitamin B6 stimulates melatonin production in pre-pubertal children, but has
no effect on adult men (Munoz-Hoyos et al. 1996, Luboshitzky et al. 2002). 
Alcohol consumption decreases melatonin in a dose dependent manner 
(Ekman et al. 1993, Murphy et al. 1996). Some changes in posture, for 
example upon standing after a recumbent period over night, cause a transient 
increase in melatonin which stabilises about 20 minutes after the posture 
change (Deacon & Arendt 1994, Deacon et al. 1994).
Caffeine may cause a delay in the clearance of melatonin resulting in an 
increase in measured plasma melatonin (Ursing et al. 2003). The metabolic 
effects of caffeine on melatonin appear to be related to the CYP1A2 pathway. 
CYP1A2 is involved in the metabolism of melatonin (Facciola et al. 2001, 
Skene et al. 2001). Drugs that have a similar metabolic process to caffeine 
(such as fluvoxamine and 5-methoxypsoralen) and drugs that affect the 
activity of CYP1A2 (caffeine) may also interfere with the metabolism of 
melatonin (Skene et al. 1994).
Smokers have been shown to have higher plasma melatonin levels compared 
to non-smokers (Tarquini etal. 1994). This effect is persistant, as 
demonstrated by a study that reported that melatonin profiles in smokers are 
unchanged following a week of smoking cessation (Ursing et al. 2005). These 
findings may also be related to CYP1A2 activity, because smoking induces
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CYP1A2 (Campbell ef a/. 1987).
There are a wide range of medications that may alter melatonin production 
and metabolism. The majority of these medications act on the melatonin 
production pathway. Adrenergic (3-receptor antagonists decrease melatonin 
synthesis almost to complete suppression during the night (Arendt et al. 
1985b, Simonneaux and Ribelayga 2003). a-adrenoceptor antagonists 
decrease melatonin in the a-1 form, but increase melatonin in the a-2 form 
(Palazidou et al. 1989b, Palazidou etal. 1989a). The selective serotonin 
re uptake inhibitor (SSRI) fluvoxamine increases melatonin production, while 
other antidepressants, such as monoamine oxidase inhibitors (MAOl) have 
been shown to both increase melatonin production and alter the phase in the 
timing of the melatonin rhythm (Hartter ef a/. 2001, Skene etal. 1994). 
Noradrenaline uptake inhibitors have a similar effect to MAOIs on the 
melatonin rhythm (Checkley et al. 1986). Benzodiazepines have a variable 
effect that is dependent on the type of drug. Both diazepam (Monteleone ef al. 
1989) and alprazolam (McIntyre et al. 1993) reportedly decrease melatonin 
production, while triazolam (Copinschi et al. 1990) and zopiclone (Mann et al. 
1996) have been reported to have no effect on melatonin production. The 
antipsychotic drug chlorpromazine elicits a metabolic increase in melatonin 
(Beedham etal. 1987, Ozaki et al. 1976, Smith etal. 1977).
Endogenous and exogenous sex-steroid hormone concentrations also 
reportedly alter melatonin levels and/or measurement. Reports of differences 
in melatonin production throughout the menstrual cycle are inconsistent and
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conflicting. One early report found an elevation of plasma melatonin during 
the follicular phase (Wetterberg et al. 1976). In contrast, an increase in 
plasma melatonin, sampled every four hours over 24 hours, was reported in 
the luteal compared to the follicular phase (Webley and Leidenberger 1986). 
Other studies using different methods have found no changes in melatonin 
throughout the menstrual cycle. One measured total urinary aMT6s each day 
throughout the menstrual cycle in two women and found no changes at any 
menstrual phase (Fellenberg et al. 1982). Another study examined 24 h 
melatonin profiles in plasma and found no changes in phase, amplitude or 24 
h level during any phase of the menstrual cycle (Brzezinski et al. 1988). 
Similarly, a study using a constant routine protocol found no changes in 
aMT6s in the luteal or follicular phases (Wright et al. 1999).
Menopausal changes in melatonin have been reported and suggest that there 
is a surge in melatonin production commensurate with a drop in oestrogen 
production at the onset of menopause (Okatani et al. 2000). The authors of 
this report found significant negative correlations between 17-beta oestradiol 
and plasma melatonin in older pre-menopausal women (age 40-50). This 
report also noted a decline in melatonin with age, which is likely a major 
confounder of cross-sectional studies (Skene et al. 1990).
Melatonin has also been studied in women with disorders known to alter 
menstrual hormone cyclicity. Amenorrhea is a disorder defined by the 
absence of menstrual periods in women of reproductive age and often occurs 
in underweight women. Women with untreated amenorrhea are reported to
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have higher melatonin levels as manifested by a higher peak and longer 
duration of production compared to healthy controls (Berga 1988, Brzezinski 
1988, Kadva et al. 1998). Polycystic Ovarian Syndrome (PCOS) is 
characterised by obesity, anovulation and increased production of androgens. 
When PCOS is untreated it results in significantly higher melatonin levels 
compared to healthy control women (Luboshitzky ef al. 2001, Luboshitzky ef 
al. 2003). Interestingly, when treated (cyproterone acetate-ethinyl oestradiol), 
melatonin levels decrease to a level within the range of healthy age-matched 
controls (Luboshitzky ef al. 2003). This has also been shown following 
treatment with testosterone in hypogonadic men who had elevated melatonin 
levels prior to treatment (Rajmil ef al. 1997) and in a case study of an 
adolescent female with invantilism who also had elevated melatonin levels 
which normalised following successful treatment for delayed puberty (Arendt 
efa/. 1989).
These changes in melatonin following treatment of various disorders suggest 
that there is some interaction between reproductive cycles and melatonin.
One study suggests that these changes are modulated through changes in 
GnRH (Kadva efa/. 1998). This study hypothesised that the high melatonin 
levels observed in hypogonadotrophic women are a symptom of GnRH 
deficiency as opposed to a cause of low GnRH levels. To test this hypothesis, 
they collected hourly plasma melatonin and urinary aMT6s over 24 hours in 
women with hypogonadotropic hypogonadism and women with Kallman’s 
Syndrome, both of which are characterised by low GnRH levels, and an equal 
number of healthy age-matched controls. Kallman’s syndrome was chosen for
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comparison, because it is characterised by defective neural migration which 
leads to low levels of GnRH and therefore it is unlikely that elevated levels of 
melatonin would cause the observed low GnRH. This study found that 
melatonin levels were elevated in Kallman’s Syndrome as well as 
hypogonadotropic hypogonadism, suggesting that the elevated melatonin 
levels are a symptom of low GnRH levels and not a cause of such changes. 
These findings suggest that elevated melatonin levels may indicate an 
imbalance in other sex-steroids, though it is not clear how such an interaction 
might occur.
Exogenously administered sex steroids have also been shown to influence 
melatonin production. In some studies, oral contraceptive pills have been 
shown to cause no change in melatonin, while other studies have found that 
they increase melatonin. A study examining melatonin measured in saliva 
over 48 hours found no changes in melatonin in non-users and users of an 
ethinyl oestradiol preparation of contraception (Reinberg et al. 1996). In 
contrast, a different study reported an increase in plasma melatonin levels in 
users compared to non-users of oral contraception, though the preparation of 
contraception used by study subjects was not defined (Kostoglou- 
Athanassioiu et al. 1998). Similarly, another report found an increase in 
melatonin with oral contraception, but only in the progestin phase of the oral 
contraception cycle (Webley and Leienberger 1986). These results are in 
contrast to a study that found no differences in plasma melatonin in groups of 
women taking either a monophasic drug containing ethinyl oestradiol and 
desogestrel, a triphasic drug with ethinyl oestradiol followed by levonorgestrel
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(progesterone) or in a group of women who took a triphasic drug with a 
double preparation of the progesterone portion of the pill sequence (Delfs et 
8/. 1994).
Some of the differences in melatonin observed with oral contraceptive use 
may be explained by metabolic competition with oestrogens in the CYP1A2 
pathway. Recent studies suggest that melatonin clearance may be affected by 
oral contraceptive use. One study demonstrated that caffeine administration is 
sufficient to reduce the onset of melatonin in the luteal phase of non-users, 
but not in oral contraceptive users (Wright et al. 2000). As caffeine is 
metabolised through the CYP1A2 pathway, these differences may result from 
clearance differences. Another study involved administration of melatonin to 
oral contraceptive users and non-users and found a significantly lower 
melatonin clearance in oral contraceptive users compared to non-users, 
suggesting that there is an inhibitory effect of oral contraceptives on CYP1A2 
melatonin metabolism (Hilli et al. 2008).
In the majority of studies, melatonin measurement has been shown to 
decrease with increasing age, however, there is controversy as to whether 
melatonin synthesis is equally affected (Bojkowski and Arendt 1990,
Kennaway et al. 1999). One highly controlled laboratory study found no 
differences in the plasma melatonin concentrations in young compared to very 
healthy older people (Zeitzer et al. 1999). Interestingly, total blindness has not 
been shown to have an effect on the amplitude or duration of melatonin 
production (Klerman et al. 2001, Lockley etal. 1997a).
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1.4.5 Physiological role of melatonin
The primary role of melatonin is to provide a biological signal for night length. 
Seasonal information is biologically encoded through a lengthening of the 
melatonin duration in the winter and a shortening of the duration in the 
summer (Arendt 1995, Goldman 2001, Malpaux et al. 2001). The functional 
significance of this information in animals is to provide a signal for seasonal 
breeding. For example, sheep are short day (winter) breeders. When sheep 
are given melatonin during a long photoperiod oestrous is advanced (Arendt 
et al. 1983) Pinealectomy studies in sheep suggest that seasonal 
reproduction is synchronised by summer days of long photoperiods (Woodfill 
et al. 1994). In Syrian hamsters, melatonin has antigonadal effects whereby 
short photoperiods and melatonin injections administered during long 
photoperiods causes a reduction in testes size in males (Tamarkin etal.
1976).
In humans, the physiological significance of melatonin is less clear. Some 
studies suggest that melatonin imparts the signal for day length in humans as 
well (Wehr 1991). Humans studied at high latitudes do have a lengthened 
melatonin rhythm and one study demonstrated that humans experience 
increased daytime levels of melatonin during the winter (Beck-Friis et al.
1984, Ronnberg et al. 1990). Humans have also been reported to exhibit a 
phase advance in the melatonin rhythm from winter to summer (Bojkowski 
and Arendt 1988, Broadway et al. 1987, Yoneyama et al. 1999). A recent
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report found that 6 out of 8 women studied in every season had significantly 
higher levels of melatonin in the autumn compared to all other seasons 
(Ueno-Towatari et al. 2007). Melatonin in humans may also serve as a signal 
for dawn and dusk (Wehr ef a/. 2001).
The functional significance of these seasonal cues in humans is not well 
understood. The increase in melatonin reported in women living in high 
latitudes coincides with impaired reproductive function, suggesting there may 
be an interaction between melatonin and the human reproductive axis 
(Kauppila et al. 1987). In addition, analyses of conception rates among 
humans living at different latitudes and seasonal variation in human pre­
ovulatory follicular fluid suggests that humans are long day breeders 
(Smolensky etal. 1981, Ronnberg etal. 1990). Additionally, bright light 
administered in the morning reportedly stimulates human LH secretion (Yoon 
efa/. 2003).
1.4.5.1 Melatonin and human puberty
Melatonin has been implicated as a facilitating factor in the onset of human 
puberty, though the evidence for a role for melatonin is mixed and 
contradictory. The majority of studies examining melatonin and the onset of 
puberty have been cross-sectional and have relied on varying methodologies 
and combining girls and boys. Several studies have reported that melatonin 
decreases with the onset of puberty as measured through a single nightly 
sample of plasma melatonin (Waldhauser ef al. 1984) and a single daytime
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sample (Silman etal. 1979). In support of decreased melatonin being 
associated with onset of puberty, a longitudinal case-study found that daily 
aMT6s levels decreased in association with successful hormonal treatment for 
delayed puberty (Arendt et al. 1989). In contrast, other reports have found an 
increase in overnight urinary melatonin in relation to puberty (Penny 1982) 
and an increase in daily aMT6s production in association with Tanner stage 2 
in girls (Tetsuo et al. 1982). Other reports measuring the plasma melatonin 
rhythm in boys did not find any differences in melatonin at any stage of 
development (Ehrenkranz et al. 1982) or in boys and girls in relation to other 
endocrine markers of puberty (Cavallo et al. 1992a). A supporting study that 
examined plasma melatonin profiles in boys and girls suggests that the 
comparison of melatonin to puberty is confounded by age, because when the 
association between decreasing melatonin and puberty is adjusted for age, 
the relationship between melatonin and puberty becomes insignificant 
(Cavallo et al. 1992b). It is currently unclear whether there is a role for 
melatonin in the onset of puberty or whether changes in melatonin are 
associated with other factors such as age.
1.4.6 Exogenous melatonin administration
1.4.6.1 Melatonin as a chronobiotic
Melatonin administration is sufficient to entrain free-running rhythms in both 
animals and humans. The first experiments to demonstrate the entrainment of 
the activity rhythm to melatonin were performed in rats held in LL or DD and
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given daily timed melatonin injections (Redman ef a/. 1983, Armstrong ef a/.
1986). The effects of melatonin administration are predicted by a PRC (Lewy 
etal. 1992, Zaidan 1994, Burgess etal. 2007). The melatonin PRC is the 
approximate inverse of the light PRC, where melatonin administered during 
the late subjective day results in phase advances and melatonin administered 
during the early subjective day results in phase delays (Arendt etal. 1985a, 
Lewy et al. 1998, Burgess ef al. 2007). There is some debate about the effect 
of melatonin administered at different circadian phases. Entrainment through 
phase advances is well established (Lewy et al. 1998), but negative results 
have been reported for entrainment via phase delays (Wirz-Justice et al. 
2002), though a recent three cycle administration of three mg of melatonin 
yielded a peak in the phase delay portion of the PRC 11.1 h after dim light 
melatonin onset (DLMO) (Burgess et al. 2007).
Timed daily melatonin administration is capable of entraining the free-running 
rhythms of some sighted and blind subjects (Lockley ef al. 2000, Middleton ef 
al. 1997, Sack ef al. 2000). The most effective dose of melatonin is not 
known, but fast release low doses near the natural physiological range (0.3- 
0.5 mg) appear to be the most effective for entraining free running rhythms 
(Lewy ef al. 2002, Hack ef al. 2003, Lewy ef al. 2004). It is not yet clear how 
exogenous melatonin is able to cause entrainment (e.g. binding sites, relation 
to endogenous melatonin in the body), but presumably melatonin binds to the 
melatonin receptors in the human SCN (Liu efa/. 1997).
1.4.6.2 Melatonin as a hypnotic
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Melatonin administered during the subjective day causes sleepiness, but has 
little effect when administered during the subjective night when endogenous 
melatonin is present (Dollins et al. 1994, Cajochen et al. 1997, Wyatt ef al. 
2006). One report found that rapid-release single melatonin doses of 0.3 to 10 
mg were as effective as the benzodiazepine temazepam at causing initiation 
of sleep (Stone ef al. 2000). A recent study found similar results with a 5 mg 
dose of melatonin administered 30 minutes before bed (Sadeghniiat-Haghighi 
efa/. 2008). In contrast, a report using timed release melatonin preparations 
found a redistribution of sleep following treatment, but no difference in total 
sleep time when compared to the placebo condition (Rajaratnam ef al. 2003). 
At this time it is still unclear whether melatonin is a true hypnotic.
1.5 Blindness and circadian rhythms
1.5.1 Hormone production in the blind
Blindness was identified as a factor associated with abnormal hormone output 
before light was confirmed as the primary synchroniser of the circadian 
system. In 1956, Migeon examined the 24-hour rhythm of 17- 
hydroxy corticosteroid (17-OHCS) and did not find differences in the diurnal 
rhythms in sighted and blind subjects (Migeon 1956). Despite the initial 
negative findings, in 1969 two separate groups reported abnormal hormone 
production in the blind. Orth and Island studied three blind people with no light 
perception and found that one had a normal 24 h rhythm of 17-OHCS, one
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had an abnormal rhythm and the third had what appeared to be a free- 
running' rhythm (Orth and Island 1969). Another group examined a cohort of 
19 blind people and found that five out of seven with light perception and nine 
out of 12 without light perception exhibited abnormal rhythms of 11- 
hydroxyCOrticosteroid (11-OHCS) (Krieger and Rizzo 1971). This group, 
however, found no correlations between the circadian pattern of 11-OHCS 
and onset of or duration of blindness or sleep pattern. A separate study 
demonstrated that daytime levels of melatonin were higher than night-time 
levels in four blind men, identifying light as a synchroniser of the melatonin 
rhythm (Smith efa/. 1981).
Other studies extended prior observations by examining larger hormone 
panels and comparing blind subjects to sighted controls. One group 
conducted a study examining hormone output in 10 blind people and 100 
sighted controls and found that there was a diurnal rhythm in thrombocyte 
activity in the controls, but not in the blind subjects (Hollwich and Dieckhues 
1971). In the same report, the investigators described the profiles of several 
hormones collected pre and post cataract surgery. Interestingly, in these 
patients the morning rise in cortisol was absent before surgery, but returned 
post-surgery. Presumably these patients would have had some degree of light 
perception before surgery, so the results of this report suggest that the 
surgery may have provided additional light sensitivity. Another group reported 
that the diurnal rhythm of cortisol differed between blind and sighted men 
(Bodenheimer ef al. 1973). Of note, this group also found diurnal rhythms in 
FSH and testosterone that were the same in the sighted and blind men. They
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also measured oestradiol levels in these blind men and found a diurnal rhythm 
in its production with a peak at 08:00h. They did not measure oestradiol in 
sighted controls, so it is unclear whether or not the observed rhythm is 
specific to blindness (Bodenheimer ef a/. 1973).
The aforementioned studies led to larger longitudinal studies in groups of 
blind people to examine circadian rhythmicity and related hormonal output. In 
one case study of a blind man studied both in the field and in the laboratory, it 
was reported that his cortisol and sleep rhythm ‘free-ran’ with a period of 24.9, 
regardless of behavioural restrictions imposed on his schedule (Miles ef al.
1977). In another case study of woman studied over 50 days, it was observed 
that her cortisol rhythm exhibited a non-24 h rhythm with a period of 24.5, 
while her sleep remained on a 24 h pattern (Orth efa/. 1979). A larger study 
found that melatonin rhythms were different among different blind people 
(Lewy and Newsome 1983). The same group later determined that these 
differences in hormonal rhythms were markers of the circadian system and 
that the original study was comprised of subjects at different circadian phases 
(Sack ef al. 1992). This finding was later confirmed in a large cohort of blind 
people studied over several weeks (Lockley efa/. 1997a).
Other hormones have also been reported to be different in blind people. 
Bellastella and colleagues conducted a series of experiments on pre-pubertal 
blind boys and found that the GH response to L-dopa was impaired 
(Bellastella ef al. 1977). In other studies, the same group found increased free 
thyroid hormone levels, thyrotropin and total thyroid concentrations in pre­
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pubertal blind boys compared to sighted controls, but no differences in these 
measures in blind adults (Bellastella efa/. 1967, Bellastella efa/. 1995).
These studies relied on measures taken at single points in time and subjects
with unknown degrees of visual loss and circadian photoreception and 
therefore the results may be confounded, because sampling was not 
controlled for circadian phase between subjects. In addition, some of the 
findings in all of the aforementioned studies may be limited by lack of 
knowledge about circadian photoreception. The aetiology of blindness varies 
by eye condition and it is possible that some eye conditions are more likely to 
lead to abnormal observations in the patterns of hormones and sleep. Figure
1.5 shows the areas of the eye affected by common eye conditions.
1.5.2 Blindness and reproductive function
There are conflicting reports on the role of blindness in reproductive function. 
In 1964, Zacharias and Wurtman compared blind girls with retinopathy of 
prematurity (ROP) to prematurely born sighted girls and found that menarche 
was advanced in girls with ROP. They found this effect to be accentuated 
among the subset of girls with ROP who had no perception of light (NPL). In 
the same report they also found that girls born at full-term and blinded within 
the first year of life had an earlier menarche compared to sighted controls also 
born at full-term (Zacharias and Wurtman 1964). The same group followed up 
their initial report with detailed information on the same cohort and showed 
that NPL blind girls with ROP experienced menarche an average of seven 
months earlier than prematurely born sighted controls (Zacharias &
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Wurtman 1969). They also found that among blind girls with light perception 
(LP) born at full term, menarche was an average of four months earlier than
their sighted counterparts. The mean ages for menarche in sighted controls 
were 12.6 years in the premature girls and 12.5 years in the full term girls, 
where menarche was 11.9 years in NFL ROP girls, 12.0 years in LP ROP 
girls and 12.2 years in LP full term girls.
In contrast to the findings of Zacharias and Wurtman, Thomas and Pizzarello 
found no differences in the time of menarche in institutionalised blind and 
sighted girls. In 81 subjects, they found the mean age of menarche to be 12.3 
years in both blind and sighted girls, however, the median age for menarche 
in blind girls was 12.0 years compared to 12.5 years in sighted girls (Thomas 
& Pizzarello 1967). The authors suggest that their study is a better 
comparison, because lifestyle factors are similar among both blind and 
sighted girls. However, this study did not account for the degree of blindness, 
the type of blindness or the reason for the institutionalisation of the sighted 
girls. A third study conducted by Magee and colleagues examined only blind 
girls, but compared age at menarche by clinically confirmed degree of light 
perception (Magee etal. 1970). This group reported a significantly earlier age 
of menarche in girls with minimal light perception and NPL (12.0 years) 
compared to those with shadow vision and guiding sight (12.8 years). All girls 
in this study lived in a similar environment, suggesting that a regularly timed 
schedule may not be important in onset of menarche as hypothesised by 
Thomas and Pizzarello.
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In a larger study examining fertility in blind women, Lehrer found no difference 
in the onset time of menarche (12.4 years vs. 12.4 years), menopause (49.0 
years vs. 49.4 years), or fertility among 24 LP and 31 NPL women (Lehrer 
1982). In addition, Elden hypothesised that a pineal or light effect caused 
sterility among blind women after he observed only one pregnancy among 
blind women in Washington State, when the expected number should have 
been 120 (Elden 1971). In the same report, Elden demonstrated that only six 
blind women gave birth in the United States in 1969, when the expected 
number should have been over 1000. This may not be a reliable report, 
however, because it is unclear what definition of blindness was used and what 
exact records were used to compile the results. Currently, the existence and 
causes for the differences in reproductive function among blind women 
remain unknown.
1.5.3 Sleep and blindness
Sleep disorders among the blind have been consistently reported as having a 
high prevalence as measured in epidemiological survey studies. In 1976,
Miles and Wilson conducted a survey of 50 blind people to assess the 
prevalence of sleep disorders among the blind (Miles & Wilson 1977). They 
found that 76% reported sleep problems and 40% identified their sleep 
problem as being “cyclic.” This cohort included both NPL and LP subjects, but 
the authors noted that subjects more likely to report a sleep disorder were 
those with NPL, those who were blind from birth, those with with ROP and 
those whose aetiology of blindness was unknown. Another group reported a
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40% prevalence of sleep phase or free-running sleep disorders in survey of 
73 blind teenagers (Sasaki ef a/. 1992). A larger study of 800 blind people 
compared to age-matched sighted controls found that 82.7% of blind people 
reported a sleep disorder and of these 18% reported sleep problems 
consistent with a free-running rhythm (Leger et al. 1999). The only 
epidemiological study to measure degree of blindness objectively found that 
50% of all subjects surveyed reported evidence of sleep problems and of 
these a higher proportion of NPL subjects reported sleep disorders (as 
measured by the Pittsburgh Sleep Quality Index (P8QI)) compared to LP and 
sighted subjects (Tabandeh et al. 1998).
An objective laboratory study examined sleep disorders in 16 NPL blind men 
and found that 71% of these men complained of chronic sleep disturbance 
(Martens et ai. 1990). This group compared sleep in the men by whether or 
not they had a sleep complaint and found that those with a sleep complaint 
slept more and more of their sleep occurred during the daytime hours 
compared to those with no sleep complaints.
Circadian rhythm disorders in the blind were first identified in a case study 
conducted by Miles in 1977 although earlier studies did identify hormonal 
changes in the blind consistent with circadian rhythm disturbance (Section 
1.5.1). This study demonstrated that a blind man with ROP was unable to 
entrain to a 24 h schedule with a strict rest-activity cycle and instead free-ran 
with a period of 24.9 h (Miles et al. 1977). A second case study found similar 
results and reported a blind woman exhibited a free-running rhythm of 24.5 h
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(Orth et al. 1979). Other case studies corroborate these results, Arendt and 
colleagues studied a blind person with a period of 24.68 h (1988), Nakagawa 
and colleagues found that in a blind person sleep propensity, temperature and 
melatonin all free-ran with at a period of 24.65 (1992), and Klein and 
colleagues studied a man with a period of around 24.25 h (1993).
Lockley and colleagues further informed these findings by illustrating the 
distribution of circadian sleep disorders across a large cohort of LP and NPL 
subjects. They demonstrated that a higher proportion of NPL subjects have 
abnormal melatonin rhythms compared to LP subjects (Lockley et al. 1997a). 
A report compiling the results of 30 blind subjects with light perception 
demonstrated that 77% have normal melatonin rhythms, 13% have 
abnormally phased rhythms (either advanced or delayed), 7% have no 
detectable melatonin rhythm and roughly 3% have a free-running rhythm 
(Skene et al. 1999, Lockley et al. 2007). Among NPL subjects they found 76% 
to have abnormal melatonin rhythms and they reported that the distribution 
varied depending on the number of eyes present. In 24 subjects with at least 
one eye, 46% exhibited free-running melatonin rhythms, 21% exhibited 
abnormally entrained rhythms, 29% had normally entrained rhythms and 4% 
had no detectable rhythm. Of 12 subjects with no eyes 100% exhibited free- 
running melatonin rhythms. This group has also demonstrated that the timing 
of sleep directly correlates with circadian phase in napping patterns in free- 
running blind people (Lockley et al. 1995, Lockley et al. 1997b, Lockley 1999).
1.5.4 Other characteristics of blindness
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The blind population differs from the sighted population on several additional 
measures. Pre-pubertal blind girls with varying degrees of LP reportedly have 
a shorter stature than age-matched sighted girls and blind adults have a 
shorter final stature than sighted adults (Bellastella et al. 1989, Bellastella et 
al. 1994). BMI has been reported to be statistically, but not clinically lower in 
blind people compared to sighted people (Leger et al. 1999). Institutionalised 
elderly blind people who develop blindness later in life have a higher rate of 
depression than elderly sighted people (Ip et al. 2000). In a large survey of 
800 blind people, it was reported that blind people drink less alcohol and 
coffee, but smoke at the same rate as sighted people (Leger et al. 1999). In 
the same study, it was reported that 26% of blind people use sleep 
medications, while only 13% of sighted controls use them. Finally, ratings of 
self-reported alertness and mood change by circadian phase in blind people 
who are not entrained (Lockley et al. 2008).
1.6 Oestrogen endocrinology
1.6.1 Neuroendocrine control of oestrogen production
Oestrogen production is controlled by the hypothalamic-pituitary-ovarian axis. 
In pre-menopausal women, the hypothalamus releases GnRH in a pulsatile 
fashion based on feedback from circulating oestradiol (Figure 1.6). GnRH is 
transported by the portal vein to the anterior pituitary where it binds to cell 
membranes on the gonadotrophs. The gonadotrophs produce LH and follicle
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Figure 1.6 Cycle of oestrogen feedback on the hypothalamus 
and pituitary to control its production in the ovary (Reproduced from 
Endocrine Pathophysiology, 2"^ edition, 2004).
GnRH = gonadotrophin releasing hormone; NE = norepinephrine 
(noradrenaline); E = epinephrine (adrenaline); DA = dopamine; FSH = follicle 
stimulating hormone; LH = luetenising hormone
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stimulating hormone (FSH) which both stimulate the ovaries. FSH causes 
ovarian follicles to grow and make oestradiol (Hillier et al. 1994). Oestradiol 
feeds back on the anterior pituitary and causes a surge in LH. This surge in 
LH acts on the ovaries to stimulate ovulation and causes the corpus luteum to 
produce progesterone. Oestradiol also feeds back on the hypothalamus to 
stop the release of GnRH. Prior to puberty the release of GnRH is inhibited by 
an unknown mechanism. As puberty approaches, gonadotrophin pulsatility 
increases at night, causing a gradual increase in circulating levels of FSH and 
LH (Apterefa/. 1993).
1.6.2 Oestrogen synthesis
There are three major oestrogens produced by the body, oestriol, oestrone 
and oestradiol (Gruber et al. 2002). Oestriol is only produced in significant 
amounts during pregnancy where it is produced by the placenta. Oestrone 
and oestradiol are both produced through a common pathway and are 
synthesised from cholesterol (Figure 1.7). Cholesterol is converted to 
pregnenolone by desmolase. Pregnenolone is then converted to 
dehydroepiandrosteron (DHEA) by the catalytic enzyme P450c17 and is 
dehydrogenased into androstenedione by 3|3-hydroxysteroid dehydrogenase. 
Androstenedione leads to the production of oestradiol via two distinct 
pathways. It is either converted to oestrone by P450 a ro mata se and then 
converted to oestradiol by 17(3-hydroxysteroid dehydrogenase or it is 
converted to testosterone by 3 p-hydroxysteroid dehydrogenase and then 
converted to oestradiol by P450 aromatase.
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In pre-menopausal women oestradiol is the dominant oestrogen and it is 
primarily synthesised in the parafolicular region of the ovary. The ovaries 
synthesise oestrogen in a cyclical manner with feedback from the gonad- 
hypothalamus-pituitary feedback axis. In the ovary, theca cells secrete 
androgens which are aromatised into oestrodial by the granulosa cells (Hillier 
etal. 1994).
The dominant post-menopausal oestrogen is oestrone. In post-menopausal
women oestrogen production is not controlled by the menstrual cycle, but is 
primarily synthesised by the mesenchymal cells in adipose tissue and skin 
(Miller 1991). Individual differences in adipose tissue availability and genetic 
variation can lead to differences in the availability of circulating oestrogen. 
Some oestrogens are also produced in the corpus luteum and the placenta, 
while smaller amounts are produced by tissues such as the liver, adrenal 
glands, breasts, brain and arterial blood vessels (Matsumine et al. 1986, Miller 
1991, Naftolin etal. 1975a).
There are large inter-individual differences in oestrogen production with 
average urinary levels of oestradiol ranging from 50-400 pg/24h in pre­
menopausal women and 5-25 pg/24h in post-menopausal women (Gruber et 
al. 2002). During the menstrual cycle, the highest level of oestradiol occurs 
just prior to ovulation and the lowest level occurs just before menses (Baird 
1974). Urinary levels of oestrone range from 30-350 pg/24h in pre­
menopausal women and around 30-80 pg/24h in post-menopausal women 
(Gruber et al. 2002). Oophorectomy reduces peripheral oestradiol levels to
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around 18 pg/mL (Hobkirk 1960). It has been shown that the urinary 
metabolite oestrone-3-glucuronide (E1G) is a reliable marker of oestradiol
production as the changes in production fluctuate in a similar manner 
throughout the menstrual cycle (Catalan et al. 1989).
1.6.3 Oestrogen metabolism
Serum and urinary oestradiol measurement in women reflect the activity of the 
ovaries in pre-menopausal women. In plasma, oestradiol is largely bound to 
sex hormone binding globulin (SHBG) and albumen, the free fraction is 
biologically active. Its deactivation involves conversion to oestrone and 
oestriol. Oestradiol is conjugated in the liver by sulphate and glucuronide 
formation and is excreted via the kidneys. The bulk of oestrone is converted to 
oestrone sulphate (by oestrone sulfotransferase) which has a long half life in 
blood. This long half life allows it to be converted back to oestrone by the 
sulphates resulting in an “oestrogen reservoir” (Miettinen et al. 2000). 
Oestrogens are also catabolised by hydroxylation reactions. These reactions 
form 2-hydroxyestrone, 4-hydroxyestrone, 4-hydroxyestradiol, 16a- 
hydroxyestrone and 16a-hydroxyestradiol (Osawa et al. 1993). The 2- and 4- 
hydroxy metabolites are then converted to methoxylated metabolites (Gruber 
and Huber 2001).
1.6.4 Rhythmic production of oestrogen
It is clear that oestrogen levels change with the menstrual cycle (Figure 1.8).
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A Human Reproductive Menstrual Cycle
B Rat Reproductive Menstrual Cycle
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Figure 1.8 Hormone fluctuation throughout the normal A) human and 
B) rat menstrual cycle (Reproduced from Emanuele et al. 2002)
LH = luetenising hormone; FSH = follicle stimulating hormone
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In the normal menstrual cycle oestradiol levels are normally around 50-70 
|ig/24h at menstruation, they rise to around 200-400 pg/24h at pre-ovulation, 
drop slightly during ovulation and rise again to around 150-300 pg/24h during 
the luteal phase for a second peak (Gruber et al. 2002). At the end of the 
luteal phase oestradiol levels drop back to their menstrual levels unless there 
is a pregnancy (Baird and Fraser 1974). The changes in oestrone are similar 
to those of oestradiol (Baird and Fraser 1974).
In a study comparing the levels of urinary oestrogen metabolites to plasma 
measures throughout the menstrual cycle, Xu and colleagues found a strong 
relationship in each of the oestrogens measured (Xu et al. 1999). This group 
found broad variation between phases with the highest levels of both plasma 
and urinary oestrogens measured just prior to ovulation followed by the mid- 
luteal phase, with the lowest values measured in the mid and early follicular 
phases.
While menstrual phase is an important consideration in measuring 
oestrogens, circadian or diurnal phase may also be of importance. One group 
examined urinary oestriol levels in a total urine collection over 12 daytime 
hours, compared with collection of urine over 12 night-time hours (Pariente et 
al. 1971). This study found statistically significant differences in oestriol, with 
higher oestriol levels observed during the day compared to the nightly 
collection. In contrast, Westerlind and colleagues found no evidence of a 
diurnal variation, however, they only examined three women with urine 
samples taken at the times of natural voids (Westerlind et al. 1999). They also
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conducted the analysis of circadian variation by “visual inspection” and 
concluded that there were no observable rhythms in the three subjects. It is 
unlikely that a visual inspection in only three subjects is sufficient for 
determination of rhythmicity.
A more thorough examination of oestradiol concentrations over 24 h (plasma 
samples taken every 7 minutes during the mid-late follicular phase) found 
significant diurnal changes in oestrogen levels within four of six individuals, 
however, two had significant increases in oestradiol at night and two had 
significant decreases in oestradiol during the night (Licinio et al. 1998). 
Another report found a distinct diurnal rhythm in oestradiol in depressed (Bao 
2004) and normal (Bao 2003) pre-menopausal women as measured in saliva 
samples at many menstrual phases. This group further reported that the 
oestradiol acrophase is dependent on menstrual phase. During menstruation 
in control subjects, they found an acrophase at 9:30 (± 3:18), which was 
significantly later than in the peri-ovulation phase when the acrophase shifted 
to 6:24 (± 3:06). These authors reported a non-significant shift in the early to 
mid-luteal phase acrophase (9:06 (± 2:12)) and in the late luteal phase, 
acrophase (8:42 (± 3:06)) compared to the menstruation phase.
1.6.5 Oestrogen receptors
Oestrogens are hydrophobic molecules and in order to circulate through the 
blood stream, they need to bind to other molecules such as SHBG and 
albumin. Although the majority of oestrogens are bound to other molecules,
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the active form is the two percent that are in unbound form. Unbound 
oestrogens are able to enter cells by passive diffusion where they bind directly 
to a nuclear oestrogen receptor (Pettersson et al. 1997). There are two 
oestrogen receptors ERa and ER(3 (Green etal. 1986, Kuiper ef a/. 1996). 
Once oestrogen binds to the receptor, the steroid-receptor complex 
undergoes an activation step which involves a conformational change and 
shedding of proteins (Beekman et al. 1993). The complex binds to hormone 
response elements (HRE) in the promoters of hormone-regulated genes 
(Cowley et al. 1997). The receptor-DNA complexes then associate with co 
activators and basal transcriptional components (Mclnerney et al 1996).
These complexes enhance transcription and translation of proteins that elicit 
specific biological responses within a tissue or organ.
Steroid receptors are part of a superfamily of more than 150 proteins (Wahli 
and Martinez 1991). The structure of all steroid receptors includes an N- 
terminal region containing ligand-independent transcriptional activating 
functions, a DMA binding domain, a hinge region with nuclear localisation 
signal elements and a ligand-binding domain in the C-terminal region of the 
protein that contains a ligand-dependent transcriptional activating function.
1.7 Breast cancer
1.7.1 Cancer development
Cancer arises from loss of control of normal cell growth through an
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accumulation of mutations within the DMA of a single cell (American Cancer 
Society 2007a). The stages leading to cancer development have been 
termed: initiation, promotion and progression.
Cancer initiation occurs when a cell loses control of growth through genetic 
mutation (Boutwell 1964). Initiation is an irreversible process. Genetic 
mutations initiating cancer can be inherited, such as when a woman inherits 
the BRCA1 mutation in breast cancer (Andersen et al. 1992), or acquired from 
environmental exposure, such as exposure to the carcinogen benzene in 
cigarette smoke (Mclemore & Martin 1977). Initiation typically involves the 
activation of an oncogene and/or the loss of a tumour suppressor gene. 
Oncogenes code for growth promoting factors in normal and tumour cells 
(Todd & Wong 1999). When oncogenes are mutated they overexpress growth 
signals and become unresponsive to growth regulators.
Tumour suppressor genes are growth gatekeepers; they normally keep cell 
growth in check (Klein 1987). When tumour suppressor genes become 
mutated, cell growth is no longer suppressed and tumour cells may 
proliferate. Cellular deregulation caused by initiating mutations lead to 
additional genetic mutations as the mutated cells proliferate and usually 
damage DMA repair genes leading to uncontrolled growth.
Cancer promotion occurs following a series of initiation events. Cancer growth 
may be promoted through exposure to a growth promoting factor after the cell 
has been damaged. For example, oestrogen acts as a growth factor in
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oestrogen receptor positive breast tumours (Mohs 1940). As promotion is 
dependent on an outside source such as the presence of oestrogen, it can be 
a reversible process and the length of the promoting time varies with respect 
to the presence of the promoting agent (Hendrich et al. 1986).
Cancer progression is an irreversible step following promotion (Foulds 1951). 
A hallmark of tumour progression is irreparable DMA damage and/or mutation 
(Knudson 2001). Such damage includes méthylation of DMA and chromatin 
restructuring, which result in amplification in oncogenes and downregulation 
of tumour suppressor genes (Verma and Srivastava 2002). In addition, a cell's 
ability to repair DMA damage and initiate apoptosis (cell death) becomes 
impaired (Harfe & Jinks-Robertson 2000, Leist and Jaattela 2001).
Progression is further characterised by morphological changes in cells which 
lead to invasion of adjacent tissues (malignancy) and drug resistance (St. 
Croix etal. 1997).
A late step in cancer progression is metastasis. Metastasis is the spread of 
cancer into other organs and tissues within the body. Tumour cells can break 
away from the primary cancer when cell adhesion is lost due to decreased 
expression of adhesion molecules such as cadherins and integrins (Paschos 
etal. 2009). When cell adhesion is lost, cancer cells are no longer anchored 
to the basement membrane of the primary tumour site and may spread 
(Sherwood 2006). Cancer cells typically spread through either the lymphatic 
system to reach local targets or through the vascular system to reach distant 
targets (Weidner et al. 1991). Some cancers are able to produce new
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vascularisation which leads to easier metastasis through the vascular system 
(Folkman 1971). Once in a new organ system, tumour cells will arrest and 
then begin to grow at the new site (Morris et al. 1997).
1.7.2 Oestrogen receptor positive breast cancer
More than 70% of human breast tumours and 70% of all invasive breast 
tumours are ER-a positive (Allred and Mohsin 2000). Normal mammary 
development requires ER-a and 7-17% of normal breast epithelial cells 
normally express ER-a (Clarke et al. 1997). The mammary cells that express 
ER-a in normal development do not proliferate. In contrast, ER-a positive 
tumours do proliferate and express ER-a. The presence of oestrogen on ER-a 
positive tumours is direct and causes rapid proliferation (Anderson et al.
1998).
In contrast to ER-a, ER-P is not typically associated with ER positive breast 
cancer. ER-p is expressed in both normal and neoplastic human breast 
tissue, but it is not involved in mammary gland development (Couse and 
Korach 1999, Leygue etal. 1998, Roger et al. 2001). ER-p is more prevalent 
in normal mammary glands than ER-a and its expression declines with breast 
cancer development (Leygue etal. 1998, Roger et al. 2001).
1.7.3 Oestrogens and breast cancer
Elevated levels of oestrogens have been implicated in breast cancer risk
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(Section 1.6.4; Henderson etal. 1988, Pike et al. 1993). Oestrogen is a key 
growth factor in ER + tumours. The action of oestrogen on breast cancer is 
very complicated due to many paradoxical actions of oestrogen on different 
tumour types. For example, in ER- tumours, oestrogen application inhibits 
tumour growth (Zajchowski et al. 1993). Ovariectomy slows MCF-7 tumour 
growth in nude rats, however, when oestrogen is applied proliferation is 
accelerated (Shafie 1980). Interestingly, oestrogen applied to MCF-7 cells in 
vitro has no effect on growth. Oestrogen deprived tumours can upregulate the 
production of oestrogen to enhance growth (Dickson et al. 1986), but only in 
tissues that are able to concentrate endogenous oestradiol (White et al.
1982). In addition, oestrogen binding to tumour cells also varies with respect 
to cell cycle phase (Chua et al. 1986).
1.7.4 Oestrogen as a biomarker of breast cancer
Evidence for the influence of oestrogen on breast tumours comes primarily 
from epidemiological studies. These studies vary dramatically in study design 
(prospective, cross-sectional etc.), collection type (plasma, urine, saliva) and 
timing of collection (first morning void, 24 h collection, 24 h circadian/diurnal 
collection). The studies also vary in whether the women studied were pre- or 
post-menopausal and by menstrual phase. An additional factor in relating 
oestrogen levels to breast cancer risk is that the result may be different 
depending on which oestrogen is measured.
While the relationship between oestrogen exposure and breast cancer risk is
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established, it is unclear which measure of oestrogen provides the best 
biomarker for cancer development. Toniolo and colleagues conducted one of 
the first prospective studies aiming to examine the relationship between 
oestrogen levels and breast cancer risk (Toniolo et al. 1995). In a nested 
case-control study, blood samples were taken from women prior to breast 
cancer diagnosis and assessed for plasma oestradiol, oestrone and oestradiol 
bound to albumin and SHBG. They found that mean oestradiol and oestrone 
levels were higher among case subjects than among control subjects.
Albumin bound oestradiol was also higher in case subjects, while SHBG 
bound oestradiol was significantly lower among cases.
In 1996, using information from the Guernsey III study. Key and colleagues 
sought to examine whether concentrations of urinary oestrogens were 
representative of plasma oestrogens (Key et al. 1996). This study compared 
33 pre- and post-menopausal breast cancer cases to 369 cancer free 
controls, matched by age, menopausal status and menstrual phase. A 
summed 24 h urine sample was collected from all women prior to diagnosis of 
cancer, at a random time during the menstrual cycle. This group found no 
associations between levels of urinary oestradiol, oestrone or oestriol and 
breast cancer risk in pre-menopausal women. Surprisingly, they found that 
oestrogen levels were lower in pre-menopausal cases compared to controls.
In post-menopausal women, the trend in risk associated with increasing 
oestrogen excretion was statistically significant for urinary oestradiol and for 
total oestrogens only. Measuring pre-menopausal women at random phases 
during the menstrual cycle may have accounted for the lack of association
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with oestrogens. A follow up experiment within the same cohort found that 
breast cancer cases had a 29% higher plasma oestradiol concentration than
controls and a 22% higher testosterone concentration than controls (Thomas 
efa/. 1997).
In an attempt to determine whether different types of tumours result in 
different levels of steroid hormones, Missmer and colleagues conducted a 
case-control study within the Nurses’ Health Study cohort in post-menopausal 
women (Missmer et al. 2004). They compared women with oestrogen and 
progesterone receptor positive or negative tumours to age-matched controls 
and did not find any associations between any steroid hormone levels and 
tumour type. However, they did find that concentrations of oestradiol, 
oestrone, androstenedione, testosterone, DHEA, DHEAS, and SHBG were all 
significantly greater in cases compared to controls. They also reported that 
there was a two-fold increase in breast cancer risk with oestradiol, free 
oestradiol, oestrone, or oestrone sulphate.
A recent examinfation of the Nurses’ Health Study cohort by Eliassen and 
colleagues examined the relationship between oestrogens and breast cancer 
risk as determined by two predictive models (Eliassen et al. 2006). A single 
randomly timed blood sample was taken prior to diagnosis from post­
menopausal breast cancer cases and age-matched controls. This study found 
that higher levels of oestrone sulphate were associated with increased risk 
across all strata of predicted risk using the Gail prediction model, though no 
significant associations were observed with oestradiol levels. This group also
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found that oestradiol was strongly associated with an increased risk of breast 
cancer regardless of whether or not the person had a family history of breast
cancer, while testosterone and oestrone sulphate were significantly 
associated with breast cancer risk only in women with no family history of 
breast cancer. The overall findings of this study demonstrated that oestrogens 
are predictive of breast cancer risk in women independent of the predicted 
risk in models.
The strongest support for a role of oestrogens in breast cancer risk comes 
from The Endogenous Hormones and Breast Cancer Collaborative Group, 
who compiled the results of nine prospective women’s health studies to 
assess the correlation between oestrogen levels and breast cancer (Key et al. 
2002). This meta-analysis included the Guernsey III Study, the Nurses’ Health 
Study, the New York University Women’s Health Study as well as several 
other large studies. The purpose of this study was to attempt to detect 
relationships between sex steroids and breast cancer risk that individual 
studies were too small to predict alone. This study included 663 post­
menopausal breast cancer cases and 1765 post-menopausal age-matched 
cancer free controls. All subjects provided a single blood sample prior to 
breast cancer diagnosis, because many studies were examined, the blood 
sampling times were not at the same time of day. This group compared 
concentrations of a wide panel of oestrogens and sex hormones with breast 
cancer risk. In the pooled analysis, all hormones including total oestradiol, 
free oestradiol, oestrone and oestrone sulphate, were significantly associated 
with breast cancer risk and all hormones showed a dose-response
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relationship with increasing levels being associated with increased risk. The 
only exception was for SHBG, which showed an inverse relationship with 
breast cancer. When the concentrations in the top quintile were compared to 
the concentrations in the bottom quintile, a nearly 2-fold difference in risk was 
observed for all hormones. This group found no differences in risk related to 
the timing of the sample relative to the timing of breast cancer diagnosis. They 
note that it is not possible to tell whether the elevated concentrations of 
oestrone and oestrone sulphate are due to a biological action or due to the 
correlation of oestrone with oestradiol. They found no differences in the levels 
of any of the hormones due to the assay technique employed by any of the 
studies. This study clearly demonstrates that oestrogens are related to breast 
cancer risk and measurement of all oestradiol, oestrone and oestrone 
sulphate in plasma in post-menopausal women are each a good marker of 
this risk.
Several researchers have suggested that the ratio of 2-hydroxyoestrogen (2- 
0HE1) to 16a-hydroxyoestrogen (16a-0HE1) may be an important marker of 
breast cancer risk. The evidence is contradictory, however, and it is not clear 
that the urinary levels of these metabolites are representative of the plasma 
levels. The reason for the difference in risk is thought to be associated with 
differences in an individual’s metabolism of oestrogen through the 2-0HE1 
and 16a-0HE1 pathways. The 2-0HE1 metabolites are considered anti- 
carcinogenic, while the 16a-0HE pathway is considered carcinogenic 
(Clemons and Goss 2001). Therefore a high 2-0HE1 ; 16a-0HE1 has been 
hypothesised to be associated with a lower risk of breast cancer, while a
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lower ratio has been thought to be associated with a higher risk. The 
proposed mechanism of this risk suggests that women who are at a high risk 
primarily metabolise oestrogen via the 16a-0HE1 pathway, while women with 
a reduced risk, primarily metabolise oestrogen via the 2-OHE1 pathway.
One study supporting this hypothesis was conducted in a large cohort of 
Italian women (Muti et al. 2000). In this prospective study, overnight urine 
samples were taken prior to cancer diagnosis in 144 pre-menopausal breast 
cancer cases. These women were matched to four control subjects for 
comparison. Among pre-menopausal women, Muti and colleagues found that 
a higher 2-0HE1:16a-0HE1 ratio was associated with a reduced risk of 
breast cancer, however, the risk did not reach statistical significance.
In a nested case-control study from the Guernsey III cohort, the ratio of the 
urinary metabolites 16-aOHE1 and 2-0HE1 and their relation to breast cancer 
was examined (Meilahn et al. 1998). In this study first morning void urine 
samples were taken prior to cancer diagnosis from 102 breast cancer cases 
and 296 age and menopausal status matched controls. The ratio of the 
metabolites were not found to be significantly associated with breast cancer 
risk factors (such as parity, lactation) in either the pre- or post-menopausal 
women. A negative relationship was observed between combined post­
menopausal cases and controls and the 2:16a-OHE1 ratio and serum 
oestradiol. There was a 15% lower ratio among post-menopausal cases 
compared to controls, but no differences in pre-menopausal women. This ratio 
differed by menopausal status, with pre-menopausal women having higher
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2:16a-OHE1 ratios than post-menopausal women. The authors found no 
correlation between the 2:16a-OHE1 ratio and time to breast cancer 
diagnosis. They suggest that because the time to breast cancer diagnosis has 
no impact on the ratio of the relationship with breast cancer, the observed 
metabolite ratios at baseline are due to inter-individual differences or 
oestrogen metabolism is a consequence of early disease.
In contrast to the studies that demonstrated an association between the 
2:16a-OHE1 ratio and breast cancer risk, Ursin and colleagues did not find 
such differences (Ursin et al. 1999). In a case control study, they found that 
levels of all urinary oestrogens including 2-0HE1 were increased in case 
patients compared to controls, contradicting the hypothesis that differences in 
risk are due to a differing metabolism of oestrogens. In addition to the above 
contradictory results, the metabolism of 2-OHE1 and 16a-0HE1 have been 
shown to be highly influenced by the environment. The levels of this ratio are 
highly affected by diet, ethnicity, smoking, alcohol and oral contraceptive use 
(Brad low etal. 2006, Brad low and Sepkovic 2004). Studies that do not control 
for these factors would be unlikely to observe true differences in biological risk 
and this may account for the differing published results.
1.7.5 Hormonal breast cancer treatment
Hormonal breast cancer therapies aim to lower circulating oestrogen or block 
the ER-a (American Cancer Society 2007). Hormonal therapies are only 
viable in ER+ cancers. In pre-menopausal women, circulating oestrogen
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levels may be reduced through surgical or radiation-induced oophorectomy or 
through luteinising hormone-releasing hormone (LHRH) agonists. LHRH 
agonists block the LHRH receptor in the anterior pituitary.
Tamoxifen is a selective oestrogen receptor modulator (SERM) that is a 
widely used drug in ER+ breast cancers (Ward 1973). Tamoxifen competes 
with oestrogen for binding and when it binds to the oestrogen receptor it 
creates a conformational change that inactivates transcription (Martin et al. 
1988). Other anti-oestrogens are less widely used and work through either 
degradation of oestrogen receptors or disruption of oestrogen receptor 
formation (O'Regan and Jordan 2001).
Monoclonal antibody treatment is emerging as a promising therapy for breast 
cancer. Monoclonal antibodies specifically target cancer cells by binding to 
antigens in order to allow the immune system to recognize the cancer cells 
and flag them for destruction. The monoclonal antibody trastuzumab has been 
shown to slow tumour progression when given in conjunction with 
chemotherapy (Slamon et al. 2001).
1.7.6 Breast cancer incidence and prevalence
According to the American Cancer Society, the lifetime risk of a woman 
getting breast cancer in the United States is 1 in 8 (12%) (American Cancer 
Society 2007). North America has the highest rate of breast cancer in the 
world. The incidence rate of breast cancer recently began to decline for the
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first time. Incidence rates rose sharply throughout the 1980s due to increased 
screening and detection methods, levelled off during the 1990s and between 
the years 2001 and 2004 dropped by approximately 3.5% per year (Ries et al. 
2007^
After skin cancer, breast cancer is the most common cancer among women 
and it is the second leading cause of cancer death among women after lung
cancer. There are ethnic/racial differences in the incidence of breast cancer. 
Breast cancer is more common in white and African American women than in 
Hispanic women or women of other races (American Cancer Society 2007). 
African American women have a higher mortality rate than women of any 
other race and have a later stage of breast cancer detection than women of all 
other races (Bach et al. 2002). The socioeconomic background of African 
American women is thought to contribute to the higher mortality rate in this 
group. However, women of lower income have a lower survival rate than high 
income women at every stage of diagnosis (Singh et al. 2003). In addition, 
women without health insurance are more likely to have cancers detected at a 
later stage (Halpern ef a/. 2007).
Age is tightly correlated with breast cancer incidence. The mean age of
diagnosis from 2000-2004 was 61 with women aged 20-24 having the lowest 
incidence rate (1.4 cases per 100,000 women) and women aged 75-79 having 
the highest incidence rate (465 cases per 100,000 women) (American Cancer 
Society 2007).
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1.7.7 Breast cancer risk factors
Many of the strongest established breast cancer risk factors are not 
modifiable. These include; female gender, age (>65 years), genetic 
background (BRCA1 or BRCA2 mutation), one or more first-degree relatives 
with breast cancer, prior personal history of breast, endometrial, ovarian or 
colon cancer, high breast tissue density, atypical hyperplasia, height and 
Jewish heritage (Hulka and Moorman 2001). Of these, family history is most 
commonly associated with breast cancer in the popular press, though it only 
accounts for 5 to 10% of breast cancer cases (American Cancer Society 
2007). It is likely that there is so much focus on genetic risk factors for breast 
cancer because women with the BRCA1 and/or BRCA2 mutations are at a 
greater individual risk for developing breast cancer sometime in their lifetime 
(approximately 65% and 45% risk, respectively; American Cancer Society
2007).
Oestrogens are central to the development of breast cancer (Henderson et al. 
1988, Pike et al. 1993; Section 1.7.3). Factors associated with increased 
levels of circulating oestrogen and thought to be related to increased breast 
cancer risk are early age of menarche (<12 years), null parity, late age at first 
birth (>30 years), late menopause (>55 years), never breastfeeding, recent 
oral contraceptive use, long-term use of oestrogen/progestin hormone 
replacement therapy and obesity (Hulka and Moorman 2001). Factors that 
decrease cumulative oestrogen exposure are associated with a decreased 
risk of breast cancer. These include early menopause, early age of first birth.
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multiple full-term pregnancies, ovariectomy and breastfeeding (Hankinson et 
al. 2004). Timing of these exposures seems to be a key factor in whether a 
woman will eventually develop breast cancer (Colditz and Frazier 1995).
Other risk factors include family history of benign breast disease and some 
dietary factors such as consumption of a high fat diet and alcohol 
consumption (Boyd et al. 1993, Colditz et al. 1996b, Fentiman 2001, 
Hankinson et al. 2004). A recent report suggests that two alcoholic drinks/day 
of any kind increases a woman's risk of breast cancer in a dose-dependent 
manner by up to 21 % (Terry et al. 2006). In most women, breast cancer 
diagnosis occurs in early menopause and its development is tightly correlated 
with age.
1.8 Breast cancer, light and melatonin
1.8.1 The melatonin hypothesis
Proposed by Stevens in 1987, the melatonin hypothesis suggests that the 
increasing rates of breast cancer observed in Western society are directly 
related to increasing rates of shift work and exposure to light at night (LAN) 
(Stevens 1987). Stevens proposed that pineal secretion of melatonin is 
inversely linked to oestrogen production and that high levels of melatonin will 
result in low levels of oestrogen and vice versa. The hypothesis was based on 
two factors that he viewed could potentially disrupt endocrine function and 
ultimately lead to breast cancer. First, he proposed that electromagnetic fields
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(EMF) could lead to melatonin suppression which would in turn lead to 
increased levels of circulating oestrogen and breast cancer risk. Second, he 
proposed that nocturnal suppression of melatonin due to LAN would ultimately 
lead to an increased risk of breast cancer.
This hypothesis has spurred many epidemiological and experimental animal 
studies to assess its validity. The EMF hypothesis has resulted in varying but 
predominantly negative associations with breast cancer risk in epidemiological 
population studies (Feychting et al. 2004). The melatonin hypothesis has 
generated some interesting results in epidemiological population studies in 
shift workers and the blind, prospective cohorts and experimental studies. It is 
extremely difficult to measure the effect of exposure to LAN on subsequent 
breast cancer development, because a long latent period likely exists from 
exposure to disease development. Researchers have taken several different 
approaches to indirectly assessing this relationship. Some of the most 
interesting work has come from the Nordic countries where near complete 
population registries make historical cross-sectional and case-control studies 
highly viable. Research exploring this hypothesis has primarily revolved 
around case-control and prospective studies of shift workers and blind 
women.
1.8.2 Breast cancer in shift workers
The primary evidence implicating low levels of melatonin in breast cancer risk 
comes from epidemiological studies in shift workers. The World Health
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Organisation recently classified shift work involving circadian desynchrony as 
a ‘probable carcinogen’ based on this evidence (Straif et al. 2007). There are 
numerous consistent epidemiological reports demonstrating an association 
between night shiftwork and an increased risk of breast cancer. Room level 
light intensities are sufficient to cause some melatonin suppression (Section 
1.4.4; Bojkowski et al. 1987, Zeitzer et al. 2000b). The results of these studies 
imply that either the removal of melatonin (through suppression) or circadian 
desynchrony as a result of shift work rotation may be partly the cause of the 
observed increased breast cancer risk.
The first indications that suggested that night shift work is associated with an 
increased risk of breast cancer came from secondary analyses of historical 
Scandinavian records aiming to examine radiation and/or EMFs and their 
relationship to breast cancer. In a retrospective study of flight attendants in 
Finland, Pukkala and colleagues were not able to find strong associations with 
radiation, which was their primary aim (Pukkala et al. 1995). Instead they 
found an association between shift work and breast cancer with a 
standardised incidence ratio (SIR) of 1.87 (Cl 1.15-2.23). This result suggests 
that an irregular pattern of light at night and/or circadian desynchrony 
associated with shift work and jet lag increases breast cancer risk in women. 
However, a follow up study by the same group found that in this case, 
differences in breast cancer risk could be attributable to family history (Kojo et 
al. 2005). A similar elevation in breast cancer risk was observed in a study of 
female radio and telegraph operators, where women over 50 who had a high 
frequency of shift work were reported to have an OR of 6.1 for breast cancer
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(Tynes et al. 1996). A retrospective case-control study examining breast 
cancer rates in Danish shift workers found a strong association with breast 
cancer in women who were believed to have worked at least 6 years on night 
shifts with an elevated OR of 1.7 (1.3-1.7; Hansen 2001 ). The retrospective 
nature of these studies probably includes a large amount of misclassification 
due to the arbitrary assignments of shift work. Each study included a large 
sample size, however, which would bias the true result towards unity.
In 2001 Davis and colleagues conducted a case-control study to examine 
history of exposure to LAN among breast cancer cases and frequency 
matched controls (Davis et al. 2001). Through personal interviews, the 
investigators collected history of sleep, bedroom light and ten-year work 
history. They defined “peak sleep” as the interval between 1:00-2:00 h when 
they assumed the average melatonin peak happens. They found that women 
incur a higher risk of breast cancer OR 1.14 (1.01-1.28) for each night they do 
not experience peak sleep. They also found that women who worked the night 
shift at least once in the 10 years prior to breast cancer diagnosis were 
associated with an increased risk of breast cancer OR 1.6 (1.0-2.5) with a 
trend (p=0.02) for increasing risk with increasing years and with more hours 
per week of shift work. A problem inherent in all case-control studies is recall 
bias, however, the investigators attempted to manage the degree of recall 
bias by limiting subject recollection to ten years. An issue with limiting the 
recollection of shift work to ten years is that if LAN does cause cancer, it is 
unknown when these effects take shape. LAN may be related to cancer via 
long duration of exposure or exposure during a sensitive developmental time.
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Prospective cohort studies avoid the biases associated with case-control and 
population studies but they are expensive and time consuming. No cohort 
study has been initiated to specifically examine the role of LAN on breast 
cancer risk; however, some studies have subsequently examined the 
relationship between breast cancer and melatonin through nested case- 
control studies within their cohorts. The Nurses' Health Study (NHS), a 
prospective cohort study of almost 80,000 women, added a question about 
shift work in 1988 allowing shift work-related associations to be examined.
The NHS researchers examined the cohort answers from 1988-1998 to 
determine incidence of breast cancer and found a RR of 1.36 (1.04-1.78) 
adjusted for a variety of known risk factors in women who worked at least 
three night shifts per month for 30 years or more (Schernhammer et al. 2001). 
They also found that a longer duration of shift work was associated with an 
increased breast cancer risk (p = 0.02). This group repeated their analysis in a 
second cohort of nurses and found that women who worked more than 20 
years on rotating night shifts have an elevated risk of breast cancer compared 
with women who never worked rotating night shifts (Schernhammer et al. 
2006b). In contrast to the findings of NHS, the Electromagnetic Fields and 
Breast Cancer on Long Island Study Group found no associations with overall 
shift work and breast cancer, a lower risk of breast cancer associated with 
night shift work and an increased risk of breast cancer among women who 
‘frequently turned lights on at home during sleep hours' (O'Leary etal. 2006).
There are several reasons for the conflicting results among these studies.
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First, none of these studies were initiated to examine the effects of shift work, 
light at night, or melatonin on breast cancer risk. Therefore the psychometrics 
of the questions addressing shift-work in these studies may not have been 
appropriate. Despite the methodological differences between the studies of 
shift work and breast cancer, a meta-analysis of 13 studies found an 
aggregate risk of breast cancer among shift workers to be significantly 
elevated at 1.48. The authors suggest that some of the studies' results are 
confounded due to incomplete adjustment for known breast cancer risk 
factors (Megdal etal. 2005).
1.8.3 Epidemiological studies; circulating melatonin and sex hormones
The central idea of the “melatonin hypothesis” is that melatonin confers 
protection against breast cancer and that low levels of melatonin remove that 
protection. Studies of melatonin levels in women have been mixed and seem 
to be dependent on several factors. In 1987, Kauppila and colleagues of 
Finland hypothesised that circulating melatonin levels change in relation to the 
seasonal changes in photoperiod (Kauppila et al. 1987). They found 
circulating melatonin levels to be significantly higher with a longer nocturnal 
duration during the dark season compared to the light season. In addition, 
they found significantly decreased oestradiol and testosterone, with significant 
increases in the concentrations of SHBG in the dark compared to the light 
season. Nearly ten years later, the same group conducted a study of seasonal 
variation in pituitary function and found mean LH pulses to be significantly 
higher in the winter compared to the spring, but found no difference in FSH
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levels (Martikainen et al. 1996). These findings suggest that there might be 
seasonal or latitude differences in breast cancer incidence with lower risk in 
the winter and at higher latitudes, however, a study conducted to examine 
death due to breast cancer and incidence by latitude found the opposite result 
with lower risk among those living in Southern latitudes and better prognosis 
among women diagnosed in the summer (Porojnicu ef a/. 2007).
While melatonin levels may fluctuate with season and menstrual cycle, reports 
of melatonin levels in shift workers and breast cancer patients are conflicting. 
Skene and colleagues measured 24 h urinary aMT6s excretion in breast 
cancer patients compared to healthy controls (Skene et al. 1990). After 
adjusting for significant differences in age they found no significant differences 
between malignant groups and benign or control groups. A similar result was 
reported from the British Guernsey III study, which found no differences in 24 
h aMT6s secretion between pre or post-menopausal breast cancer cases and 
controls (Travis et al. 2004). In addition, they reported that melatonin was not 
significantly associated with breast cancer when comparing the highest 
category of concentration to the lowest category (OR = 0.99). A recent report 
also did not find any differences in melatonin measured in overnight urine 
collections in women with and without breast cancer (Carlson et al. 2007).
In contrast to these findings, the NHS measured aMT6s in a first morning void 
sample and found lower levels of aMT6s to be related to development of 
invasive breast cancers, BMI, older age and heavy smoking, whereas parity 
was significantly associated with higher aMT6s levels (Schernhammer et al.
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2006a, Schernhammer and Hankinson 2005). Methodological differences 
surrounding the collection of urine samples (24 h vs. first morning void) likely 
account for the different observations in melatonin levels. The NHS samples 
are likely confounded by the timing of collection in relation to the internal 
circadian phase of the shift workers being examined. For example, it is 
possible that the night shift workers were phase delayed due to working night 
shifts and therefore a first morning void collection would not be representative 
of 24 hour production. In addition, due to individual differences in adaptation 
to shift work it is impossible to estimate how shifted a given subject may have 
been at the time of collection.
Another recent study found similar results using a 12 h overnight urine 
collection in a prospective cohort of Italian women (Schernhammer et al.
2008). This study found that increased aMT6s levels were associated with a 
decreased risk of invasive breast cancer in post-menopausal women. All 
subjects in this study were instructed to keep only urine from 19:00 -  7:00. 
Interestingly, this study only found a significantly lower risk in women who 
developed invasive cancer, adjusted for testosterone levels and in non- 
smokers. Using a 12 h urine collection may be better than a first morning void 
collection, but this study did not control for shift work, season or morning and 
evening types, which suggests that these results may also be confounded.
A recent study attempted to compare aMT6s levels to sex hormones in a 
retrospective cohort study (Nagata et al. 2008). Subjects in this study 
provided a single blood sample at approximately 14:00 h and a first morning
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void urine sample. Subjects were asked to self-report history of shift work and 
habitual bed time. The study found significantly increased oestrone levels in 
women who reported a history of working night shifts, however, they found no 
associations between melatonin and any other hormone measured. It is 
difficult to interpret these results, because the researchers do not account for 
morningness or eveningness or recent shift work. Furthermore, the timing of 
the blood and urine collections do not seem comparable given the time of day 
differences in these collections.
In an attempt to directly measure sex hormone levels in relation to breast 
cancer, Verkasalo and colleagues examined a sample of subjects 
participating in the European Prospective Investigation into Cancer and 
Nutrition study (EPIC; Verkasalo et al. 2001). They found SHBG decreased 
with increasing BMI and increasing waist-hip ratio in both pre and post­
menopausal women. In this sample post-menopausal women had higher 
levels of oestradiol. They found that oestradiol decreases as physical activity 
increases and is higher in current smokers than in ex- and non-smokers. They 
also found that FSH levels decreased with increasing alcohol intake. Contrary 
to most findings, they found no associations between breast cancer and 
reproductive risk factors such as age at menarche, parity, age at menopause 
or oral contraceptive use. It is unclear why these results differ from other 
reports. These subjects were recruited at health food stores and it is possible 
that the women who comprised this cohort were different than the general 
population.
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1.8.4 Epidemiological studies: visually impaired
Several studies have shown that blind women have a reduced risk of breast 
cancer compared to the general population. As some totally blind people have 
melatonin rhythms that are unaffected by light, the theory suggests that the 
observed reduced risk is due to the preservation of the melatonin rhythm. In 
1998 Feytching published a report suggesting total blindness is protective 
against cancer in men and women (Feychting et al. 1998). In a historical 
population study of around 1500 NPL Swedes they reported a SIR of 0.69 
(0.59-0.82) and among those identified as severely visually impaired they 
report a risk of 0.95 (0.91 -1.00). When stratified for age, gender and cancer 
type, they did not observe significant decreases in rates of breast or prostate 
cancer, the two types of cancers thought to be most affected by pineal 
disruption.
In contrast to the Swedish study, a retrospective cohort study of visually 
impaired Finns found an increase in overall cancer rates among NPL men 
compared to the Finn population with a significant SIR of 2.2 (Pukkala et al.
1999). In follow-up studies, the same group found a dose-response 
relationship for protection against breast cancer in women by degree of 
blindness (Verkasalo etal. 1999, Pukkala etal. 2006). Total blindness was 
reported to be the most protective with an SIR of 0.47. Similar findings have 
been reported in the US, where Hahn found that blind women had a lower 
than expected incidence of breast cancer when compared to incidence of 
heart attack and stroke in a study of hospital medical records (Hahn 1991).
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Finally, a Norwegian group found similar, but non-significant results (Kliukiene 
ef a/. 2001). The conflicting results arising from these studies are likely due to
the historical nature of the cohorts. There is likely some misclassification of 
degree of LP due to the nature of the records and the lack of a precise 
method of documentation for blindness (e.g. the same level of blindness might 
be documented as “legally blind,” 20/200, or “ability to count fingers”).
1.8.5 Animal models of light and cancer
Numerous reports exist on the role of light exposure and cancer development 
in animal models. Several studies have been conducted to examine the effect 
of pinealectomy or constant light on breast tumour growth. One of the first 
studies on this topic found that pinealectomy increases tumour growth and 
supplemental melatonin administration following pinealectomy reduces 
tumour incidence (Tamarkin et al. 1981). In this study, the decrease in tumour 
incidence with melatonin dropped from 87% to 63%, which was still higher 
than the 27% incidence in tumours observed among intact rats. Another 
series of studies observed that constant light conferred similar results (Kothari 
et al. 1982, Shah et al. 1984). This group found that exposure to constant light 
and pinealectomy significantly increased breast cancer development and 
melatonin administration reversed this effect. Interestingly, melatonin 
administration was more potent in rats exposed to the constant light condition. 
This group also found that pinealectomised rats kept in a 10:14 LD cycle had 
lower cancer incidence and longer cancer latency compared to 
pinealectomised rats kept in LL (Kothari et al. 1984). Later reports suggest
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that the pineal accentuates the tumour suppressive effects of melatonin 
during cancer initiation, while melatonin administration alone can significantly 
slow growth during the cancer promotion phase (Subramanian and Kothari 
1991).
These studies were replicated and confirmed in later reports. One study found 
that rats administered 9,10-dimethyl-1,2-benzanthracene (DMBA) at age day 
26 and exposed to constant light have accelerated tumour growth compared 
to animals exposed to DMBA and kept in an LD cycle (Anderson et al. 2000). 
Similarly, another report demonstrated that DMBA-induced tumours in rats 
exposed to constant light had higher rates of tumour growth and higher 
concentrations of oestradiol compared to animals kept in a LD cycle (Cos et 
al. 2006). Another report suggests that melatonin treatment of 10 mg/kg for 15 
days prior to DMBA administration may have prophylactic effects in 
preventing the occurrence of future breast cancer in rats (Lenoir et al. 2005).
In support of the relationship between continuous light and/or circadian 
desynchrony and cancer, another report found an increase in the size of 
Erlich tumours in rats in LL compared to rats held in a 14:10 LD cycle (Bartsch 
and Bartsch 2006).
Finally, a conflicting report suggests that the effect of light on cancer 
development may be dependent on the type of cancer acquired. Stan berry 
and colleagues conducted a study comparing pinealectomy to two LD 
regimens and injections of melatonin and found that pinealectomy slowed 
progression of melanoma growth in hamsters and melatonin injections
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accelerated melanoma growth (Stanberry et al. 1983).
The common assumption with the studies described above, is that the 
differences in cancer risk are due to melatonin, however, it may be that these 
studies were actually simulating circadian desynchrony. A problem inherent in 
all of the studies described above is the lack of information on eye closures 
during LL exposures. Many of the studies describe the LL condition as a 
functional pinealectomy,’ however, in all cases animals’ eyelids were kept 
intact and it is unclear whether burrowing occurred. This confound may 
account for the differences observed in animals with pinealectomy compared 
to animals in LL. It seems plausible that melatonin administration in animals 
kept in LL may have facilitated circadian entrainment, while pinealectomised 
animals would have potentially lost crucial feedback to the SCN and 
peripheral clocks. It may be that these studies are actually comparing 
circadian syncronisation to circadian desynchronisation
1.8.6 Animal models of circadian and peripheral clock desynchrony and 
cancer
It has been hypothesised that the observed increases in breast cancer risk 
among shift workers are due to circadian desynchrony as opposed to a direct 
effect of reduced melatonin by LAN. A recent report found that female rats 
with DMBA-induced mammary adenocarcinoma exposed to LAN have 
significantly higher rates of tumour growth and lower survival than controls 
(Cos et al. 2006). This group also found large differences when rats were
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exposed to dim light at night, including decreased aMT6s and increased 
serum oestradiol. Another study that examined rats with fibrosarcoma or 
Erlich tumours held in a short or long photoperiod found that timed melatonin 
injections produced mixed results, in some cases accelerating tumour growth 
and in other cases slowing tumour growth (Bartsch and Bartsch 2006).
Jet-lag protocols have also been used as models to examine circadian 
desynchrony and cancer development. A study using SCN ablation and a jet- 
lag protocol found that both conditions resulted in accelerated malignant 
growth in Glasgow osteosarcoma and pancreatic adenocarcinoma (Filipski et 
al. 2006). Another report found that older mice (uninfected with any cancer 
promoting agent) have greatly impaired survival on rapidly advancing (47% 
survival) and delaying (68% survival) light dark cycle shifts as compared to 
young mice (Davidson et al. 2006a). This observation led to the investigation 
of peripheral oscillator contribution to cancer development. The same group 
examined in vitro circadian oscillation of hepatocellular carcinoma compared 
to adjacent normal tissue in rats on day-restricted, night restricted and ad 
libitum feeding schedules and found that cancerous and adjacent normal 
tissue phase shift at the same rate, but that the phase relationship of the shift 
relative to the SCN rhythm was altered, suggesting that the phase change of 
peripheral oscillators in some tissues relative to the SCN may lead to cancer 
acceleration (Davidson et al. 2006b).
1.8.7 Animal models of melatonin and cancer
1-92
A collection of in vivo and in vitro studies in animals and human cancer 
patients have also been conducted to attempt to elucidate the potential action 
of melatonin on cancer cell proliferation. These experimental studies have 
suggested several mechanisms of action of melatonin on breast cancer.
Animal studies have supported a role for melatonin in modification of tumour 
growth. It has been hypothesised that the protection of melatonin against 
breast cancer tumours works through the inhibition of 17 p-oestradiol at the 
cellular level of the tumour or through competition for oestrogen receptors 
(Cos and Blask 1994). Some animal studies using hepatic tumours have 
demonstrated that melatonin may protect from cancer proliferation through a 
mechanism independent of oestradiol action, through suppression of cAMP 
levels, which in turn suppress linoleic acid uptake to hinder cancer cell 
proliferation (Blask et ai. 2003). Another hypothesis suggests that melatonin 
may interfere with fatty acid release from fat pads and suppress fatty acid 
uptake by tumour cells (Blask et ai. 1999, Sauer et al. 2001). Further evidence 
for a role of melatonin in tumour suppression comes from studies in rats with 
either MCF-7 or NMU breast tumours exposed to constant light (Blask et al. 
2002). An animal study implicating light-induced low levels of melatonin in 
tumour progression showed that human breast tumour-bearing nude rats 
experienced rapid tumour growth when injected with human blood drawn from 
either the daytime or during the night immediately following light exposure 
compared to when injected with blood drawn during the darkness at night 
(Blask et al. 2005). A study conducted at the National Institute of Health found 
that melatonin administration through feeding resulted in mice with the c-neu
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oncogene developing significantly fewer tumours (Rao et al. 2000). Together, 
these studies suggest that nightly suppression of melatonin by light may 
promote tumour growth, though it is still not clear whether this mechanism is 
due to a relationship with oestrogen.
1.8.8 Other theories involving an interaction between light at night, melatonin, 
circadian desynchrony and breast cancer
There are many other theories on how light at night may be related to breast 
cancer risk. Many of these theories have developed from the results of one or 
two studies and further research is needed to determine how each of these 
theories may contribute to either protection or acceleration of breast cancer.
One study supporting a protective effect of melatonin on breast cancer risk 
found that MCF-7 cells in vitro pre-treated with melatonin are not easily able 
to bind oestradiol to the ERa receptor (Hill et al. 2000). Similarly, 
overexpression of MT1 receptors in in vitro MCF-7 models of cancer reduces 
aromatase activity and thereby may reduce cancer proliferation (Gonzalez et 
8/. 2007).
Another theory suggests that melatonin interacts with oncogenes. Melatonin 
has been shown to down regulate cyclin D1 expression in microarray studies 
of oestrogen treated MCF-7 cells, suggesting it has a direct effect in 
suppressing the activity of this oncogene (Cini et al. 2005).
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other research implicates melatonin as a free radical scavenger and 
antioxidant, and some research has suggested that it is this mechanism of 
action that leads to a protection against cancer by melatonin (Hardeland et al. 
1993, Montilla et al. 1997), however, no such mechanism has been 
demonstrated in breast cancer.
1.8.9 Circadian clock genes and cancer
Human circadian clock genes have been associated with malignancy in a 
variety of cancers. Zhu and colleagues reported that the Per3 VNTR genotype 
(Archer et al. 2003; heterozygous and homozygous 5-repeat allele) is 
associated with breast cancer using a case control study (Zhu et al. 2005). 
This group followed up these results and reported that the Ala394Thr 
genotype of the circadian gene NPAS2 is also associated with breast cancer 
(Zhuef a/. 2007).
Further evidence for a role of the circadian clock genes in breast cancer 
comes from several studies that compared cancerous tissue to normal tissue 
and found differences in the expression of circadian genes. One study 
compared cancerous breast tissue to adjacent non-cancerous breast tissue 
and found that 95% of breast tumours had absent or unregulated expression 
of the circadian genes Perl and Per2 (Chen et al. 2005). Another group found 
significantly reduced levels oi Perl gene expression in sporadic tumours 
compared to normal tissue (Winter et al. 2007). In the same report, this group 
also found levels of gene expression of Perl and Per2 to be significantly
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reduced in both familial and sporadic breast cancers compared normal breast 
tissue. In addition, this group found lower Perl mRNA expression levels to be 
associated with ER- breast cancer, suggesting an interaction between 
circadian and breast cancer genes. Gery and colleagues found that binding of 
Per2 protein degrades ERa, inhibits cell growth and induces apoptosis, while 
suppression of Per2 stabilises ERa in breast cancer (Gery et al. 2007b). Other 
reports have associated low levels of Perl protein with lung cancer (Gery et 
al. 2007a), colon cancer (Krugluger et al. 2007) and endometrial cancer (Yeh 
efa/. 2005).
Overexpression of the mPER2 gene in mice has been shown to induce 
apoptosis in lung cancer (Hua et al. 2006) and microarray studies have 
demonstrated that the majority of circadian clock genes are under expressed 
in the blood of leukaemia patients compared to healthy patients (Yang et al. 
2006).
1.8.10 Melatonin as cancer therapy
Despite the unclear relationship between endogenous melatonin production 
and breast cancer, some researchers have initiated clinical trials 
administering melatonin as adjuvant cancer therapy. Melatonin has been 
administered to cancer patients with modest success (Lissoni et al. 1991,
Shiu et al. 2003). One of these trials suggests that melatonin alone may not 
act on cancer, but instead a panel of pineal indoles may slow tumour growth 
when tumours of various sites are otherwise untreatable (Lissoni et a/. 2003).
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The results of the clinical trials must be interpreted with caution, however, 
because melatonin administration commenced following the failure of other 
types of treatment. Further it is still not clear whether exogenous melatonin
administration mimics the effects of endogenous melatonin
1.9 Conclusion
Although the animal and epidemiological evidence in night shift workers and 
blind people suggests that endogenous melatonin may play a role in breast 
cancer risk, there are still many unanswered questions. As all of the 
epidemiological studies in the blind have been record-linkage studies, it is 
unclear whether melatonin is the actual cause of the reported reduced risk, or 
whether some other factor contributes to the findings, such as circadian 
desynchrony, age, stress etc. For example, when compared to sighted 
women, reproductive risk factors such as age of menarche have been 
reported to be both earlier and unchanged in the blind. However, parity, 
menopause and medical procedures such as hysterectomy have never been 
clearly assessed as they relate to breast cancer risk in the blind (Magee et al. 
1970, Thomas and Pizzarello 1967, Zacharias and Wurtman 1964). It is also 
unclear how other known lifestyle factors such as body mass index (BMI), 
exercise, alcohol use and socio-economic status relate to breast cancer risk in 
blind women. Further, while some studies have shown a dose relationship 
between degree of light perception in the blind and breast cancer risk, it is not 
clear how degree of visual or circadian photoreception or cause of blindness 
contributes to a women’s risk. Specifically, it is unclear how some eye
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conditions may result in the loss of the melanopsin-containing RGCs that
transmit the primary light signal to the circadian pacemaker or how degree of 
circadian photoreception may alter breast cancer risk. Finally none of the prior 
studies examining breast cancer risk among the blind have measured 
melatonin or oestrogen levels. The melatonin hypothesis suggests that blind 
women would have higher circulating melatonin levels, but this has not been 
demonstrated in the limited number of studies of circadian rhythms in the blind 
(Klerman etal. 2001, Lockley et al. 1997).
The aims of the present cross-sectional epidemiological study are to test the 
hypothesis that blind women with NPL experience a lower risk of breast 
cancer compared to blind women with LP when adjusted for demographic, 
lifestyle and reproductive characteristics. A further aim of this thesis is to test 
the hypotheses that the reproductive outcomes menarche and menopause 
are timed differently in blind women with NPL compared to blind women with 
LP. The aims of the field study (conducted in a subset of the women who 
participated in the survey) are to test the hypotheses that women with NPL 
produce significantly more melatonin (as measured in aMT6s) than women 
with LP and that women with NPL produce less oestrogen (as measured in 
e lg) than women with LP. A final aim of the field study is to develop an 
objective measure of circadian rhythm disorders in women with varying 
degrees and aetiology of blindness and further, to produce a model for 
determining circadian rhythm type using questionnaire-based methods.
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CHAPTER 2
GENERAL METHODOLOGY
CHAPTER 2 -  GENERAL METHODOLOGY
2.1 Survey
Ethical permission for the study was granted from the Institutional Review 
Board at Partners Healthcare (2003-P-000263) and the United States 
Department of Defense Human Subjects Research Review Board (HSRRB 
#A-12744).
2.1.1 Survey Formats
After obtaining informed consent, each subject was provided with the survey 
in the format of their choice. In order to ensure that the survey was not biased 
due to a given subject’s inability to respond in a particular format, the survey 
was translated into multiple formats. Available survey formats included e-mail 
(n = 77), compact disc (n = 2), audio tape (n = 20), large print (n = 334),
Braille n = 103), in person (n = 4), or verbally over the telephone (n = 422). In 
addition, the survey was available on a HIPAA compliant website where 
subjects with computer skills could self-ad minister the survey using a screen 
reader or enlarged font (n = 430). The website was compliant with the 1998 
US Rehabilitation Act (Section 508-compliant) and extensively beta-tested 
with a computer users group of blind people to ensure its functionality and 
ease of use.
2.1.2 Survey questions
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The complete survey is presented in Appendix A. In brief, the survey
consisted of 120 questions and included demographic information, personal 
and parental medical histories, detailed information on eye conditions, history 
of blindness and visual acuity, reproductive history, medication use, the 
Harvard National Depression Screening scale (HANDS; Baer etal. 2000), the 
Pittsburgh Sleep Quality Index (PSQI; Buysse et al. 1989), and additional 
questions about sleep and other lifestyle factors of interest.
2.2 Study staff
There was a substantial amount of time involved in data collection for the 
survey. Administration of each survey took 45 minutes to two hours to 
complete over the phone. In addition, any survey not completed over the 
phone or via the website needed to be mailed to each subject and the data 
entered into the survey database. Subjects also needed to be tracked and 
reminded to complete the survey if they had not returned paper or Braille 
versions in a reasonable amount of time. As such, a large staff was required 
to answer phones and distribute surveys. In order to achieve this, eight 
volunteer undergraduate students were recruited to work on the study over a 
10-week period each summer in the years 2005 and 2006. In addition, 19 
undergraduate students were recruited to assist with the study part-time 
during the university semester. All students were fully trained on the goals of 
the study, study screening and interviewing skills. All students shadowed the 
project leader (Erin Evans) prior to working with study subjects and were
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regularly audited, both in their interviewing procedures and in their data entry 
tasks.
2.3 Study eligibility and subject recruitment
There were three basic criteria for study eligibility for the survey. Each person 
was screened for female gender, adult age (over 18) and a visual acuity of 
legally blind (20/200 on the Snellen Scale) or less. There were no further 
restrictions placed on study enrolment.
Subjects were recruited from a variety of sources throughout the course of the 
22 month study. The number of subjects who completed the survey each 
month are presented in Figure 2.1. At the launch of the study in April 2005, 
partnerships were established with the American Council of the Blind (ACB) 
and the National Federation of the Blind (NFB), who each published study 
advertising and articles detailing study procedures, which were distributed to 
their approximately 84,000 female and male members. Each advertisement 
contained a free phone number, e-mail address and web address that 
subjects could contact for more information and to complete the study. For 
ethical reasons, subjects were required to contact the study staff directly. 
Study staff were not given individual contact information for any member list. 
Recruiting efforts via these sources was lower than expected, yielding 
approximately 200 subjects who completed the survey.
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Figure 2.1 Number of subjects who completed the survey during each month 
of data collection (April 2005 -  February 2007).
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In order to boost survey participation, numerous additional recruiting avenues 
were pursued. Merchant booths were set up at the ACB and NFB national 
conventions in July of 2005, in an attempt to recruit subjects in-person. Again, 
this recruiting effort yielded lower than expected participation (n ~ 150). 
Additional recruitment efforts were made through approximately 200 
advertisements placed on radio reading services, magazines for the blind, 
newsletters targeting blind consumers, radio interviews on programs targeting 
blind women, ‘list servs’, postings at guide dog schools and through postings 
at state rehabilitation centers. These efforts yielded modest results, with no 
single venue producing more than 50 subjects.
The most successful recruitment strategy began with a partnership with the 
Perkins Braille and Talking Book Library in Watertown Massachusetts. The 
Perkins library agreed to send personalized letters to all female members 
from the head of the library on behalf of the study investigators. This effort 
was initiated in March of 2006 and was distributed in 2000 letter batches over 
the course of four months in order to allow staff to manage the response to 
the mailings. Following the success with this approach, the same process was 
initiated with the ACB in July of 2006 and the Canadian National Institute for 
the Blind (CNIB) in December of 2006 (Figure 2.1). Approximately 25,000 
letters were sent through these initiatives yielding a 3% participation rate.
2.4 Survey database
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All data were ultimately entered into a single database. Research assistants 
entered survey data during telephone interviews or following receipt of written 
or audio surveys. Braille surveys were transcribed by a third party and entered 
into the database upon transcription. Survey entries were audited for accuracy 
on a weekly basis. All data entry was manually checked and corrected on a 
weekly basis and again at the completion of the study. When necessary, 
subjects were re-contacted and asked to clarify responses. Data comprising 
the present analysis were exported on March 21, 2007.
Test entries, duplicate subject survey entries, data from subjects who 
completed <30% of the survey, data from participants outside North America 
and data from male participants were removed from the analysis. Data was 
sorted and answers to open ended survey questions were coded to correct 
misspellings and ensure consistency between responses. For example, all 
subjects reporting retrolental fibroplasia' as the primary eye condition were 
recoded to the ‘retinopathy of prematurity’ group (they are the same eye 
condition). The final data set included 1392 participants.
The survey database was coded, so that each categorical response was 
represented numerically. A data dictionary was created in order to determine 
which numerical values corresponded to which survey answers. The final 
dataset was not altered in any way, however, additional variables were 
created in subsequent analyses and were added to the data dictionary (e.g. 
BMI was created using height and weight information).
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2.5 Survey analysis
Survey analysis is described in detail in the relevant methods sections for 
each chapter. SAS software version 9.1 (Copyright (c) 2002-2003 by SAS 
Institute Inc., Cary, NC, USA) was used for all survey analyses.
2.6 Field study
2.6.1 Field study recruitment
Subjects were recruited for the field study among those who completed the 
survey. Subjects were provided with a description of the field study and asked 
if they would be interested in participating. Eligibility for the field study was 
more restrictive than for the survey and interested subjects were asked a 
series of questions to determine their eligibility. Subjects were excluded from 
the field study if they were taking any medications known to interfere with 
melatonin (e.g. melatonin supplements, beta-blockers, anti-depressants etc.), 
oestrogen (e.g. hormonal contraception, hormone replacement therapy etc.) 
or sleep (e.g. sleep medications, barbiturates etc.). They were also excluded 
or deferred (to begin the study after a three month wash out) if they had taken 
any of these medications within three months of screening. If a woman was 
taking melatonin supplements and still wished to participate, she was asked to 
refrain from taking supplements for two weeks prior to study and throughout 
the duration of the study. All medications and supplements regularly 
consumed were documented during the screening process for each field
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study subject. Subjects were asked to inform study staff of any changes in 
their medications during the study, but were not asked to alter any lifestyle 
habits throughout the field study.
2.6.2 Field study procedures
2.6.2.1 Sleep diary and actigraphy
The sleep diary questions are presented in Appendix B. Subjects were asked 
to answer each question in the morning of each day of the study. Subjects 
were scheduled to begin the study on a specific start day and a specific end 
day lasting eight weeks. Some subjects did not have eight weeks available for 
study and so in some cases the duration of collection was shortened to as few 
as four weeks. Additionally, some subjects completed additional days of sleep 
diaries, because they had to reschedule their urine collections and as a result 
they were asked to keep their sleep diaries until the urine collections were 
finished. A representative raster plot compiled from an eight-week sleep diary 
is presented in Figure 2.2.
At the point of screening, subjects were asked for their preferred method of 
communication and were provided with field study instructions in Braille, large 
print, regular print, audiotape or e-mail. Each packet of field study information 
was sent to subjects a few days in advance of their scheduled start day. After 
the subject was able to review the sleep diary and instructions, they were 
contacted and also provided with verbal instructions (with the exception of one
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Figure 2.2 shows a representative double-plotted raster plot derived from 
sleep diary data for one subject (25BC108) who completed all days of the 
study. Filled bars represent sleep (nightly and naps), open bars represent 
time in bed awake.
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subject who was blind and deaf; this subject received all communication via e-
mail and in Braille). Subjects were asked to return sleep diaries weekly at 
which point they were reviewed and subjects were provided with additional 
instruction if necessary. Some subjects were unable to return their sleep 
diaries weekly and instead provided them at the end of the study. Five of 
these subjects claimed that they lost their sleep diary information and three 
subjects returned information that was not in an appropriate format (e.g. 
subjects did not answer questions and/or include necessary information for 
analysis like dates) and therefore these data could not be included in the 
analyses.
There were not enough activity monitors available for all subjects to wear 
monitors throughout all weeks of the study. Instead activity monitors were 
sent to subjects when available. An attempt was made to collect at least four 
weeks of activity monitor data from each subject. Two types of activity 
monitors were used; Motionloggers (Ambulatory Monitoring Inc., Ardsley NY, 
USA) and Actiwatches (Mini-mitter Corp, Bend OR, USA). In order to collect 
four consecutive weeks of data, monitors were set to collect in two minute 
epochs.
2.G.2.2 Urine sample collection
Subjects were asked to spend two or three 48 h periods collecting urine 
samples during the weeks while they recorded their sleep. The first 88 
subjects were only asked to complete two sets of urine samples; however.
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preliminary analyses revealed some difficulty in determining circadian rhythm 
type through visual inspection of these data. Therefore, the final 42 subjects 
were asked to collect three 48 h periods of urine samples. The urine sample 
blocks were scheduled in advance and were spaced two to four weeks apart 
and following two to four weeks of sleep diary records.
The subjects were instructed to collect all urine over the course of 48 hours in 
four-hourly bins throughout the waking period and eight-hourly bins 
throughout the sleep period (Figure 2.3). Subjects were instructed to collect all 
urine starting after the first morning void on the first day of collection. They 
were instructed to weigh each sample using speaking scales (Cobolt Norfolk, 
UK) at the end of each sample period and were instructed to pipette a small 
sample from each collection into a 7mL tube and immediately freeze each 
sample. Subjects were asked to record the times of each void, the start and 
end time for each four or eight-hour sample period and the total urine volume 
for each sample period. Subjects were provided with this information in their 
preferred format and also contacted by phone prior to starting sample 
collection to go through instructions and the urine kit. Subjects were also 
provided with a 24 h pager number to contact in the event of any difficulties 
with urine sampling. Subjects were given instructions about how to package 
urine samples for return and all samples were returned using an overnight 
courier.
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2.6.3 Field study analysis
2.6.3.1 Sleep diary data
The sleep diary data yielded the following variables for analysis: sleep 
latency, sleep onset, sleep offset, time-in-bed, number and duration of 
awakenings, total sleep duration (onset plus latency to offset minus 
awakenings), number and duration of naps and subjective sleep quality. 
Means for each of these variables were calculated by subject and by group 
and sub-groups (Chapter 6).
Sleep diary data were converted to cumulative time for all variables and were 
plotted in double-plot raster format using the program Double32 (courtesy of 
Mr. Joseph M. Ronda and the Division of Sleep Medicine, Brigham and 
Women’s Hospital) to create an individual plot for each subject.
2.6.3.2 Urine samples -  assays
The urinary metabolite of melatonin, aMT6s was assessed by Stockgrand 
Ltd., University of Surrey (Guildford, UK) and was measured by 
radioimmunoassay (RIA) in 120 subjects (collected during 250 48h collection 
periods) using the method described by Aldhous and Arendt (1988). All 
samples from an individual were measured in a single assay. The inter-assay 
coefficients of variation for aMT6s were 11.6% for 4.4 ± 0.5 ng/m l (n = 62),
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11.0% for 13.5 ± 1.5 ng/mL (n = 62) and 9.5% for 25.5 ±2.4 ng/mL (n = 62; 
provided by Dr. Benita Middleton).
The oestrone metabolite oestrone-3-glucuronide (e1g) was also assayed by 
Stockgrand Ltd., University of Surrey (Guildford, UK) and was measured in 
920 samples provided by 46 subjects using an enzyme-linked immunosorbent 
assay (ELISA) kit purchased from Immunometrics Ltd. (London, UK). The 
inter-assay coefficients of variation were 23.8% for 49.9 ±11.9 nmol/L and 
15.4% for 212.4 ± 32.7 nmol/L (n = 39; provided by Dr. Benita Middleton).
2.6.3.3 Urine samples -  analysis
Assay results for aMT6s were returned in ng/mL and were converted to ng/hr 
by the following calculation:
ng/h = (ng/mL x urine weight (g)) / hours in collection period 
These data were also converted to pg/h for plotting and mean pg/24 h was 
also calculated.
The ng/h calculations were subjected to cosinor analysis (software provided 
by Dr. D.S. Minors, University of Manchester, UK) for the 48 h collection 
periods. This analysis provided the acrophase (peak of the rhythm) and the 
probability of significance of the sine curve fit. In the event that a urine 
collection block was missing data, the longest possible series of data was 
used in the analysis. If weight information was missing for any sample, it was
2-14
estimated using the mean values from the same windows of time on other 
collection days (<5%).
In addition to cosine fitting, the time of the mid-range crossing of the aMT6s 
peak was calculated for all subjects. The mid-range crossing of the aMT6s 
rhythm was determined by calculating the times when the rising and declining 
phases of the aMT6s rhythm reached half the peak value of the collection 
period (ng/h). The midpoint was calculated as the time between the rising and 
declining melatonin phases. Details of the comparisons between these 
methods are described in Section 6.2.4.
Assay results for e l g were returned in nmol/L and were converted to ng/mL 
for comparability with the aMT6s values. The ng/mL value was converted to 
ng/h using the same method as for aMT6s and analysed using cosinor 
analysis as described above.
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CHAPTER 3
SUBJECT DETAILS
CHAPTER 3 -  SUBJECT DETAILS
This chapter describes the general characteristics of the participants in the 
survey cohort and the field study cohort. Descriptions of specific subgroups 
and associations are described in subsequent chapters.
3.1 General details -  survey cohort
The final survey cohort consisted of 1392 blind women from the United States 
and Canada. The geographic distribution of subjects is presented in Figure 
3.1. There were 968 subjects (70%) who reported having some degree of IP  
and 417 subjects (30%) who reported having NPL in both eyes. Seven 
subjects did not report whether or not they had light perception and were 
excluded in several analyses as indicated in each relevant chapter. The 
subjects were recruited for the study through a variety of sources as 
described in Section 2.3. The cohort was predominantly white (cohort = 91%; 
NPL = 91%; LP = 91%), with 4% of subjects reporting being black or African 
American (NPL = 5%; LP = 4%) and each other race/ethnic category 
representing less than 1% of the total. Table 3.2 shows basic demographic 
information for the entire cohort and for those with and without light 
perception. NPL subjects were significantly younger (Student’s t-test p < 
0.0001) and reported an earlier loss of vision compared to LP subjects (p < 
0.0001). The height and BMI for the survey cohort was similar to the general 
US population averages for adult women (Table 3.2; US average height mean 
= 64.0 inches, BMI mean = 28.2 kg/m^; Ogden et al. 2004). NPL subjects also
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had a slightly, significantly higher BMI compared to LP subjects (p = 0.01) due 
to decreased height (p < 0.001). NPL subjects were also less likely to have 
ever smoked (chi-square test p <0.0001). Finally, NPL subjects had 
significantly fewer full term pregnancies than LP women (Student’s t-test p = 
0.003). Other baseline characteristics were similar between subjects.
3.2 Vision loss -  survey cohort
There were a wide range of eye conditions reported as the primary cause of 
blindness among survey subjects. All information on visual acuity and 
aetiology was self-reported. A list of the major eye conditions reported in the 
survey are presented in Table 3.2. The most common eye condition reported 
among all subjects was retinopathy of prematurity (17%), followed by 
unknown or unclassifiable eye conditions (13%) and retinitis pigmentosa 
(10%). The unclassifiable group includes many subjects who reported having 
multiple eye conditions, but were unable to determine which eye condition 
was responsible for vision loss and in some cases subjects in this category 
were unable to report which eye was afflicted with which disorder. Eye 
conditions affecting the lens and iris were almost always associated with a 
report of having LP (e.g. anterior segment disease), while absence of the eye 
was always associated with NPL (e.g. bilateral enucleation and 
anophthalmia). POP was not specific to LP or NPL conditions, though 
subjects with ROP represented a larger proportion of the NPL cohort (29%) 
compared to the LP cohort (12%).
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Cohort 
n (% total)
2 (0 .1)
1 (0 .1)
j ] M r
61 (4.4)
"81Ô.6)"
23(1.7)
7 5  (5 j )  
90 (6.5)
22 (1.6) 
A io Æ
48 (3.5)
Table 3.1 Eye diseases reported as primary eye conditions causing blindness.
Disease 
characteristics/area
Primary eye condition______________ affected______
Visual cortex disease___________  brain
visual transmission to
Amblyopia________ _______  brain impaired
Endophthalmitis___________  interior eyeball
Aniridia__________________  absent iris
cornea, iris, ciliary
Anterior segment disease   body, lens
Coloboma________________  hole/cleft in lens, iris
iris or choroid plexus
Uveitis____________________ sometimes optic nerve
Glaucoma________________  optic nerve
Optic atrophy________________________ nerve
loss of retinal
Albinism__________________  pigmentation
Stickfer's syndrome_________  retinal holes
Macular degeneration^ _________ retinal macula
vessel pressure under 
Wet macular degeneration /etina] macula
dried out retinal
Dry macular degeneration   macula
Diabetic retinopathy____________  retina
Retinopathy of prematurity  retina
Retinal detachrnent___________  retina
Retinitis pigmentosa_________  rods, cones, retina
retina, photoreceptor 
Leber’s congenital amaurosis cells
Other retinal dystrophies  retina
Retinal disease -  mise  retina
Retinoblastoma________________ retina (cancer)
congenital absence of
Anophthalmia_________________ eye
congenital malformed
Microphthalmia____________  small eyes
Congenital defects -  mise variable
Brain tumour__________________ variable
Ocular trauma variable
Enucleation of any cause   . : ____
LP 
n (% LP)
NPL 
n (% NPL)
2_(P^)
1 (0 .1)
A ( P 6 ) . 
60 (6.2) 
sio.sy
13(1.3)
5 f ^ 3 )  
67 (6.9)
61 (4.4)
62 (4.5)
236i17^P)
144(10.3) 
35 (2.5)
30 (2.2)
23 0 ^  
5 (0.4)
5 (0.4)
22 (2.3)
^ T ( 0 3 I"
48 (^ 0  
61 (6.3)
61(6.3)
"27(2^8)" 
116(1^0) 
10 ( 1 .0 ) 
125 (12.9)
27 (2.8)
30(37T)
2 2 { i3 )
2 (0 .2)
1 (0 .2 ) 
1 (0 .2 )
10(2.4)
24 (5.8) 
23(5,5)
1 (0 .2 )
7(1.7) 
119(28.5) 
8(1.9) 
19 (4,6)
8(1.9)
Unknown/unclassifiable variable
2 (0,5) 
4(1.0)
18(1.3) 7(0.7) 11(2.6)
7 3 ^ ^ 3 3  24 (275) '  11 (2 .6)
20(1.4)____ 14(1.5) 6(1.4)
25(1.8) 11(11) 13(3.1)
123 (8 8^) :  '  123 (29.3)
184(13.2) 149(15.4) 34(8.2)
Seven subjects did not report their level of light perception and are not included in the 
stratified counts.
7ota l includes macular degeneration when subtype (wet or dry) was unknown or 
unspecified.
LP = light perception; NPL = no perception of light
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The majority of subjects with light perception reported having vision good 
enough to see the top letter on the vision chart (n = 445, 46%), with other LP 
categories containing much fewer subjects (counting fingers, n = 198, 20%; 
shadows and hand movement, n = 155, 16%; light perception only, n = 160, 
17%) compared to the 417 subjects who reported having NPL (Figure 3.2).
3.3 Lifestyle characteristics -  survey cohort
3.3.1 Living arrangements, marital status, social activity
A high proportion of study participants reported being currently married (38%), 
with 25% reported single status, 16% reported being widowed and 15% 
reported being either divorced or separated and 6% reported living with a 
partner. The marital status of women stratified by light perception is shown in 
Figure 3.3. The majority of subjects reported living with a spouse, partner or 
family (56%), however, more than a third of the entire cohort reported living 
alone (38%). The distribution of living arrangements for subjects with and 
without light perception are presented in Figure 3.4. Among all subjects, 24% 
reported owning a guide dog and this was significantly more common among 
subjects with NPL (34%) compared to subjects with LP (19%; chi-square test
p< 0.0001).
The majority of subjects reported being frequently engaged in social activities 
(83%) with no differences reported between NPL and LP subjects (83% and 
83%, respectively). Among all subjects 50% reported ‘sometimes’ feeling
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Vision
chart
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Count Hand LP
fingers movement only
198 155 160
NPL
417
Figure 3.2 Number of subjects by degree of visual impairment among the 
entire cohort. Note: n = 10 subjects with LP who did not answer the question 
about level of vision.
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Figure 3.3 Marital status of subjects NPL (black bars) and LP (gray bars) 
subjects expressed as a percentage of each group among the entire cohort.
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% of group 
(NPL or LP)
30  -
20
10 -
h L MM III
Alone With spouse With other With Other 
partner family roommates
Figure 3.4 Living arrangements of NPL (black bars) and LP (gray bars) 
subjects expressed as a percentage of each group among the entire cohort.
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% of group 
(NPL or LP)
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I
K-8 Some HS Technical Some College Post-college 
HS graduate school college graduate degree
Figure 3.5 Educational achievement of NPL (black bars) and LP (gray bars) 
subjects expressed as a percentage of each group among the entire cohort. 
K-8 = primary-middle school, HS = high school.
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Figure 3.6 Employment status for NPL (black bars) and LP (gray bars) 
subjects expressed as a percentage of each group among the entire cohort.
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lonely, with 52% of LP subjects and 44% of NPL subjects reporting 
sometimes feeling lonely. Eight percent of all subjects reported not having 
enough friends and this was the same for those with NPL and LP.
3.3.2 Education, employment and income
The cohort was highly educated with 56% of all subjects reporting attainment 
of a college degree or higher with a significantly higher proportion of NPL 
subjects reporting this outcome (NPL = 61%; LP = 54%; chi-square test p = 
0.02). The distribution of educational achievement for subjects stratified by 
LP/NPL status is presented in Figure 3.5.
Approximately a third of the cohort reported being employed (n = 483) and 
another third reported being retired (n = 458), while 14% reported being 
unemployed, 6% reported being students and 10% reported being full-time 
homemakers. The distribution of employment status for subjects with and 
without light perception is presented in Figure 3.6. A greater percentage of 
subjects with NPL reported being currently employed and a greater 
percentage of subjects with LP reported being retired (chi-square test p = 
0.004). Only 5% of the entire cohort reported current night shift work (NPL = 
6%; LP = 4%; chi-square test p = 0.39), while 34% of subjects reported 
working night shifts in the past (NPL = 26%; LP = 37%; chi-square test p = 
0.0001). Annual household income was similar among subjects with LP and 
NPL (Figure 3.7).
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Less than $20,000 
$20,000-$30,000  
$30,000-$50,000  
$50,000-$75,000  
$75,000-$100,000 
More than $100,000
Figure 3.7 Annual household income among NPL (A) and LP (B) subjects in 
the entire cohort.
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3.3.3 Diet, exercise, smoking and alcohol
The majority of subjects reported having a predominantly Northern European 
diet (cohort = 64%; NPL = 66%; LP = 62%), with 17% reporting a
Mediterranean diet ( NPL = 17%; LP = 17%), 11% reporting being vegetarian 
or vegan (NPL = 8%; LP = 12%) and 9% having an Eastern diet (NPL = 9%; 
LP = 10%). Most subjects believed that they ate average size portions (cohort 
= 67%; NPL = 68%; LP = 66%), compared to heavy or light portions.
Table 3.2 shows hours of exercise per week, number of caffeinated 
beverages consumed per day and number of alcoholic drinks consumed per 
week among all subjects and stratified by LP status. None of these outcomes 
were significantly different between subjects with and without light perception.
3.3.4 Reproductive outcomes
Reproductive outcomes are described in detail in Chapter 4.
3.3.5 Prevalence of major medical conditions
Table 3.3 shows the reported prevalence of major medical conditions (heart 
disease, diabetes, all cancers combined [prevalence of breast cancer is 
described in Chapter 5] and depression) among the cohort and stratified by 
LP/NPL status. There was a significantly lower prevalence of heart disease
3^M
Table 3.2 Demographic characteristics of the survey cohort, with NPL and LP.
Characteristic Cohort NPL LP
n^ 1392 417 968
Age at survey, y 56.8(17.7) 54.1 (13.9) 57.8(19.0)*
Age at legal blindness, y 19.2 (26.9) 6.7(13.6) 24.7 (29.3)*
Age both eyes NPL, y 16.9(18.3) 16.9(18.3) -
Weight, lb 164.0 (44.2) 166.5 (44.9) 163.0 (43.9)
Height, in 63.5 (3.0) 63L1 (3.0) 63.7 (3.1)*
BMI, kgAn^ 28.6 (7.4) 29.4 (7.5) 28.2 (7.3)*
Exercise, h/week 6k4(7.8) 6L1 (8.1) 6L6(7.5)
Caffeine intake cups/day 3.0 (2.8) 3.2 (2.8) 2.9 C2 8)
Alcohol use drinks/week 1.7 (4.4) 1.7 (6.1) 1 ^(3 .5)
Ever smoker % 32 23 36*
Age at first birth, y ^ 25.4 (5.3) 25.7 (5.4) 25.2 (5j^
No. of pregnancies ^ 2 8(1.8) 2.5 (1.6) 2.9 (1.9)*
^Seven subjects did not report whether or not they had light perception
Among parous women only
* = p < 0.05
All results are mean (standard deviation) unless otherwise indicated.
NPL = no perception of light; LP = light perception
Table 3.3 Major chronic medical conditions reported among the survey cohort.
with LP and NPL.
Diagnosis Cohort NPL LP
n^ 1392 417 968
Heart disease (%) 170(12) 26(6) 143 (15)*
Diabetes (%) 178(13) 56(13) 121(13)
Cancer (any) (%) 240(17) 69(17) 171(18)
Depression (%) 359(26) 116(28) 241 (25)
V  subjects did not report whether or not they had light perception
* = p < 0.05, for LP compared to NPL
NPL = no perception of light; LP = light perception
3^^
among women with NPL (chi-square test p < 0.0001), but no differences with 
any other major diseases by light perception status.
3.4 Field study cohort
3.4.1 General characteristics
There were 130 subjects who participated in the field study, resulting in 6,749 
days of sleep diary data and 476 days of urine collection yielding nearly 5,000 
individual urine samples. Among all field study subjects, 32% reported having 
NPL (n = 42) and 68% reported having LP (n = 88). There were 39% who 
reported being pre-menopausal (NPL, n = 12; LP, n = 38), 13% reported 
being peri-menopausal (NPL, n = 9; LP, n = 9), and 48% reported being post­
menopausal (NPL, n = 20; LP, n = 41). One subject did not report her 
menopausal status. The individual demographic details for each subject are 
presented in Table 3.4. General characteristics are presented in Table 3.5 for 
the field study cohort and by light perception status.
Field study subjects were significantly younger than the survey cohort (field 
study cohort, mean age (±SD) = 50.52 (±13.42) years; survey cohort, mean 
age = 56.79 (±17.68) years; Student’s t-test p < 0.0001) and had a 
significantly earlier onset of legal blindness compared to the survey cohort 
(field study cohort, mean onset = 11.37 (±18.18) years; survey cohort, mean 
onset = 19.21 (±26.90) years; Student’s t-test p < 0.0001). The field study 
cohort also reported significantly more exercise per week than the survey
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Table 3.4 General characteristics of all post-menopausal subjects with LP.
A.
Legal
Subject
Code
Survey
age
blind
age
NPL
age Level of vision^ Eye condition
25BC365* 58 3 vision chart anterior segment disease
26BC1332 58 1 light only brain tumour
25BC232 57 12 vision chart congenital defect
26BC809 72 63 vision chart diabetic retinopathy
26BC873 76 25 vision chart diabetic retinopathy
26BC1010* 63 - diabetic retinopathy
26BC1251 65 11 counting fingers dry macular degeneration
26BC908* 72 61 vision chart dry macular degeneration
26BC1272 83 82 vision chart dry macular degeneration
26BC1389* 67 40 vision chart dry macular degeneration
25BC189 54 0 Shadows/HM glaucoma
26BC1245* 81 53 vision chart glaucoma
26BC1442 64 2 counting fingers Glaucoma
26BC1131 49 12 light only Glaucoma
26BC1273* 62 0 vision chart Glaucoma
26BC1365* 71 52 Shadows/HM optic atrophy
26BC1237 36 26 light only optic atrophy
26BC713 50 19 vision chart retinal dystrophies
26BC1329 60 13 light only retinal dystrophies
25BC167 54 0 light only ROP
25BC254 59 0 light only ROP
26BC819* 55 0 Shadows/HM ROP
26BC924* 52 0 light only ROP
26BC1266 52 0 vision chart ROP
26BC14ir 62 0 vision chart ROP
26BC1226* 65 0 vision chart ROP
26BC970 60 0 light only ROP
26BC607* 64 0 light only RP
26BC988 55 28 vision chart RP
25BC475* 67 39 light only RP
26BC678 50 0 Shadows/HM RP
26BC1364 66 23 counting fingers RP
26BC1427* 82 vision chart RP
26BC1434 59 17 Shadows/HM RP
26BC1489* 71 0 Light only RP
26BC1528 50 1.5 Shadows/HM RP
26BC1345 80 50 light only Unknown
26BC966 44 38 Shadows/HM Unknown
26BC1323 65 9 light only Unknown
26BC707 54 50 vision chart Uveitis
26BC831* 78 70 vision chart wet macular degeneration
Tevel of vision when corrected in the better eye, vision chart = able to see the vision chart, 
counting fingers = able to see to count fingers, shadows/HM = able to see shadows and hand 
movement, light only = light perception with no visual acuity
^This subject did not answer the question on menopausal status, but is included here 
because of her age.
* = lives alone
NPL = no perception of light; LP = light perception; HM = hand movement; ROP = retinopathy 
of prematurity; RP = retinitis pigmentosa
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Table 3.4 General characteristics of all pre- (B) and peri-menopausal (C) 
subjects with LP. For details see Table 3.4 A.
B.
Legal
Subject
Code
Survey
age
blind
age
NPL
age Level of vision Eye condition
25BC396 45 0 vision chart anterior segment disease
26BC1435 40 0 counting fingers anterior segment disease
25BC456 29 0 vision chart anterior segment disease
25BC177 50 0 vision chart anterior segment disease
25BC259 42 0 light only congenital defects
25BC143 27 0 light only Glaucoma
26BC1421* 35 18 counting fingers Glaucoma
25BC108 29 0 Shadows/HM Leber’s congenital amaurosis
26BC753 46 0 Shadows/HM microphthalmia
26BC995 24 0 counting fingers microphthalmia
26BC1362 47 5 counting fingers ocular trauma
26BC1383 24 0 counting fingers optic atrophy
26BC640 50 35 light only retinal disease - mise
25BC124
25BC356*
32
46
0
14 shadows/HM
retinal dystrophies 
retinal dystrophies
25BC293 41 0 counting fingers ROP
25BC418* 23 0 vision chart ROP
26BC1314 36 0 light only ROP
25BC584* 51 29 shadows/HM ROP
25BC153 42 0 shadows/HM RP
25BC576 42 0 vision chart RP
25BC598* 50 20 light only RP
26BC602 45 0 light only RP
26BC706 46 22 vision chart RP
26BC752* 42 27 counting fingers RP
26BC855 31 14 vision chart RP
26BC906 33 16 vision chart RP
25BC369 28 0 shadows/HM Unknown
26BC975* 29 0 counting fingers Unknown
26BC1024 45 0 vision chart Fuch s disease
26BC976 50 23 vision chart ROP
26BC1006 45 37 vision chart Histoplasmosis/accident
25BC244 22 4 shadows/HM uveitis/retinal detachment
25BC572 41 3 shadows/HM uveitis/solsman’s nodule
26BC874* 36 2 shadows/HM hydrocephalus
25BC109 45 21 shadows/HM Glaucoma/corneal disease
25BC516 28 20 counting fingers Aniridia/glaucoma/corneal disease
26BC1378 50 7 shadows/HM Steven Johnson syndrome
25BC126 32 0 vision chart Aniridia
c.
26BC1385 40 0 vision chart Albinism
25BC292 49 0 vision chart Aniridia
25BC113* 53 6 light only brain tumour
25BC399 49 7 vision chart brain tumour
26BC674 51 0 light only Leber's congenital amaurosis
25BC384 53 33 counting fingers macular degeneration
26BC1336 39 0 light only Microphthalmia
25BC309 54 0 Jlaüienlï-------- ROP
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Table 3.4 General characteristics of all post- (D), pre- (E) and peri- 
menopausal (F) subjects with NPL. For details see Table 3.4 A.
D.
Subject
Code
Survey
age
Legal
blind
age
NPL
age Level of vision Eye condition
25BC324 45 0 0 NPL bilateral enucleation
25BC373 59 0 27 NPL bilateral enucleation
25BC562* 51 0 NPL bilateral enucleation
26BC1154* 53 0 18 NPL bilateral enucleation
25BC256* 58 34 5 NPL bilateral enucleation
25BC320* 54 3 NPL bilateral enucleation
25B C 4lf 55 2 2 NPL bilateral enucleation
26BC620 79 70 71 NPL glaucoma
25BC179 58 43 45 NPL glaucoma
26BC828 37 0 0 NPL ocular trauma
26BC915 33 15 15 NPL optic atrophy
26BC1085* 76 4 4 NPL optic atrophy
25BC105* 56 0 18 NPL ROP
25BC141* 57 0 22 NPL ROP
25BC149* 52 0 NPL ROP
25BC152 52 0 10 NPL ROP
25BC236 54 0 0 NPL ROP
25BC460 52 0 0 NPL ROP
25BC529 53 0 24 NPL ROP
25BC265 58 0 14 NPL ROP
E.
25BC934 61 0 12 NPL RP
25BC239 47 0 0 NPL anterior segment disease
25BC121* 47 0 16 NPL bilateral enucleation
25BC333 46 0 12 NPL bilateral enucleation
25BC119 33 2 NPL bilateral enucleation
25BC485* 34 25 28 NPL diabetic retinopathy
26BC1424 30 0 0 NPL leber’s congenital amaurosis
25BC159 51 3 NPL ocular trauma
26BC647* 45 26 27 NPL ocular trauma
25BC207 52 0 0 NPL ROP
25BC252 43 0 20 NPL ROP
26BC765 48 41 42 NPL Unknown
25BC43f 30 0 0 NPL optic atrophy
25BC544* 48 3 30 NPL Uveitis
F.
26BC840 53 0 37 NPL bilateral enucleation
25BC218* 51 19 20 NPL bilateral enucleation
25BC208* 56 0 0 NPL ROP
25BC359 55 0 40 NPL ROP
25BC447* 52 0 15 NPL ROP
25BC539* 53 0 28 NPL ROP
26BC1016 54 0 10 NPL ROP
26BC1361 57 2 26 NPL bilateral enucleation
This subject did not indicate her menopausal status.
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cohort (field study cohort, mean hours exercise/week = 9.15 (±11.26); survey 
cohort, mean hours exercise/week = 6.44 (±7.79); Student's t-test p <
0.0001). All other variables were similar between the survey and field study 
cohorts.
3.5 Lifestyle characteristics -  field study
The distribution of marital status and living arrangements for subjects with and 
without light perception are presented in Figures 3.8 and 3.9, respectively. As 
in the survey cohort, field study subjects were highly educated, with 66% of all 
subjects reporting attainment of a college degree or higher (NPL = 63%; LP = 
67%). The distribution of educational achievement for subjects stratified by 
LP/NPL status is presented in Figure 3.10.
Nearly half of the field study subjects reported being employed (n = 59, 45%), 
while 20% reported being full-time homemakers, 17% reported being retired, 
7% reported being students and 10% reported being unemployed. The 
distribution of employment status for subjects with and without light perception 
is presented in Figure 3.11.
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Table 3.5 Demographic characteristics of field study subjects with NPL and 
LP.
Characteristic Cohort NPL LP
n 130 42 88
Age at survey, y (SD) 50.5(13.4) 50.9(10.06) 50.3(14.8)
Age at legal blindness, y 
(SD) 11.4(18.2) 7.0(15.2) 13.5(19.2)
Age both eyes NPL, y (SD) 17.2 (16.1) 17.2 (16.1) -
Weight, lb (SD) 159.4 (43.3) 161.6 (39.5) 158.3 (45.1)
Height, in (SD) 63.5 (2.6) 63.2 (3.0) 63.6 (2.4)
BMI, kg/m' (SD) 27.7 (6.9) 28.3 (6.2) 27.4 (7.2)
Exercise, h/week (SD) 9.2 (11.3) 9.0(11.6) 9.2(11.2)
Caffeine intake cups/day 
(SD) 2.8(2.3) 2.7 (2.2) 2.8 (2.4)
Alcohol use drinks/week (SD) 1.3 (2.6) 1.3 (2.6) 1.3 (2.6)
Ever smoker % 26 32 23
Age at first birth, y (SD)^ 25.3 (5.7) 26.4 (6.2) 24.9 (5.5)
No. of pregnancies (SD)^ 2.9 (1.7) 3.0 (1.7) 2.8 (1.7)
Among parous women only 
NPL = no perception of light, LP = light perception 
BMI = body mass index, SD = standard deviation
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Figure 3.8 Marital status of NPL (black bars) and LP (gray bars) subjects 
expressed as a percentage of each group among field study subjects.
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Figure 3.9 Living arrangements of NPL (black bars) and LP (gray bars) 
subjects expressed as a percentage of each group among field study 
subjects.
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Figure 3.10 Educational achievement for NPL (black bars) and LP (gray bars) 
subjects expressed as a percentage of each group among field study 
subjects.
K-8 = primary and secondary school; HS = high school
40
30 -
% of group 2 0  _ 
(NPL or LP) ^
10 -
h
Full Part Home- Student Retired Unemployed
time time maker
Figure 3.11 Employment status of NPL (black bars) and LP (gray bars) 
subjects expressed as a percentage of each group among field study 
subjects.
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CHAPTER 4 -  REPRODUCTIVE CHARACTERISTICS OF BLIND WOMEN WITH 
AND WITHOUT LIGHT PERCEPTION
4.1 Introduction
The role of light on human reproductive development is unclear. Blind women with 
varying levels of vision are reported to have altered reproductive function when 
compared to sighted women (Thomas and Pizzarello 1967, Zacharias and Wurtman 
1969, Magee et al. 1970, Elden 1971, Lehrer 1982, Bellastella et al. 1989, Bellastella 
et al. 1994). These differences have been attributed by some to differences in light 
perception between the sighted and the blind. There are few and conflicting reports 
on the role of blindness on basic demographic measures (e.g., body mass index 
[BMI], education) and reproductive function and history (e.g., age of menarche, 
menopause, and fertility). The blind population has been shown to differ from the 
sighted population in that blind women are reportedly shorter in stature (Bellastella et 
ai. 1994) and have a lower BMI (Bellastella et ai. 1989). Further, menarche in blind 
women has been reported to be both earlier (Zacharias and Wurtman 1969, Magee 
et ai. 1970) and the same (Thomas and Pizzarello 1967) as in sighted women. 
Women with NPL compared to women with LP have been reported to have no 
differences in the timing of menopause or fertility (Lehrer 1982). By contrast, other 
reports suggest that blind women have impaired reproductive function and suggest 
that blindness may be linked to reproductive sterility (Elden 1971).
Animal research has demonstrated that light is critically important in reproductive 
success for seasonally breeding mammals. For example, blinded female sheep are
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unable to maintain estrous cycling synchronised to their winter breeding season in 
the absence of secondary photic cues, such as the presence of a ram (Legan and 
Karsch 1983). Similarly, pubescent hamsters blinded at birth have been reported to 
have uterine regression and ovaries of a size consistent with anovulatory phase 
hamsters, though they reportedly have no differences in pubertal timing compared to 
sighted controls (Darrow et al. 1980). Hypothalamic lesions, which destroy light input 
from the eyes to the hypothalamus, including the circadian pacemaker in the SCN, 
induce estrous 3-4 weeks following the lesion in ferrets (Donovan et al. 1956) and 
advance the first estrous by around 10 days in pre-pubertal rats (Donovan et al. 
1956). These findings suggest that light may influence reproductive development in 
some species or that the correct timing of the clock is necessary for reproductive 
function. Currently, the existence of and causes for the differences in reproductive 
function among blind women remain unknown.
The aim of this portion of the study was to test the hypothesis that some reproductive 
outcomes are different in blind women with NPL compared to women with LP. A 
further aim was to determine whether the onset of the timing of blindness 
corresponds to any observed difference. This chapter describes differences in 
reproductive characteristics of LP and NPL blind women.
4.2 Methods
4.2.1 Subjects
Subjects included 1392 blind women who participated in the survey portion of the
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study. Details of the survey data collection are described in Chapter 2.
4.2.2 Statistical methods
Subjects were divided into two groups; 1) those with any LP in either eye; and 2) 
those who reported having NPL in both eyes. NPL subjects were further subdivided 
into three ordinal categories by the age that light perception was lost in both eyes as 
1 ) onset of NPL from birth; 2) onset of NPL from age one until two years prior to 
menarche; and 3) onset of NPL from two years prior to menarche and after. The data 
were limited to two years prior to menarche in order to account for pubertal 
development prior to menarche. Participants who did not report their degree of light 
perception for both eyes were excluded from comparisons (n = 7).
Menarche was defined as the age (whole year) of the subject's first reported period. 
Subjects were asked to define their current menopausal status as pre-menopause, in 
menopause or post-menopause. ‘Menopause start’ was defined as the age (whole 
year) when the subject started experiencing menopausal symptoms such as 
regularly missed periods, intermittent bleeding and/or hot flashes. Menopause stop’ 
(whole year) was defined as the age that the subject’s periods had stopped 
completely. The present analysis includes menopausal information for only those 
who experienced a natural (not surgical or medical) menopause. Those who 
reported experiencing a surgically or medically induced menopause were excluded 
from baseline comparisons (n = 289). Pre-menopausal subjects were asked to report 
their average menstrual cycle duration over the past six months, defined as from the 
beginning of one menstrual period until the day before the start of the next menstrual
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period. Responses were given in the categories <21 days, 21-25 days, 26-31 days, 
32-39 days, 40 to 50 days, >= 51 days, or too irregular to estimate. These categories 
were collapsed into two categories to compare the normal range of menstrual cycle 
durations (21-39 days) to menstrual cycle durations outside the normal range (<21 
days, >40 days and too irregular to estimate). Seven pre-menopausal subjects did 
not answer the question about menstrual cycle length and were excluded from these 
comparisons.
Univariate summary measures were calculated for primary demographic 
characteristics and compared between groups of light perception. Between-group 
assessments were calculated using Student’s two-sample f tests for continuous 
variables and chi-square tests for categorical variables. Multivariate odds ratios (OR) 
and 95% confidence intervals (01) were estimated by logistic regression using light 
perception status (NPL/LP) as the dependent variable (Prentice 1976). Comparisons 
of menstrual cycle length and history of miscarriages in relation to LP/NPL were 
adjusted for age. Independent variables considered for inclusion in multivariate 
logistic regression examinations of menarche were selected from variables with a 
hypothesised relationship with menarche (e.g. BMI) and where p < 0.10 in univariate 
comparisons. Multivariate models were ultimately adjusted for the continuous 
variables current age, BMI and BMI at age 18. Subjects with missing data for any of 
these variables were excluded from the model. Tests for trend were conducted using 
linear regression to compare the continuous variable age of menarche’ to the 
increasing category of ‘age of loss of NPL’ used as a continuous variable. All p- 
values were two-tailed. All statistical comparisons were made using SAS software 
(SAS Institute Inc., version 9.0, Cary, NC).
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4.3 Results
Some degree of light perception was reported in 968 subjects (70%), while 417
women reported being NPL (30%) and 7 did not report their degree of light 
perception. Table 4.1 presents baseline demographic and reproductive 
characteristics of the study participants. Subjects ranged in age from 19 to 98 years 
at the time of the survey, with a mean age of 56.8 years (SD ±17.7). The mean BMI 
for the cohort was overweight at 28.6 kg/m  ^(±7.4). Of all women, 53% reported a 
history of at least one full term pregnancy. Approximately 70% of all subjects 
reported ever being married, with LP subjects being significantly more likely to have 
reported a history of marriage. At the time of the survey, 58% of all women reported 
being post-menopausal, 11% reported being in menopause and 28% reported being 
pre-menopausal (3% did not report menopausal status).
NPL women differed from LP women for several demographic measures (Table 4.1). 
NPL women were significantly younger than LP women (mean age 54.1 ±13.9 years 
versus. 57.8 ± 19.0 years, respectively) in this cohort. They were also shorter than 
LP women (mean height 63.0 ± 3.0 inches versus 63.7 ± 3.1 inches; respectively) 
but were the same weight, resulting in a significantly higher current BMI for NPL 
versus LP women (mean BMI, 29.4 ± 7.5 kg/m^ versus 28.2 ± 7.3 kg/m^). This BMI 
difference did not exist at age 18, with NPL women reporting being significantly 
lighter at that age than LP women (Table 4.1). There was some evidence that study 
subjects rounded their current weight to the nearest five pounds.
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This rounding effect was similar among women with LP and NPL and there was no 
rounding effect for any other variable. There were no significant differences in the 
timing of natural menopause measures or the mean age of first full term pregnancy 
(Table 4.1). There were also no differences in normal compared to abnormal 
menstrual cycle duration in NPL versus LP women in age-adjusted analysis (odds 
ratio [OR] = 1.02, 95% confidence intervals [01] 0.40-1.27). A significantly smaller 
proportion of NPL women reported a history of at least one full term pregnancy and 
NPL women reported a fewer total number of pregnancies (Table 4.1). There were 
no differences in history of miscarriages between parous LP and NPL women (age- 
adjusted OR: 1.02, 95% Cl: 0.72-1.46). However, NPL women reported having a 
significantly earlier menarche than LP women by four months (mean age at 
menarche, 12.2 years versus 12.5 years, respectively; Table 4.1).
In logistic regression models, the unadjusted odds ratio for each increasing year of 
menarche among NPL women compared to LP women was 0.88 (95% Cl: 0.82- 
0.96) i.e., for every year that a woman with LP attained menarche it was 0.11 times 
less likely that a woman with NPL of the same age would have attained menarche. 
After adjustment for confounders, the odds ratio was virtually identical (OR: 0.88, 
95% Cl: 0.81-0.96).
In order to assess the potential effects of light on age at menarche in more detail, 
women with NPL from birth (n = 93) were compared to all other participants. Women 
NPL from birth reported experiencing menarche approximately six months earlier 
than participants with LP at birth (11.9, ±1.7 years versus 12.4, ±1.6 years, p = 
0.006). As -50% of women with NPL from birth reported that their blindness was due
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to ROP, the mean age of puberty among those blind at birth due to ROP (n = 50) 
was compared to those who were blind at birth due to other causes. No other eye 
disorder represented >8% of the NPL from birth subgroup. There was no significant 
difference in age at menarche between those blind at birth with ROP compared to all 
others (11.9, ±1.3 years versus 12.0, ±2.0 years, p = 0.92). When comparisons on 
reported age of menarche were made between those who reported having NPL from 
birth compared to all others, the unadjusted and adjusted odds ratios were 
strengthened (OR: 0.81, 95% Cl: 0.70-0.94; OR: 0.80, 95% Cl: 0.68-0.94, 
respectively). When logistic regression analysis was restricted to those with NPL at 
birth, compared to those with NPL after birth, the effect was consistent but 
attenuated in both unadjusted and adjusted models (OR: 0.89, 95% Cl: 0.75-1.05; 
OR: 0.83, 95% Cl: 0.69-1.01, respectively). Further examinations of the association 
between age at onset of NPL and age at menarche revealed a significant positive 
association with earlier menarche being associated with an earlier age category of 
loss of light perception (Table 4.2). In addition, women with LP who became legally 
blind prior to menarche had an earlier menarche compared to those who became 
legally blind after menarche (mean age at menarche when onset of legal blindness 
was from birth up to two years prior to menarche: 12.3, ±1.6 years, mean age at 
menarche when onset of legal blindness was lost from two years prior to menarche 
or after: 12.6, ±1.6 years, p = 0.02).
4.4 Discussion
These results demonstrate that several demographic and reproductive differences 
exist between LP and NPL blind women in the current study. NPL women were
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Visual Category n Mean age of menarche, y (SE)
NPL from birth 93 11.94 (0.17)
Onset of NPL from age 1 until 2
years prior to menarche 64 12.13(0.13)
Onset of NPL 2 years prior to 
menarche and after 253 12.22 (0.11)
LP from birth 938 12.45 (0.05)
p for trend: <0.01
LP = light perception, NPL = no perception of light, SE = standard error
significantly shorter than LP women, with a higher current BMI, but a lower weight 
and lower BMI at age 18. A smaller proportion of NPL women were parous and they 
reported fewer total pregnancies. NPL women also reported a significantly earlier 
age of menarche than LP women. In multivariate analyses, adjusted for current age, 
current BMI and BMI at age 18, menarche remained approximately four months 
earlier in NPL women, compared to blind women with LP. Further examinations 
revealed that age of menarche was even earlier in those women NPL from birth 
compared to the all other women in the cohort. In addition, a significant positive 
association between early loss of LP and early onset of menarche was observed.
The finding that menarche is earlier in blind women with NPL confirms and extends 
earlier reports by Zacharias and Wurtman (Zacharias and Wurtman 1964, Zacharias 
and Wurtman 1969) and Magee (Magee etal. 1970). Zacharias and Wurtman 
compared blind girls with ROP to prematurely-born sighted girls and found that 
menarche was advanced in girls with ROP. They found this effect to be accentuated 
among the NPL subset of girls with ROP (Zacharias and Wurtman 1969). In a follow 
up study, they reported that NPL blind girls with ROP experienced menarche an
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average of seven months earlier than prematurely born sighted controls. They also 
found that among LP blind girls born at full term, menarche was an average of four 
months earlier than their sighted counterparts. The present results were observed in 
a cohort of women with a variety of eye conditions suggesting that differences in 
menarche are not due to a factor specifically related to ROP, but instead result from 
a direct effect of loss of light perception.
Further observations revealed that women with NPL from birth and women who 
reported being NPL at least two years prior to menarche experienced a significantly 
earlier menarche compared to women who reported NLP occurring within the two 
years prior to onset of or after menarche, suggesting that timing of blindness is an 
important factor influencing the reproductive axis. These findings differ from earlier 
reports, in that all of the women in this cohort reported being at least legally blind in 
contrast to prior studies that used sighted girls as controls. This methodological 
difference likely accounts for the smaller differences in the current findings. As in the 
present study, Magee and colleagues examined only blind girls and found a 
significantly earlier age of menarche in girls with clinically confirmed minimal and 
NPL (12.0 years) compared to those with shadow vision and guiding sight (12.8 
years; Magee et al. 1970). Additionally, the mean menarche in that cohort occurred 
at 12.4 years while similar studies suggest that sighted women of the same age 
range experience menarche around 12.7 years (McDowell et al. 2007).
In contrast to these and others’ findings, two reports found no differences in age at 
onset of menarche in blind as compared to sighted women. Thomas and Pizzarello 
found no differences in menarche in 26 institutionalised blind and 69 institutionalised
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sighted girls (Thomas and Pizzarello 1967), and Lehrer found no differences in a 
comparison of 24 LP and 31 NPL women (Lehrer 1982). There are several possible
reasons for the conflicting results. The study by Thomas and Pizzarello did not 
account for degree of blindness, type of blindness or the reason for the 
institutionalisation of the sighted girls, any of which may be important factors in the 
timing of menarche. Lehrer examined a small cohort of blind women and did not 
account for when each woman became blind.
In addition to differences in reproductive outcomes, these findings showed that NPL 
women are shorter than LP women. This finding is consistent with that of Bellastella 
and colleagues, who reported that blind girls and adults with varying degrees of LP 
had a shorter stature than age-matched sighted controls (Bellastella et al. 1989, 
Bellastella et al. 1994). The mean BMI in the present cohort was overweight and 
bordered on obese, and the BMI of NPL women was statistically higher than in LP 
women due to decreased height. This finding is similar to that of the general US 
population for women in this age range, who reportedly have an average BMI of 29.2 
(Ogden et al. 2004). These findings are also similar to those of Leger and 
colleagues, who found BMI to be marginally lower in blind people compared to 
sighted people (Leger et al. 1999). The increased current BMI in NPL women does 
not account for the earlier menarche observed in this group, as could be 
hypothesised (Kaplowitz et al. 2001), as their weight and BMI were significantly 
lower than LP women at age 18. Consistent with prior reports, this study exposed no 
differences between LP and NPL women in age at natural menopause, which 
occurred around age 50 (Leger et al. 1999). There were also no differences in 
menstrual cycle length or history of miscarriages in LP and NPL women. There were
4 -1 1
no differences in the age of first birth in LP and NPL women; however, only 42% of 
NPL women reported being parous compared to 57% of LP women. NPL women 
also reported fewer total pregnancies than LP women. The different pregnancy 
outcomes appear to be related to social factors as significantly fewer NPL women 
reported ever being married.
Given the role that light plays in mediating seasonal reproduction in other mammals 
(Donovan etal. 1956a, Donovan etal. 1956b, Darrow 1980, Legan and Karsch 
1983), these findings may have important implications for how light may affect the 
human reproductive system. Seasonal and daily circadian cycles are synchronised 
by light via specialised photoreceptors in the ganglion cell layer of the retina (Section 
1.3.2.1). One of the primary targets of this light signal is the endogenous circadian 
pacemaker, located in the SCN of the hypothalamus (Section 1.3). This clock 
controls the timing of internal rhythms such as melatonin and sleep (Section 1.2). In 
the absence of ocular light information reaching the SCN, as in bilaterally enucleated 
and most NPL subjects, the endogenous pacemaker reverts to its internal period 
(Section 1.5). This inability to entrain the internal clock to the environmental light- 
dark cycle induces a chronic cyclic sleep disorder called non-24-hour sleep-wake 
disorder characterized by cyclic episodes of good and bad sleep for many weeks or 
months (Section 1.5.3). In addition, the pineal hormone melatonin is acutely 
suppressed by ocular light exposure via the same pathway (Section 1.4.4), and 
people with NPL lacking circadian photoreception do not experience light-induced 
melatonin suppression (Section 1.5.3).
It is unclear how attenuated light input to the SCN clock and/or disordered or non­
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entrained circadian rhythms may play a role in human reproductive development. 
Importantly, however, photoperiodic timekeeping via melatonin duration signalling is 
a major mechanism for control of seasonal reproduction in seasonally breeding 
mammals (Tamarkin et al. 1985). Seasonal reproduction is maintained through light- 
mediated signalling of long or short night length, which is translated by the circadian 
system and pineal gland into long or short nocturnal melatonin duration, respectively. 
The duration of these melatonin pulses confers day/night length information to the 
reproductive axis to signal appropriately timed seasonal breeding (Tamarkin et al. 
1985). When an animal is blinded, night length information is removed, and in the 
absence of non-photic cues the animal is no longer able to synchronise breeding to 
the appropriate season (Legan and Karsch 1983). While data on the role of 
endogenous melatonin in reproductive development in humans are not available, it is 
possible that a similar mechanism is responsible for our observed differences in 
menarche in blind women. Humans can detect photoperiodic changes via their 
melatonin rhythm (Wehr 2001) and given that light can alter melatonin duration and 
timing, it is conceivable that attenuation of circadian photoreception due to extensive 
ganglion cell damage may interfere with light-related reproductive development. 
Similarly, melatonin has been implicated in the achievement of puberty in humans 
(Section 1.4.5.1), though it is currently unclear how melatonin may be involved in 
reproductive development. It could be hypothesised that the duration of the 
melatonin pulse, the amount of the melatonin produced, or the timing of the peak of 
melatonin may be different in blind girls with NPL compared to sighted girls and 
those with LP; any of which might be responsible for the observed differences in 
menarche.
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One limitation of this analysis is that the categorisation of blindness may suffer from 
some degree of misclassification. It is likely that a small subset (-5%) of the women 
who reported being totally functionally blind still retain circadian photoreception 
without realising it, as the cells that transmit the light signal to the SCN are different 
from those used for sight (Section 1.3.2.1 ). This would mean that some women 
whose melatonin rhythms are sensitive to light are included among the NPL group. 
Such misclassification would likely have lead to an underestimate of the association 
between NLP and age at menarche, when compared to women with LP. It is also 
possible that there are unknown co-morbid conditions associated with certain types 
of blindness that could influence these results. This seems unlikely, however, as the 
mean age of menarche was unchanged when women with NPL from birth due to 
ROP were compared to women NPL from birth due to other causes. Finally, due to 
the retrospective nature of this cohort it is possible that some women did not 
accurately report their LP status or age at menarche. A recent report, however, 
found that recall of age of menarche in women after 30 years is highly correlated to 
the actual age of menarche (Must et al. 2002).
In summary, these findings revealed differences in reproductive characteristics in 
women with and without light perception. NPL women were somewhat shorter than 
LP women accounting for a slightly higher BMI in NPL women. LP women were 
more likely to have children than NPL women and also had more children on 
average than NPL women, though the average age of the first birth between these 
groups was the same. These findings extend and confirm prior reports that NPL blind 
women experience earlier menarche, with an even earlier menarche among those 
women NPL from birth to two years prior to menarche. These findings suggest that
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the level of light perception is important in the timing of menarche, but not in other 
reproductive milestones.
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CHAPTER 5
BREAST CANCER RISK IN BLIND WOMEN 
WITH AND WITHOUT LIGHT PERCEPTION
CHAPTER 5 -  BREAST CANCER RISK IN BLIND WOMEN WITH AND 
WITHOUT LIGHT PERCEPTION
5.1 Introduction
Breast cancer rates are reportedly lower among blind women when compared 
to the general population (Hahn 1991, Feychting et al. 1998, Pukkala et a i 
1999, Kliukiene et a i 2001). In 1991, Hahn reported that blind women had a 
lower than expected incidence of breast cancer compared to cardiovascular 
disease and stroke (Hahn 1991). Three population-based record linkage 
studies in Scandinavia each reported a lower breast cancer risk among totally 
blind as compared to sighted women (Feychting et a i 1998, Pukkala et a i 
1999, Kliukiene et a i 2001). Examinations of historical records in Finland 
have also shown that blind women have a lower relative risk of cancer 
compared to the sighted population, and that this lower risk follows a dose 
response with breast cancer risk decreasing with decreasing visual acuity 
(Verkasalo et a i 1999, Pukkala et a i 2006).
It has been hypothesised that the observed lower risk of breast cancer among 
blind women is due to differences in ocular light exposure compared to 
sighted women and that the observed increased risk of breast cancer among 
shift workers (Straif et a i 2007) is mediated through the same, albeit opposite, 
mechanism. To date, all studies examining the relationship between blindness 
and breast cancer risk have been based on historical records, with minimal 
information on other known breast cancer risk factors. This aim of this chapter
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is to test the hypothesis that blind women with NPL have a lower risk of breast 
cancer compared to blind women with LP, after adjustment for known breast 
cancer risk factors. An additional aim of this chapter is to test the hypothesis 
that there is a dose response in breast cancer risk among the blind with 
decreasing vision associated with lower risk.
5.2 Methods
5.2.1 Subjects
Subjects included 1392 legally blind adult women who participated in the 
survey portion of the study (Chapter 2). In the cohort described in this chapter, 
12 women (4 NPL, 8 LP) were excluded from all comparisons because they 
did not report their age at the time of the survey. The distribution of subjects in 
each data analysis cohort is presented in Figure 5.1. Further details of subject 
recruitment and the survey data collection are described in Section 2.1.
Self-reported breast cancer was confirmed through review of medical records 
or, if unavailable, from verbal confirmation or a letter from the subject. Eighty- 
four breast cancer cases were reported among all blind women studied. Of 
these, 15 were excluded as their breast cancer diagnosis occurred before the 
onset of their blindness. Three subjects were considered non-cases because 
their physician had no record of their reported diagnosis. Physician validation 
was obtained for 31 of the included cases (31/66, 47%) and verbal
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confirmation or a letter from the subject was obtained in another 18 (27%). Of 
the remainder, 9 were lost to follow-up, four withdrew from the study, three 
could not obtain a medical report and one had died by the time she was 
contacted for validation. Of the 31 physician-confirmed cases, 45% were 
reported to be in situ breast cancer and 32% were metastatic or invasive; 23% 
of reports had insufficient information for further classification.
Subjects’ self reported visual acuity was categorised as; 1) those with any 
vision or LP in either eye; and 2) those who reported having NPL in both eyes. 
Participants not reporting their visual acuity for both eyes were excluded. 
Visual acuity was further split into four self-reported categories selected from 
the following options; “able to see the top letter on the vision chart,” “unable to 
see the chart, but able to count fingers,” “unable to count fingers, but able to 
see shadows and hand movements,” “able to see light only.”
For the present analyses, age at menopause was defined as self reported age 
at which menstrual periods stopped plus one year.
5.2.2 Statistical methods
Multivariate odds ratios and 95% confidence intervals were estimated using 
logistic regression. Independent variables considered for inclusion in the 
model were selected from established breast cancer risk factors and for other 
variables where p < 0.10 in univariate comparisons. Indicator variables were 
created for missing values and included in the analyses. The proportion of
5-4
missing data did not exceed 3% for any variable. Ultimately, odds ratios were 
adjusted for age (continuously), age at menarche (< 12, 13, and > 14 years),
parity (nulliparous, 1-2, 3-4, and > 5 births), age of subject at birth of first child 
(< 25, 25-29, and > 30 years), body mass index (< 21, 21-22.9, 23-24.9, 25-
28.9, and > 29 kg/m^), family history of breast cancer in mother (yes/no), 
history of benign breast disease (yes/no), oral contraceptive use (ever/never), 
age at menopause (<44, 44-46, 47-49, 50-52, 53-55, 56-58, and > 58 years), 
use of hormone replacement therapy (HRT, ever/never), menopausal status 
(pre-menopausal, peri-menopausal, post-menopausal), and height (< 59, 59-
61.9, 62-65.9, 66-69.9, > 70 inches). All statistical comparisons were made 
using SAS software (SAS Institute Inc., version 9.0, Cary NO).
5.3 Results
Women with NPL accounted for 30% of the survey cohort but only 17% of 
breast cancer cases (Table 5.1). Baseline characteristics of women with NPL 
differed slightly from those of women with LP (Table 5.2, Chapter 3). NPL 
women were slightly younger, had a higher BMI, and tended to use oral 
contraceptives more often than women with LP. They also reported an earlier 
age at menarche and were less likely to be parous than LP women. The mean 
time between onset of legal blindness and breast cancer diagnosis for all 
subjects was 42.9 years (SD, ± 18.8).
Breast cancer risk was lower among women with NPL compared to women 
with LP (age-adjusted OR = 0.52, 95% Cl = 0.27 to 1.01 ; Table 5.3), a finding
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which became statistically significant after additional adjustment for breast 
cancer risk factors (OR = 0.42, 95% 01 = 0.21-0.85). When restricting to post­
menopausal women, the results were similar (Table 5.3). Moreover, removing 
the few (n = 8) women who reported night shift work also did not alter these 
results (Table 5.3). To preclude diagnostic bias and allow for sufficient lag 
time between onset of NPL and breast cancer, in secondary analyses, women 
who developed breast cancer within 2 and 4 years after self-reported NPL 
blindness were excluded; again, results remained virtually unchanged (Table 
5.3).
When analysed by degree of visual impairment, approximately the same 
number of cases was reported in each vision category (Table 5.4). The odds 
ratios for breast cancer for each category of visual impairment compared to 
NPL are reported in Table 5.5. In age-adjusted and multivariable-adjusted 
comparisons, the visual categories associated with severe visual impairment 
(light perception only, shadows and hand movement) were associated with an 
increased risk of breast cancer compared to NPL, while the visual categories 
comprising those with the best vision (counting fingers, top letter on the vision 
chart), were not associated with an increased risk of breast cancer.
Older current age, older age of first pregnancy and higher BMI were 
associated with a significantly increased risk of breast cancer (OR = 1.03, 
[1.01-1.04]: OR = 1.05 [1.00-1.11]; OR = 1.03 [1.00-1.07]; respectively [Figure 
5.2]). History of benign breast disease (OR = 1.13 [0.60-2.13]), ever use of 
oral contraceptives (OR = 1.47 [0.83-2.59]) and history of a mother with breast 
cancer (OR = 1.80 [0.89-3.64]) were all associated with a non-significant
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Table 5.2 Demographic characteristics of the survey cohort, with (LP) and
Characteristic Blind women Blind women
with NPL with LP
Total No. § n = 411 n = 947
Number of breast cancer cases ¥ 11 55
Age at survey, y 54.1 (13.8) 57.51 (18.9)
Age at menarche, y 12.2 (1.5) 12.45(1.6)
Age at menopause, yf 49.1 (6.2) 48.68 (7.6)
Weight, lb 166.3 (45.0) 163.10 (43.8)
Height, in 63.1 (3.0) 63.69 (3.0)
BMI, kgW 29.4 (7.5) 28.26 (7.3)
Parous (%) 42.5 57.0
Mean no. of births* 2.5 (1.6) 2.94 (1.9)
Age at first birth, y* 25.7 (5.4) 25.18(5.2)
History of benign breast disease (%) 14.6 16.2
Family history of breast cancer in 10.7 9.6
mother (%)
Ever use of oral contraceptives (%) 50.9 42.9
Ever use of hormone replacement 31.4 32.0
therapy (%)
Post-menopausal (%) 58.9 59.9
Ever night shift work (%) 6.6 10.7
Mean years between onset of
blindness and breast cancer 53.3(13.1) 40.96 (19.1)
diagnosis^
Values are mean (standard deviation) except where indicated; See Figure 4.1 
for sample size flow chart (n is different for 
Chapter 4 due to breast cancer classifications)
§ 7 subjects did not report whether or not they had light perception and were 
excluded from comparisons.
¥ 15 subjects reported a history of breast cancer after loss of vision and were 
excluded from comparisons.
f Age of last period + 1 year, among women with a natural menopause only.
* Among parous women only 
n Among breast cancer cases only
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Table 5.3 Odds ratios (and 95%  confidence intervals) for breast cancer by
Blind women 
with LP*
Blind women 
with NPL*
All Women
No. of case patients/ No. of control 55 / 947 11 /411
subjects §F
Age-adjusted OR 1.0 0.52 (0.27-1.01)
Multivariable OR* 1.0 0.42 (0.21-0.85)
Post-menopausal women
No. of case patients/ No. of control 46 / 550 11 / 236
subjects!
Age-adjusted OR 1.0 0.54 (0.27-1.07)
Multivariable OR* 1.0 0.49 (0.24-1.00)
Excluding night shift workers î
No. of case patients/ No. of control 48 / 846 11 / 384
subjects!
Age-adjusted OR 1.0 0.58 (0.30-1.15)
Multivariable OR* 1.0 0.48 (0.23-0.97)
Excluding women with a cancer
lag time <2 years after onset of
legal blindness
No. of case patients/ No. of control 54 / 946 11/411
subjects!
Age-adjusted OR 1.0 0.52 (0.27-1.02)
Multivariable OR* 1.0 0.43 (0.21-0.86)
Excluding women with a cancer
lag time <4 years after onset of
legal blindness
No. of case patients/ No. of control 53 / 945 11/411
subjects!
Age-adjusted OR 1.0 0.53 (0.27-1.03)
Multivariable OR* 1.0 0.43 (0.22-0.87)
Bold values indicate statistical significance (confidence intervals do not include 1.0)
§ 7 subjects did not report whether or not they had light perception and were excluded from 
comparisons
*Women who reported that onset of legal blindness occurred after breast cancer diagnosis 
were excluded from comparisons (n = 15)
f Women who did not report their current age were excluded from all comparisons (n = 12) 
*Odds ratios adjusted for age (continuously), age at menarche (S12, 13, and >14 years),
parity
(nulliparous, 1-2, 3-4, and >5 births), age at first birth (<25, 25-29, and >30 years), body mass 
index (<21, 21-22.9, 23-24.9, 25-28.9, and ^ 9  kg/m )^, family history of breast cancer in 
mother
(yes/no), history of benign breast disease (yes/no), oral contraceptive use (ever/never), age at 
menopause (<44, 44-46, 47-49, 50-52, 53-55, 56-58, and >58 years), use of hormone 
replacement therapy (ever/never), menopausal status (pre-menopausal, perimenopausal, 
post-menopausal), and height (<59, 59-61.9, 62-65.9, 66-69.9, >70 inches)
Î Night shift work was defined as ever or current work on night shifts 
LP = light perception, NPL = no perception of light
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Table 5.4 Distribution of breast cancer cases among 1392 blind women by
visual acuity
Current degree of visual 
impairment
n(%) Breast cancer history (%)
Top letter on the vision chart 417(32) 15(23)
Counting fingers 180(14) 13(20)
Shadows and hand 141 (11) 13(20)
movements
Light perception only 145(11) 13(20)
NPL 400 (31) 11 (17)
Un re ported 16(1) 1 (1)§
Total 1299 66* Î
LP = light perception 
NPL = no light perception
* 15 women were excluded from calculations, because they reported that their cancer 
occurred before their visual impairment
Î 12 women were excluded from calculations, because they did not report their current age at 
the time of the survey
§ Note, degree of visual impairment is as reported at the time of the survey. The degree of 
impairment may have been different at the time of breast cancer diagnosis. For the majority of 
women this information is unknown, however, one woman reported that her current level of 
vision was NPL, but she reported that she did not lose her light perception until after 
diagnosis of breast cancer. This case has been categorised as "unreported" for this level of 
comparison.
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elevation in breast cancer risk. Number of pregnancies (OR = 0.87 [0.72- 
1.07]) and older age at menarche (OR = 0.91 [0.77-1.08]) were associated
with a non-significant reduction in risk. Age at menopause (OR = 1.03 [0.98- 
1.09]) and ever use of hormone replacement therapy (OR = 1.03 [0.61-1.75]) 
were not associated with any change in risk of breast cancer (Figure 5.2).
5.4 Discussion
These data support findings that suggest totally blind women have a lower 
risk of breast cancer. NPL women have a significantly lower risk of breast 
cancer when adjusted for reproductive risk factors in this large cohort of 
legally blind LP women. These findings are consistent with that of prior 
studies, and suggest that the lower risk is not due to differences in the 
majority of known breast cancer risk factors. The findings did not change 
substantially when night shift workers were removed from the analysis or 
when comparisons excluded those whose breast cancer diagnosis was within 
two or four years of onset of blindness. Further, the results remained virtually 
unchanged when the analysis was limited to comparisons among post­
menopausal women. This is the first cross-sectional study to find a lower risk 
of breast cancer among NPL compared to LP blind women.
The finding that NPL women have a lower risk of breast cancer compared LP 
women is similar to prior reports (Hahn 1991, Feychting et al. 1998, Pukkala 
et al. 1999, Kliukiene et al. 2001). Hahn found that blind women had a lower 
than expected incidence of breast cancer, but the same incidence of
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cardiovascular disease and stroke when compared to sighted women (relative 
risk 0.57, Cl: 0.35-0.92; Hahn 1991). The present results are consistent with 
this finding, as the adjusted OR among NPL compared to LP women was 
0.42. This study is also consistent with three population-based record-linkage 
studies that each reported a lower breast cancer risk among totally blind 
women compared to sighted women. These studies reported standardised 
incidence ratios of 0.82 (01: 0.47-1.34) among Swedish women (Feychting et 
al. 1998), 0.52 (01: 0.01-2.91) among Finnish women (Pukkala et al. 1999) 
and 0.64 (01: 0.21-1.49) among Norwegian women (Kliukiene et al. 2001).
The odds ratios in the present cohort were lower, which is not unexpected 
considering this cohort was comprised entirely of blind women and prior 
reports compared blind women to the general sighted population.
It is likely that there are other differences between the prior reports and the 
present study. The current results are based on subjective data; by contrast, 
all prior reports are based on historical records that did not necessarily 
provide accurate data on each subject’s visual acuity. The present results also 
differ from prior reports, in that participants were asked questions about a 
variety of known breast cancer risk factors in order to determine whether 
reproductive lifestyle differences between the sighted and the blind could 
have accounted for the reported reduced risk. Chapter 4 describes these 
reproductive differences in detail. In brief, age at menarche differed between 
NPL and LP subjects with NPL subjects having an earlier menarche, opposite 
to that expected for a reduced cancer risk (Kelsey et al. 1993).
5 -1 4
There was no effect of age at menopause, or HRT use on breast cancer risk 
when comparing LP to NPL blind women. There was a modest increased risk 
associated with older age at first full term pregnancy, higher BMI, ever use of 
oral contraceptives and history of benign breast disease, whilst later age at 
menarche and a greater number of pregnancies were modestly associated 
with a decreased risk. The greatest increase in breast cancer risk was 
associated with women who reported that their mothers had breast cancer. 
The majority of these findings are in line with prior observations examining the 
relationship between known reproductive risk factors and breast cancer 
(Kelsey et al. 1993); however, in this study only one of the reproductive 
modifiers of breast cancer (greater number of pregnancies) was statistically 
associated with differences in risk. These findings suggest that blind women 
may differ from sighted women on some lifestyle variables, but such 
reproductive differences do not account for the lower breast cancer risk in 
NPL compared to LP women.
As expected, older current age was strongly associated with reporting a 
history of breast cancer. When analyses were restricted to post-menopausal 
women, age-adjusted and multivariable-adjusted results were similar to 
analyses of the entire cohort. It is important to note that a stratified analysis 
was not possible for pre-menopausal women, because there were no NPL 
women who reported pre-menopausal breast cancer. Therefore, it is not 
possible to determine whether the lower risk among NPL women is confined 
to pre or post-menopausal cancers.
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There was a significantly increased risk of breast cancer among women with 
low vision when LP women were categorised by level of visual acuity. Women 
who could only perceive light or see shadows and hand movement had a 
significantly increased risk of breast cancer when compared to women with 
NPL, while women with better vision (able to count fingers and able to see the 
top letter on the vision chart) had a higher, but not statistically significant 
increase in breast cancer risk compared to NPL women. There was no 
evidence of a dose response with visual acuity and breast cancer risk. This 
finding is contrary to the inverse association reported by Verkasalo and later 
by Pukkala (Verkasalo et al. 1999, Pukkala et al. 2006). There are several 
possible reasons for the differences in results. First, the differences could be 
due to differences in the definitions between prior studies and the present 
study. For example, the category with the highest visual acuity in the Finnish 
reports (moderate low vision) was defined using the World Health 
Organisation classification system as 20/70 to 20/160 on the Snellen Scale. In 
the present study, women with a visual acuity better than 20/200 were 
excluded from participation in the study and the highest level of visual acuity 
was defined as being able to see only the top letter on the vision chart using 
the Snellen Scale. In addition, the present analysis is confounded by an 
anachronistic comparison between visual acuity and history of breast cancer. 
This study was cross-sectional and women reported their current visual 
status. A woman’s visual acuity may have been different at the time of breast 
cancer diagnosis. Presumably visual acuity would have worsened over time 
and therefore it is likely that some women would have had better vision at the 
time of breast cancer diagnosis. There is evidence that this was the case for
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at least one subject who reported her current visual acuity as NPL, but 
reported that she lost her light perception after her cancer diagnosis. In this
single case, the subject was classified as LP in grouped analyses and 
removed from sub-analyses of visual acuity and breast cancer. If present in 
more women, this type of bias would change the results by increasing the risk 
observed in the lower visual categories. It is unclear whether visual acuity 
relates to level of light perception, but it is clear that women with any 
conscious vision have a higher risk of breast cancer compared to NPL 
women.
It is unknown how total blindness relates to breast cancer risk. The World 
Health Organisation recently categorised shift-work involving circadian 
desynchrony as a “probable carcinogen,” (Straif et al. 2007) based on findings 
that female night shift workers (Davis et al. 2001, Schernhammer et al. 2006) 
and flight attendants (Pukkala et al. 1995) have an increased risk of breast 
cancer. It has been suggested that the differences in risk observed between 
shift workers and the blind operate through similar, yet opposite mechanisms 
involving melatonin (Coleman et al. 1992) and/or internal circadian 
synchronisation (Stevens et al. 2007), both of which are directly influenced by 
ocular light exposure (Sections 1.2.2 and 1.4.4). The pineal hormone 
melatonin has a 24-hour circadian rhythm that is synchronised to the daily 
light-dark cycle and, under normal conditions, peaks during the night (Section
1.2.1). Light exposure at night acutely suppresses melatonin production via 
the same pathway (Lewy et al. 1980). These responses are mediated 
exclusively through the eyes via a specialised subset of retinal ganglion cells
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that project to the hypothalamic suprachiasmatic nucleus, where circadian 
rhythms are generated (Section 1.3). Totally blind people lacking functional 
retinal ganglion cells do not experience light-induced melatonin suppression 
or entrainment of their endogenous circadian rhythms (Section 1.2.2 and 
1.4.4). Animal and in vitro research suggests that preservation of melatonin 
production (Blask et al. 2005) or normal circadian entrainment (Filipski et al. 
2004) may confer protection against tumour growth (Lenoir et al. 2005). There 
are no reports as yet, however, that support the hypothesis that blind women 
have higher levels of melatonin than sighted women and it is unclear how 
blindness affects internal circadian synchronisation of peripheral clocks 
relative to the SCN pacemaker.
In addition to aforementioned limitations, this analysis may be limited by the 
classification of total blindness. It is possible that a small proportion (-5%) of 
women who report having NPL still retain the cells necessary for circadian 
photoreception (Section 1.2.2). This type of misclassification would have led 
to an underestimate of the difference in breast cancer risk. Additionally, these 
data are comprised of breast cancer survivors and no information is available 
on the number of women who may have died of cancer. There is no reason, 
however, to suspect that there would be differences in mortality rates among 
women previously diagnosed with breast cancer with and without light 
perception.
In summary, total visual blindness is associated with a reduced risk of breast 
cancer. This effect cannot be explained by known reproductive differences
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between women with and without light perception. Further analyses are 
needed to examine how melatonin production or internal circadian 
coordination may be responsible for the lower risk observed. Understanding 
these mechanisms may not only prove beneficial for blind women, but may 
also help guide future circadian interventions in the general population.
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CHAPTER 6
SLEEP CHARACTERISTICS AND 
CLASSIFICATION OF CIRCADIAN TYPE
CHAPTER 6 -  SLEEP CHARACTERISTICS AND CLASSIFICATION OF 
CIRCADIAN TYPE
6.1 Introduction
The human circadian rhythm is entrained to the 24 h day through ocular 
exposure to the solar light-dark cycle (Section 1.2.3). Entrainment is 
classically defined as occurring when one's endogenous period is equal to the 
external synchroniser at a stable and appropriate circadian phase (e.g. 
entrainment to the 24-hour light-dark cycle, Section 1.2.1 or entrainment to 
melatonin treatment when given at the appropriate phase in the blind. Section
1.4.6.1). Entrainment may be determined by measurement of the aMT6s 
rhythm. The peak of the melatonin rhythm (Section 1.2) is a reliable marker of 
the endogenous circadian clock. A melatonin peak that remains stable with a 
24-hour measured period within the range of 1.7-7.3 h is considered entrained 
at a normal phase (Lockley et al. 1997). Typically, normal entrainment is 
characterised by sleep at night with few to no daytime naps.
In contrast to normal entrainment, a person may be abnormally phased with 
respect to the 24 h solar day. Abnormal phase entrainment is characterised 
by a melatonin peak that remains at a stable time with respect to the 24 h 
solar cycle, but that is outside the range for normally entrained people. 
Abnormal timing of the melatonin peak is typically characterised by early or 
late sleep related to the timing of the melatonin peak.
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Blind individuals who lack photic input to the SCN do not have daily photic 
resetting of their circadian rhythms and therefore their circadian systems are
not entrained (desynchronised) with the 24 h solar day. The typical method for 
determining circadian rhythm type is through collection of sequential blood or 
urine samples over 36-48 hours to assess the pattern of melatonin production 
in an individual and then repeating this procedure on subsequent 
weeks/months to analyse changes in the timing of the peak of the melatonin 
rhythm (Lockley et al. 1997). Changes in melatonin timing across weeks are 
presumed to represent changes in the timing of the phase of the pacemaker 
and for example the difference between phases with respect to time is a 
measure of the circadian period. In the case of a blind person who has an 
internal rhythm of 24.2, the peak of the rhythm would shift later by 12 minutes 
each day so that peaks measured 2 weeks apart would differ by 2.8 hours.
The consequence of a person trying to maintain a 24 h schedule while living 
on a 24.2 internal day is often observed in a napping pattern that closely 
follows the melatonin peak (Nakagawa etal. 1992, Sack et al. 1992, Lockley 
et al. 1995, Lockley et al. 1999). Other sleep measures such as sleep latency, 
total sleep time and number of nightly arousals have not been well correlated 
with circadian rhythm type (Lockley et al. 1999).
The majority of studies that have examined circadian rhythm type in the blind 
have used these methods to assess changes in the melatonin or cortisol 
rhythm overtime (Lewy and Newsome 1983, Sack et al. 1992, Sack et al. 
2000, Lewy et al. 2001, 2002) or have conducted interventions, such as
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through melatonin administration, to attempt to entrain the rhythms of subjects 
who are not entrained (Arendt et a/. 1988, Lockley et a/. 2000, Hack et a/.
2003). The largest collection of these studies has demonstrated that 
approximately 76% of subjects with NPL have either free-running (non­
entrained) or abnormally entrained rhythms, while 77% of subjects with light 
perception LP exhibit normal entrainment (Skene eta/. 1999a, Lockley eta/. 
2007).
There have been few large cohorts assembled to assess the prevalence of 
circadian rhythm and sleep disorders among blind people. The two largest 
cohorts were conducted in the United Kingdom (Tabandeh etal. 1998) and 
France (Leger et al. 1999) and used questionnaires about sleep to determine 
the prevalence of sleep disorders among blind people with and without light 
perception. One study found a higher prevalence of sleep disturbance in 
subjects with NPL compared to sighted control subjects (Tabandeh eta/. 
1998). The same study also reported that nearly 49% of blind people with and 
without LP had disturbed sleep according to the PSQI and interview when 
compared to sighted control subjects. The primary complaints of the blind 
subjects in this cohort included interrupted sleep, increased sleep latency, 
short sleep duration and daytime sleepiness/napping. This study did not find 
any correlation between the extent of sleep disturbance and the aetiology of 
visual loss.
The second large cohort study to assess sleep disturbance in the blind found 
that 82% of blind people with and without light perception reported sleep
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problems compared to 57% of controls (Leger et al. 1999). The blind subjects 
had longer sleep latency, more night awakenings and were more likely to 
report use of sleep medication than sighted controls. In addition, parasomnias 
were more common among blind people compared to sighted controls. This 
study attempted to extrapolate their findings to circadian rhythm type and 
based on their assumptions found a prevalence of 18% free-running (non­
entrained) rhythms among those who reported total blindness compared to 
13% of those who reported near total blindness.
Sleep disruption has been consistently observed in blind people, even in 
those who do not have circadian rhythm abnormalities. It is unclear whether 
the pattern of sleep can be consistently related to circadian rhythm type. In 
addition, it is unclear whether certain eye conditions may predispose specific 
circadian rhythm types and/or specific patterns of disrupted sleep. The aims of 
the present chapter are to explore new methods for classification of circadian 
rhythm type and to determine the prevalence of circadian rhythm type among 
field study subjects. In addition, this chapter aims to assess the pattern of 
sleep disruption among blind women by circadian type and to determine the 
prevalence of sleep disorders among women who completed the survey as 
measured by the PSQI. Finally, this chapter attempts to compare cause of 
vision loss to circadian rhythm type and presence of disrupted sleep in order 
to determine whether certain eye conditions are related to disrupted sleep 
among the blind.
6.2 Methods
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6.2.1 Urine collection
Details of the urine collection are described in Section 2.6.2.2. In brief, 
subjects were asked to collect 48 h sequential urine samples in 4 h bins 
during the day and 8 h bins overnight on two or three occasions during the 
eight-week field study. Each subject was asked to document the total urine 
volume at the end of each collection and aliquot a ~4 m l sample into a 
collection tube.
6.2.2 Cosine analysis
Samples were analysed for the melatonin metabolite aMT6s as described in 
Section 2.6.3.2. aMT6s values in ng/mL were converted to ng/h and subjected 
to cosinor analysis (software provided by Dr. D.S. Minors, University of 
Manchester, U.K.) to determine the melatonin acrophase. Results were used 
in the present analysis if they showed a significant cosine fit at the p < 0.15 
level, yielding 197 significant acrophases.
6.2.3 Mid-range crossing analysis
In addition to cosine fitting, mid-range crossing of the aMT6s peak was also 
calculated. The mid-range crossing of the aMT6s rhythm was determined by 
calculating the times when the rising and declining phases of the aMT6s 
rhythm reached half the peak value of the collection period. The midpoint was
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calculated as the time between the rising and declining aMT6s phases. The 
rising phase, declining phase and midpoint calculations were each plotted 
against the cosine derived acrophases.
6.2.4 aMT6s peak comparison
Significant (p <0.15) aMT6s acrophases were compared to the rising, 
declining and peak mid-range crossing values to determine reliability between 
analysis types (Figure 6.1). If one or more of the cosine results for a given 
subject was not significant, the rising phase of the midpoint crossing value 
plus the intercept of the relationship between the cosinor acrophase and the 
rising phase of the midpoint crossing for all subjects (2.77h) was used for 
classification. The same analysis was used for each collection block within a 
subject.
To assess changes in timing of the aMT6s peak, tau (x) was calculated from 
the first two data collection points as:
(aMT6s peak of collection 2 -  aMT6s peak of collection 1 )
X =   + 24
number of days between collections
6.2.5 Sleep parameter calculation -  field study
Details of sleep diary data collection are described in Section 2.6.2.1. In brief, 
subjects were asked to complete a sleep diary for eight weeks. This diary 
included information regarding timing of all sleep during the day and night as
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A 1 8 : 0 0
12:00 -
0 6 : 0 0  -
Q. 2 4 : 0 0
1 8 : 0 0  -
12:00
B 1 8 : 0 0  -
^  12:00 -
S  0 6 : 0 0  -
2 4 : 0 0  -
R = 0.99 
= 0.9912:00
1 8 : 0 0
12:00
0 6 : 0 0
5  2 4 : 0 0
1 8 : 0 0
R = 0.99 
R  ^= 0.99
12:00
12:00 1 8 : 0 012:00 1 8 : 0 0 2 4 : 0 0 0 6 : 0 0
Cosinor derived acrophase
Figure 6.1 Correlation between cosinor-derived melatonin acrophase and the 
half-peak upward crossing (A), the mid-range crossing peak (B) and the half­
peak downward crossing (C).
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well as sleep latency, number and duration of night awakenings, naps, drowsy 
periods and daily subjective sleep quality (Appendix B).
Mean values and standard deviations were calculated for each variable by 
subject. Sleep parameters were scored to describe an individual subject’s 
level of sleep disruption using a global sleep score. To calculate the global 
score, the standard deviation of the mean for all subjects combined was 
calculated for each of the following variables; sleep latency, number of 
arousals from sleep, total sleep, duration of night awakenings, sleep efficiency 
(calculated as time asleep/time in bed), sleep onset, sleep offset, number of 
naps, nap duration and time in bed. If a subject’s mean for a particular 
variable was outside the standard deviation of the group mean, the subject 
was given a score of 1 for that variable. If the subject’s mean for a particular 
variable was within the standard deviation of the group mean, the subject was 
given a score of 0 for the variable. Similarly, if a subject’s upper or lower 
standard deviation for a particular variable fell outside the group standard 
deviation, the subject was given a score of 1 for the standard deviation on that 
variable. If the standard deviation fell within the group standard deviation, the 
subject was given a score of 0 for the variable. The sum of the scores for 
each of the variables and their upper and lower standard deviations were 
calculated to create a global sleep disruption score with a possible range from 
0- 20 .
6.2.6 Assessment of circadian rhythmicity -  field study
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Only subjects who had two reliable aMT6s peaks (as described above, using 
either cosinor or midrange crossing analysis) and who completed sleep 
diaries were used in this analysis (n = 118 of 130).
6.2.6.1 Determination of entrainment -  field study
A subject was considered entrained at a normal phase (NE) if the mean of the 
aMT6s peak from collection 1 and collection 2 fell within the normal range 
described for sighted subjects (1.3-7.1 ; Lockley et al. 1997a) and the 
calculated period between collections 1 and 2 fell within the normal range of 
periods as calculated for sighted subjects living in a dim 24 h light-dark cycle 
(23.88-24.12; Wright ef a/. 2001).
A subject was considered entrained at an abnormal phase (AP) if the 
calculated period fell within the normal range described above and the timing 
of the mean aMT6s peak between collection 1 and collection 2 fell outside of 
the normal range described above. The crossing point between advances and 
delays was selected at 16:12 h as it is 180 degrees out of phase from the 
midpoint of the aMT6s peak range of normally entrained subjects. Subjects 
with mean acrophases before 16:12 were classified as entrained at an 
abnormally delayed phase and those with mean acrophases after 16:12 were 
classified as entrained at an abnormally advanced phase.
6.2.6 2 Determination of non-entrained rhythms -  field study
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A subject was considered non-entrained (non-E) if she met one of two criteria. 
First, if both the timing of the mean aMT6s peak and period were outside the 
normal ranges, a subject was considered to be non-entrained. A subject could 
also be classified as non-entrained if her period was outside the normal 
range, but the timing of her mean aMT6s peak was within the normal range if 
she presented a global sleep disruption score of > 6. The cut off point of six 
was chosen, because all subjects who were classified as non-entrained using 
aMT6s peak and period information had global sleep disruption scores > 6. 
Therefore, scores of six or greater provided additional evidence to classify a 
subject as non-entrained when both aMT6s peaks were not outside the 
normal range.
6.2.6.3 Unclassifiable rhythms
A subject was classified as “unclassifiable” (UN) if she had a period outside 
the normal range, but a mean melatonin peak within the normal range and a 
global sleep disruption score of < 6.
6.2.7 Sleep analysis by circadian type
Subjects were classified using the methods described above. Subjective sleep 
diary variables were grouped by circadian type and subjected to a one-way 
AN OVA. Duncan’s new multiple range test was performed to assess between 
group differences.
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Daily phase was calculated by extrapolating the daily change in period to all
days of study. For example, a subject with a calculated period of 24.2 would 
change by 0.2 hours each day. Therefore, if the aMT6s peak derived from her 
urine samples on day 14 occurred at 5:00 h, then her peak would be assumed 
to change to 5:12 on day 15 and 5:24 on day 16 etc. These extrapolated 
values were converted into 360 degrees, where 0 degrees was defined as the 
time of the peak of the aMT6s rhythm each day. Bedtime was used as a 
reference point for plotting other sleep variables. For example, if a subject had 
an aMT6s peak at 14:00 h on a given day and attempted to sleep at 2:00 h on 
that day, her attempt to sleep would be occurring 180 degrees out of phase 
from her aMT6s peak. Other sleep variables (latency, subjective quality, 
duration, arousals etc.) for that particular day would be binned in the circadian 
degree bin for the attempted sleep relative to the extrapolated aMT6s peak. 
These data were then organised into 60 degree bins as follows 331-30 
degrees, 31-90 degrees, 91-150 degrees, 151-210 degrees, 211-270 
degrees, and 271-330 degrees.
6.3 Results
6.3.1 Assessment of circadian rhythmicity
6.3.1.2 Subjects with light perception
There were 118 field study subjects with complete data sets available for 
circadian classification. Of these, 78 subjects self-reported having LP. The
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Table 6.1 The distribution of circadian type by light perception status using 
melatonin peak, calculated period and eight-week sleep diary parameters for 
classification.
NPL (%NPL) LP (% LP) Total (% total)
Normally entrained 13(33) 38 (49) 51 (43)
Abnormally phased 10(25) 13(17) 23(19)
Advanced 7(18) 8(10) 15(13)
Delayed 3(8) 5(6) 8(7)
Non-entrained 16(40) 22 (28) 38 (32)
Unclassifiable 1 (3) 5(6) 6(5)
Total 40 78 118
NPL = no perception of light; LP = light perception
circadian classification of LP subjects by self-reported level of vision is 
presented in Table 6.1. The majority of subjects with LP were classified as 
normally entrained (n = 38, 49%). Of the 13 subjects (17%) determined to be 
abnormally entrained, eight were entrained to an advanced phase and five 
were delayed. There were 22 LP subjects (28%) who were classified as non- 
entrained and five (6%) who were unclassifiable.
Figure 6.2 shows the distribution of circadian classification among LP subjects 
by self-reported level of vision.
6.3.2.2 Subjects with no perception of light
There were 40 subjects with NPL with complete data sets available for 
circadian classification. The distribution of the circadian classification for NPL 
subjects is shown in Table 6.1. A large proportion (40%) of subjects with NPL 
were classified as non-entrained (n = 16). There were 13 subjects who were 
classified as normally entrained (33%) and 10 subjects (25%) classified as
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abnormally phased. Of the abnormally phased subjects, seven were classified 
as entrained at an advanced phase and three were classified as delayed. One 
subject was unclassified (3%).
Figure 6.3 shows the distribution of circadian classification among NPL
subjects with the presence of one, two or no eyes. The proportion of subjects 
classified as non-entrained, entrained and abnormally entrained was the 
same for those with two eyes present as it was for those with no eyes present.
6.3.2.3 Circadian period
As expected based on the criteria used for classification of normal 
entrainment, the mean circadian period among all normally entrained subjects 
was 24.00 h (± SD 0.05 h) regardless of light perception (LP = 24.00 ± 0.05 h; 
NPL = 24.00 ± 0.05 h). Similarly, the mean circadian period among 
abnormally phased subjects was 23.99 h (± 0.07 h; LP = 23.98 ± 0.08 h; NPL 
= 24.00 ± 0.07 h). Among non-entrained subjects, the group mean was 24.22 
h (± 0.47 h) and was 24.17 h (± 0.52 h) among subjects with LP and 24.28 h 
(± 0.40 h) among subjects with NPL. In addition, the mean including only 
those subjects with periods > 24 h was 24.45 h (± 0.33 h) and among those 
with periods < 24 h was 23.65 h (± 0.18 h). Among non-entrained subjects, 
29% were classified as having circadian periods shorter than 24 h and 71% 
had periods longer than 24 h.
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Number of 
subjects 1 5  -
Vis Chart Count Fingers Shadows LP Only
Figure 6.2 Distribution of circadian type among LP subjects by degree of 
visual impairment, black bars = normally entrained; light gray bars = 
abnormally phased; dark gray bars = non-entrained; white bars = 
unclassified
vis chart = able to see the vision chart; count fingers = able to count fingers; 
shadows = able to see shadows; LP only = no vision other than light
25 -
Number of 20 - 
subjects
15 -
10 -
2 Eyes Present 1 Eye Present 0 Eyes Present
Figure 6.3 Distribution of circadian type among NPL subjects by number of 
eyes present, black bars = normally entrained; light gray bars = abnormally 
phased; dark gray bars = non-entrained; white bars = unclassified
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Figure 6.4 shows the mean (± SD) subjective measurement for sleep latency (A) and sleep 
onset time (B) for 118 field study subjects with complete datasets. Subjects with LP are 
indicated by open symbols and subjects with NPL are indicated by filled symbols. Circadian 
type Is indicated as follows (o, NE; □, AP -  advanced; 0, AP -  delayed; ^ Non-E; A, UN). The 
shaded area represents the standard deviation of the group mean which is shown by the 
white line.
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Figure 6.4 shows the mean (± SD) subjective measurement for number of night awakenings
(C) and total nightly sleep loss (D) for 118 field study subjects. See Figure 6. A-B for details.
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Figure 6.4 shows the mean (± SD) subjective measurement for sleep offset time (E) and total
sleep duration (F) for 118 field study subjects. See Figure 6. A-B for details.
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G -  Time In bed H. -  Sleep efficiency
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Sleep Efficiency
Figure 6.4 shows the mean (± SD) subjective measurement for time in bed (G) and sleep
efficiency (H) for 118 field study subjects, See Figure 6. A-B for details.
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I -  Number of naps J -  Nap duration
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Number of naps
Figure 6.4 shows the mean (± SD) subjective measurement for number of naps (I) and nap
duration (J) for 118 field study subjects. See Figure 6. A-B for details.
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K -  Daily sleep quality
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Daily Sleep Quality Rating
Figure 6.4 shows the mean (± SD) subjective measurement for daily sleep quality (1 = the 
best sleep ever, 9 = the worst sleep ever, [K]) for 118 field study subjects. See Figure 6. A-B 
for details.
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6.3.2 Daily mean sleep
Figure 6.4 shows the mean (± SD) for subjective sleep parameters for 
individual subjects grouped by circadian rhythm type. There were several 
subjects with mean sleep parameters outside the group mean range. Subjects 
with outlier variables were apparent in each classification group, which 
contributed to wide and overlapping ranges in the global sleep disruption 
scores in each group (Table 6.2).
Table 6.4 shows the group means (± SEM) for subjective sleep parameters by 
circadian rhythm type. Between group differences were observed in the 
number of night awakenings and time in bed (p < 0.05, one-way AN OVA). It 
was not possible to determine which groups contributed to the differences in 
these variables due to low power in the classification subgroups.
Figure 6.5 shows the distribution of sleep outcomes across different circadian 
phases for subjects with LP (n = 22) and NPL (n = 16) who were classified as 
non-entrained.
6.3.3 Circadian type and eye condition
There were 20 different primary eye conditions reported among the 118 field 
study subjects used in the circadian type analysis (Table 6.3). Several eye 
condition categories had few subjects and therefore it was not possible to
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Table 6.3 Number of field study subjects of each circadian type by eye 
condition.
Primary Eye Condition Non-E AP UN NE
Enucleation of any cause 5 3 - 4
Retinitis Pigmentosa 6 1 - 10
Retinal Dystrophies other than Retinitis 1 9Pigmentosa
Diabetic Retinopathy 1 - 1 -
Retinopathy of Prematurity 7 9 1 11
Congenital Defects -  IVIiscellaneous - 1 1
Retinal Disease -  Miscellaneous - - 1 1
Brain Tumour (other than 2Retinoblastoma)
Ocular Trauma 2 2 - -
Optic Atrophy 3 1 - 1
Glaucoma 4 1 - 2
Leber’s Congenital Amaurosis - - - 3
Dry Macular Degeneration 1 - 1 1
Wet Macular Degeneration 1 - -
Anterior Segment Disease 2 - - 4
Microphthalmia 1 1 - 1
Aniridia 1 1 - -
Uveitis 1 - - 1
Unknown 2 4 1 7
Total 38 23 6 51
Non-E = non-entrained; AP = abnormally phased; UN = unclassified; NE
normally entrained
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Figure 6.5 shows the distribution of sleep throughout the eight week field 
study in subjects classified as non-entrained with NPL (n = 16; left column) 
and LP (n = 22; right column). Data are double plotted by circadian phase 
relative to the subject’s bedtime (± SEM) during each day of the protocol.
Data were binned in 60° bins (~4 h) and are double plotted. See Section 6.2.7 
for details.
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Figure 6.5 shows the distribution of sleep throughout the eight week field study in subjects 
classified as non-entrained with NPL (n = 16; left column) and LP (n = 22; right column). Data 
are double plotted by circadian phase relative to the subject’s bedtime (±SEM) during each 
day of the protocol. Data were binned in 60° bins (-4  h) and are double plotted. See Section 
6.2.7 for details.
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correlate specific eye conditions to circadian type. In the categories with the 
most subjects, the conditions most associated with abnormal entrainment 
and/or non-entrained type were enucleation of any cause (63%), retinopathy 
of prematurity (57%) and glaucoma (71%). By contrast, 59% of subjects with
retinitis pigmentosa were classified as normally entrained.
6.3.4 Sleep outcomes -  survey cohort
The prevalence of sleep disorders as assessed using the PSQI was 76% for 
subjects with NPL and 66% for subjects with LP.
Group means and standard deviations for selected sleep parameters are 
presented in Table 6.5. All categories of blindness except for amblyopia and 
retinoblastoma had mean PSQI scores indicative of a sleep disorder (score > 
5, Buysse et al. 1989).
6.4 Discussion
This chapter shows the prevalence of circadian rhythm type among a large 
cohort of visually impaired subjects using objective criteria from two aMT6s 
urine collections and eight weeks of sleep diary collection. Further, this 
chapter confirms the high prevalence of sleep disturbance among those with 
all types and degrees of blindness and presents data on how certain eye 
conditions may be related to circadian type or sleep disturbance.
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The distribution of circadian rhythm disturbance in this cohort was similar to 
what has been previously reported for those with NPL. Using alVITGs peak
timing, calculated period and sleep disturbance as methods of classification, 
65% of subjects with NPL were classified as having an abnormal circadian 
rhythm type, including 40% who were classified as having non-entrained 
rhythms. This is somewhat lower than the aggregated prevalence of 76% for 
NPL subjects with abnormal aMT6s rhythms reported by Skene and 
colleagues (1999a). The incidence of non-entrained rhythms is also slightly 
lower than was reported in a study by Sack and colleagues (1992), who found 
that 56% of totally blind subjects studied had non-entrained rhythms. The 
current finding is, however, much higher than the 18% prevalence estimate 
reported by Leger and colleagues (1999) in a study based solely on sleep 
reports. The finding that blind women with NPL have a higher prevalence of 
non-entrained rhythms is expected, as it is likely that most blind women with 
self-reported NPL do not retain the photoreceptor cells required for light- 
induced entrainment. While the prevalence of non-entrained sleep disorders 
in NPL is somewhat lower than prior reports, it is consistent with expectations. 
There are several explanations for the small differences across these studies, 
however. First, the current study was conducted in a cohort of North American 
women as compared to the Skene cohort which was comprised of men and 
women from the United Kingdom and the Leger cohort which included both 
genders in France (n = 901 NPL). Further, the Sack cohort was comprised of 
men and women in the United States, but it only included 20 NPL subjects 
compared to the 40 NPL subjects used in the present analysis. In addition, 
both the Skene and Sack cohorts used different methodologies for
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classification, each collecting multiple melatonin and/or aMT6s rhythms 
across many weeks to use in a regression analysis to determine circadian 
rhythm type. Using regression analysis provides estimates of the error around 
the rhythm peaks through the collections. Using only two sample periods as 
has been done in the present study, it is not possible to account for the 
possibility of error and a straight line relationship is assumed. The present 
analysis was limited to the aMT6s peak from two collection periods which 
restricted the types of analyses that could be conducted. The differences in 
the methods may account for some of the observed differences between 
studies.
Among field study subjects, only 49% of subjects with LP were classified as 
having normally entrained rhythms, compared to 77% as reported in prior 
studies (Skene et al. 1999a, Lockley et al. 2007). In addition, 28% of field 
study subjects in the present analysis were classified as non-entrained, while 
only one other study has reported non-entrained rhythms in blind people with 
light perception and in that study the prevalence was estimated at 13% (Leger 
et al. 1999). The Leger study did not collect hormonal information about 
subjects, but rather made assumptions about circadian rhythm type based on 
responses to a questionnaire. It is likely that there is some degree of mis- 
classification of LP subjects described in this chapter. The fact that the 
prevalence of non-entrained rhythms was estimated to be higher in the LP 
group is likely due to the strict application of rules. An alternative methodology 
could have assumed that those subjects self-reporting light perception would 
not be capable of having non-entrained rhythms due to the presence of light
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cues, however, the stricter methodology was chosen for several reasons.
First, it is unclear how certain eye conditions may affect the non-visual 
pathway from the eye to the SCN. It is possible that some of the LP subjects 
have non-entrained rhythms due to damage to the melanopsin-containing 
photosensitive retinal ganglion cells or the retino-hypothalamic tract. It has 
been previously demonstrated that up to 30-40% of blind people who lack 
conscious vision retain the cells necessary for circadian entrainment (Czeisler 
etal. 1995, Klerman et al. 2002, Zaidi et a i 2007), however, it has not been 
shown that the reverse may occur (i.e. that people with some degree of vision 
lack circadian photoreception). If it is possible to lose the cells responsible for 
circadian photoreception without losing vision, it is likely that such a condition 
would be extremely rare as there is no known eye condition that selectively 
destroys melanopsin containing retinal ganglion cells (or that results in 
melanopsin deficiency). Given the high proportion of subjects with LP who 
were classified as non-entrained, it is unlikely that such an explanation would 
be responsible for the classification of all of these subjects. A plausible 
alternative explanation is that some of the non-entrained LP subjects have 
non-entrained rhythms due to inappropriately timed self-selected light 
exposure. It is also likely that social factors may account for some of the 
abnormal rhythms among non-entrained subjects with LP, as 23% of the 
subjects classified as non-entrained reported living alone (Section 3.3.1). 
Living alone, these subjects may not use indoor lighting at all and therefore 
may never receive sufficient light exposure to achieve entrainment. Similarly, 
64% of the LP subjects classified as non-entrained were not employed and an 
additional 18% were only employed part-time. Figure 6.6 shows a
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representative raster plot and alVITGs profile for a subject who was classified
as non-entrained, but who self-reported having LP. As observed on the plot, 
the subject clearly experiences a later aMT6s peak and later sleep onsets and 
offsets throughout the course of the study. It is possible that this subject 
experienced a phase delay due to self-selection of light exposure, as there 
are some nights during the study when the subject does not attempt to sleep 
until very late. It is not clear whether this is the case, however, as light 
information was not collected for the majority of study subjects.
The distribution of sleep by circadian phase in non-entrained LP and NPL 
subjects (Figure 6.5), suggests that these two groups are different. As 
observed on the plots, the non-entrained NPL subjects have characteristics 
consistent with prior reports, such as an increase in night awakenings and 
decrease in total sleep duration in the circadian bins corresponding to going to 
bed out-of-phase (bins 120°-240°; Figure 6.5 B, Lockley et al. 1999). In 
addition, NPL subjects have an observable increase in the number and 
duration of naps when they coincide with the aMT6s peak and a decrease in 
naps at the time when the wake maintenance zone would be expected to 
occur (bin 240° Figures 6.6 F and G). By contrast, the LP subjects classified 
as non-entrained do not appear to have these characteristic features 
suggesting that they may be different.
Lifestyle choices may also explain why 17% of subjects with LP were 
entrained at an abnormal phase. Figure 6.7 shows a representative subject
6-33
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with LP who likely had a light-induced delayed entrained phase. This subject 
woke to a series of 3 alarm clocks each day with the first one going off at 4.00 
h. It is likely that this subject exhibited a delayed aMT6s rhythm due to this 
self-selected early light exposure just before the transition point on the phase 
response curve (Section 1.2.2). This subject’s raster plot is also interesting in 
that it demonstrates how even when she slept later on her days off work 
(vacation on days 17-29 and numerous weekends e.g. days 40-41), she never 
slept at what would be considered a normal phase angle relative to her 
aMT6s peak.
It has been reported that the period of non-entrained blind subjects is longer 
than the period in sighted subject studied under dim light constant routine or 
forced desynchrony conditions (Czeisler et al. 1999, Sack at al. 2000, Hack at 
al. 2003). The range of periods in the present cohort extended from 23.35- 
25.44 h with a mean of 24.45 h (including periods >24 h only, Table 6.2). This 
range and mean is similar to the slightly longer periods that have been 
reported previously. Although, the mean for the entire cohort of non-entrained 
subjects was 24.22 h, which is similar to the average period reported in 
sighted subjects (Czeisler at al. 1999). Over a third of the non-entrained blind 
subjects with i  > 24 h had periods less than 24.3 h, which is the shortest 
period reported by any of the aforementioned studies in the blind. It is 
possible that studying subjects over a long duration of eight weeks makes it 
easier to observe slow non-entrained rhythms. For example, if a subject had 
an endogenous period of 24.3 h and was asked to complete collection periods 
at week two and four over a diary collection of four weeks it might not be
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possible to distinguish the observed period from an entrained period of 24 h.
In this example, if the peak of the first collection period was at 2:00 h, the
peak collected two weeks later would occur at 6:12 h. Though these peaks 
differ by 4.2 h, they both fall within the range of normal aMT6s peak times in 
sighted subjects (Lockley et al. 1997a) and using the classification 
methodology described in the present chapter, would be classified as 
entrained. If the collection periods were spaced four weeks apart (as in the 
present study) with the peak of the first collection period occurring at 2:00 h, 
the peak of the collection four weeks later would occur at 10:24 h. In this case 
the second peak would occur outside the normal range and the subject would 
be classified as non-entrained.
As previously noted this classification includes subjects with LP and a gradual 
light-induced delay may also account for the lower mean in period. The mean 
period for the NPL subjects alone was only slightly longer at 24.45 h (range 
24.12 - 25.16 h. Table 6.2). Another explanation for the differences may be 
that the cohorts using extensive physiological methodology specifically 
recruited participants in an attempt to examine circadian rhythmicity and 
therefore may have been more likely to study subjects with longer non- 
entrained rhythms as they would have been more obvious to both the subjects 
and the researchers.
The PSQI score for all but two eye condition groups was > 5, which is the cut­
off score that indicates likelihood of a sleep disorder (Buysse et al. 1989). In 
addition, nearly all categories had long mean sleep latencies (> 20 minutes)
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and a wide range of mean sleep durations. The prevalence of sleep disorders 
among the blind has been reported to be as high as 82% (Leger et al. 1999), 
though it is unclear why blind people with LP have such disturbed sleep. The 
prevalence of sleep disturbance (as measured by PSQI scores > 5) among all 
subjects in the present cohort was 69%, with 76% of NPL and 66% of LP 
subjects, very similar to Tabandeh et al. (1998). There are several possible 
hypotheses to explain the disturbed sleep among the blind. First, as in the 
glaucoma subjects, it is possible that progressive degradation of the eye 
ultimately leads to loss of or impaired light input to the circadian pacemaker. 
Alternatively, there have been reports that certain types of blindness are co- 
morbid with sleep disorders such as sleep apnea (Waller et al. 2008) and 
parasomnias (Leger et al. 1999). It is possible that lifestyle differences 
between the sighted and the blind account for these coexisting conditions.
The elevated BMI among subjects in this cohort is consistent with the 
hypothesis that blindness itself may be associated with low physical activity, 
which is associated with an elevated BMI and ultimately an elevated risk for 
sleep apnea. An additional explanation for disturbed sleep among the LP blind 
subjects may be symptoms of depression. It has been reported that older 
institutionalised blind subjects have a higher incidence of sleep disorders and 
depression (Ip et al. 2000). The association with depression may exist across 
all types of blindness or it may be limited to certain types of blindness or onset 
of blindness, as in age-related macular degeneration where onset of 
blindness occurs late in life. In this cohort there was not a significant 
difference in history of depression between LP and NPL subjects, however, 
history of depression was slightly higher among the blind women in this cohort
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than in the US female population (26% vs. 20%, respectively. Table 3.3,
Bhatia and Bhatia 1999). Finally, the prevalence of sleep disorders reported 
may be elevated in the survey cohort due to selection bias. It is possible that 
subjects viewed the study as a sleep study and therefore those with pre- 
existing sleep disorders may have been more likely to participate.
In summary, the prevalence of circadian rhythm disorders in this cohort was 
similar to previous reports for women with NPL. However, the application of 
strict classification methodology resulted in what is a higher than expected 
proportion of women with LP being classified as non-entrained. A longer 
duration of blindness was also associated with disturbed sleep, however, 
disturbed sleep as measured by PSQI was apparent across all categories of 
vision loss, regardless of circadian rhythm type. Future studies should screen 
for other sleep disorders and examine lifestyle differences in blind people 
when determining circadian rhythm type and the reasons for their sleep 
disruption.
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CHAPTER 7
PREDICTING CIRCADIAN TYPE USING A 
QUESTIONNAIRE BASED MODEL
CHAPTER 7 - PREDICTING CIRCADIAN TYPE USING A QUESTIONNAIRE 
BASED IVIODEL
7.1 Introduction
As described in Chapter 6, the optimal screening method for determining 
circadian rhythm type is very time consuming (e.g. collection of sleep diaries 
along with urine/blood samples for 24-48 h at a time across several weeks or 
months). Questionnaire-based screening tools to determine circadian rhythm 
type may be very useful in clinical practice to help distinguish people who may 
be non-entrained with a non-24 h circadian rhythm sleep disorder from those 
who have other sleep disorders. Current screening tools, such as the PSQI 
are unable to differentiate between those blind people with sleep problems 
due to non-entrained rhythms and those with other sleep disorders like 
insomnia (Chapter 6).
To date, there have been two questionnaire-based studies that have 
examined circadian rhythm type in the blind. The first study did not define 
circadian rhythm types, but instead examined the prevalence of sleep 
disorders using the PSQI in NPL compared to sighted subjects and found a 
higher prevalence of sleep disorders in those with NPL (Tabandeh et al.
1998). The same study also reported disturbed sleep in LP blind people 
compared to sighted controls. The second questionnaire based study used 
the Stanford Sleepiness Questionnaire and Evaluation of Wakefulness 
(SQAW) to determine circadian rhythm type and the level of sleep disturbance
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in blind people with varying degrees of light perception (Leger et al. 1999). In 
this study the prevalence of non-entrained circadian type was assessed using 
only survey questions. This study estimated the prevalence of non-entrained 
rhythms at 18%. It is unclear that this is a valid estimate, because the 
published SQAW criteria for non-entrained classification includes collection of 
objective measures of internal period, which the authors did not collect. 
Instead, they relied solely on the questions from the SQAW to estimate the 
prevalence of non-entrained subjects.
It has been shown that certain eye conditions appear to be related to 
circadian rhythm type. For example, retinitis pigmentosa has been 
consistently associated with normally entrained or abnormally phased status, 
while bilateral enucleation is associated with non-entrained status (Lockley et 
al. 1997a). It may be useful to determine which eye conditions are more 
associated with non-entrained circadian type in tandem with questionnaire- 
based screening methods for clinical use. Similarly, it may be hypothesised 
that certain eye conditions cause progressive degeneration of the retinal 
ganglion cell layer and may not be associated with non-entrained circadian 
type at the onset of disease, but may be associated with loss of circadian 
photoreception following many years of disease progression. In addition, such 
information may help reveal which cells within the eye outside the retinal 
ganglion cell layer may be important in modulating circadian coordination.
The aims of the present chapter are to identify survey questions that are 
predictive of non-entrained and normally entrained circadian rhythm types and
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to develop a model to predict circadian type using only a questionnaire. 
Further aims of this chapter are to apply the questionnaire-based model to the 
survey data to reveal how eye conditions may relate to circadian rhythm type 
and to test the hypothesis that eye conditions such as glaucoma are 
associated with non-entrained circadian type after many years with the 
disease.
7.2 Methods
7.2.1 Predicting circadian type using a survey model
A model was developed to predict circadian rhythm type using questions from 
the survey. Survey questions with a hypothesised relationship with circadian 
rhythm type were subjected to univariate chi square tests for subjects 
classified by that circadian type. For example, for univariate comparisons 
subjects were classified as “normally entrained” vs. “all other classifications,” 
and “non-entrained” vs. “all other classifications.” Abnormally phased subjects 
were not considered separately due to the variability in responses in subjects 
with advanced compared with delayed phases and due to the low sample size 
in each of these categories.
The variables considered for the model are presented in Table 7.1 (See 
Appendix A for complete survey questions and answers) Briefly, categorical 
variables such as arising from the question; during the past month how often 
has it taken longer than 30 minutes to get to sleep,' with the possible
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responses not during the past month,’ less than once a week,’ once or twice 
a week,' or ‘three or more times a week,' were treated continuously with not 
during the past month being coded as O' and three or more times a week 
being coded as ‘3.’ In all cases the score related to better sleep was 
hypothesised to be related to normal entrainment, while the score related to 
poorer sleep was hypothesised to be related to non-entrained circadian type.
Two models were developed based on these univariate predictors. The first 
model included only variables that were associated with normally entrained 
status at the p < 0.15 level. The second model included only variables that 
were associated with non-entrained status at the p < 0.15 level. Both models 
included light perception status (dichotomously, yes/no).
7.2.1.1 Model development
There were 11 variables included in the model for normal entrainment and six 
variables included in the model for non-entrained type (see Table 7.1 for the 
questions included in each model). Each variable included in the models was 
scaled equally with a maximum score of three. For categorical variables with 
four answer outcomes, a higher score correlated with poorer sleep 
parameters in the model. For example, for the question 'How would you rate 
your sleep quality overall,' subjects were given the response options ‘very 
good,' fairly good,' ‘fairly bad' or very bad.' For the models, this response 
was scaled so that very bad’ would result in a score of 3 and very good’ 
would result in a score of 0. Continuous variables, such as PSQI score were
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Table 7.1 Variables considered for inclusion in the circadian type models and 
their p-value associations with normal entrainment (NE; yes/no) or non-
Variable (survey question number**) NE Non-E
Use of sleep medication (87; yes/no) 0.01* 0.001*
PSQI score (81-90) 0.09* 0.04*
Hours of sleep/night (84) 0.01* 0.10*
Sleep quality"' (86) 0.07* 0.11*
Cyclic sleep pattern (94; yes/no) 0.34 0.12*
Daytime enthusiasm  ^(89) 0.35 0.17
Consistent breakfast time (65; yes/no) 0.93 0.47
Consistent lunch time (65; yes/no) 0.74 0.57
Consistent dinner time (65; yes/no) 0.06* 0.19
LP/NPL status 0.09* 0.20*
Good/bad sleep phases (93; yes/no) 0.34 0.19
Skip nights of sleep (96; yes/no) 0.52 0.20
Scleral shell use (15a; yes/no) 0.18 0.22
Sleep efficiency (84/(83-81)) 0.54 0.36
Melatonin use (68; ever/never) 0.42 0.55
Guide dog owner (15; yes/no) 0.79 0.59
Time in bed (83-81) 0.11* 0.97
Fall asleep during conversations^ 0.07* 0.92(100)
Fall asleep with TV on'* (100) 0.02* 0.39
Daytime sleepiness^ (88) 0.09* 0.67
Latency > 30 min® (85a) 0.10* 0.27
*Variables ultimately included in each model; see text for details 
**Full survey questions may be found in Appendix A
^^Categorical variables treated continuously (e.g. never, rarely, sometimes, often; see 
appendix for full survey questions)
NE = normally entrained; Non-E = non-entrained; PSQI = Pittsburgh sleep quality index; LP 
light perception; NPL = no perception of light
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also re-scaled from 0-3 and dichotomous variables were included using the 
scores 0 and 3. Hours of sleep per night was categorised so that reporting < 6 
hours per night would equal a score of 3, > 6 < 7 hours per night would equal 
2, > 7 < 7.5 hours per night would equal 1 and > 7.5 hours per night would 
equal 0. Use of sleep medications was a highly significant predictor for both 
models, so that variable was given additional weight by multiplying it by 3. 
‘Hours of sleep per night' was also a highly significant predictor of non- 
entrained, and so after categorical transformation, it was multiplied by a factor 
of 1.25. The weighting process for each variable was adjusted to achieve 
maximum sensitivity and specificity to the circadian type of interest (see 
description below). This resulted in a maximum score of 39 for the model of 
normal entrainment (10 variables each having maximum scores of 3, plus one 
weighted variable having a maximum score of 9) and a maximum score of 
24.75 for the model of non-entrained type (4 variables having maximum 
scores of 3, plus one weighted variable having a maximum score of 9, plus 
one weighted variable having a maximum score of 3.75). Scores were 
summed for all variables to create a model score (Table 7.2). For model 
application, subjects with missing data for any variable were excluded from 
analysis. Data were sorted and cut off scores were determined based on 
maximisation of sensitivity and specificity analysis (described below).
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Table 7.2 Example of score calculation for the non-entrained model________
Variable (survey question Raw model Weighted
number**)_____________________ Response______ score_______ score
Use of sleep medication (87; 
yes/no)*
Calculated PSQI score (81-90)^ 
Hours of sleep/night (84)^
Sleep quality (86)^ *
Cyclic sleep pattern (94; 
yes/no)®
LP/NPL status^______________
Total Score
yes
9
6
fairly bad 
yes 
NPL
1.35
3
2
3
1.35
3.75
2
3
22.T
raw score, yes = 3, no = 0; weighted score = raw score x 3 
 ^raw score = (calculated PSQI score/6.67) to scale from a maximum of 20 to a maximum of 3
 ^raw score, < 6 h = 3, > 6 < 7 = 2, > 7 < 7.5 = 1, > 7.5 = 0; weighted score = raw score x 1.25 
raw score, very bad = 3, fairly bad = 2, fairly good = 1, very good = 0 
 ^raw score, yes = 3, no = 0 
® raw score, NPL = 3, LP = 0
7.2.2 Sensitivity and specificity analysis
Sensitivity and specificity of the models were calculated by applying subject 
classification scores from the models to the physiological classification 
(Chapter 5) which included urinary aMT6s peak information along with 
extended sleep diary measures. Each model was tested based on the 
following matrix:
Physiological Classification 
(e.g. non-entrained)
Physiological Classification 
(e.g. any classification but 
non-entrained)
Model Classification 
(e.g. non-entrained) a B
Model Classification 
(e.g. any classification but
non-entrained)
c D
Sensitivity was calculated as a / (a + c) and specificity was calculated as d / (b 
+ d).
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The non-entrained model cut off was set at a model score of nine, so that any 
subject who achieved a model score < 9 would be classified as non-entrained 
and any subject who achieved a score less than nine would be classified as 
“not non-entrained.” This cut off score allowed maximum sensitivity and 
specificity in predicting non-entrained circadian type. Similarly, the cut off 
score for the normal entrainment model was set at 11, so that any subject with 
a score < 11 was classified as “normally entrained” and any subject with a 
score of 12 or more was scored as “not normally entrained.” Similarly, this cut 
off score was chosen, because it allowed maximum sensitivity and specificity 
for predicting normal entrainment status.
A final sensitivity/specificity analysis was conducted using only NPL subjects 
in the non-entrained model. This model used > 9 as a cut off score in order to 
compare it to the model including all subjects.
Subjects who did not answer all of the questions in each respective model 
were excluded from sensitivity and specificity comparisons (Figure 7.1). 
Unclassified subjects were excluded from the sensitivity and specificity 
analyses for both models.
7.2.3 Application of the model to the survey dataset
Both models were applied to the survey dataset. Only subjects who 
responded to all questions of interest were included in the application of the 
models.
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Group means for the sleep parameters, PSQI, cyclic sleep questions, 
morningness/eveningness questions were calculated based on the model 
grouping.
7.2.4 Eye disease and lag-time calculation
In order to determine whether deterioration of the eye due to disease 
progression over time was associated with sleep disruption and/or circadian 
rhythm type, mean sleep parameters were calculated for subjects by eye 
condition. The total duration of time since disease onset (lag-time) was 
calculated as the date of survey minus the onset of visual loss. The lag time 
was calculated for ROP, glaucoma and for enucleated subjects.
7.3 Results
7.3.1 Circadian type model application -  sensitivity and specificity
The normally entrained model resulted in 24 of the 47 subjects appropriately 
classified as normally entrained subjects and 23 subjects who were classified 
by the model as “not normally entrained,” but were classified using 
physiological measures as being normally entrained (4 NE subjects excluded 
due to missing information; Figure 7.1). This yielded a sensitivity of 51%. 
There were 35 of the 52 subjects who were appropriately classified as “not 
normally entrained,” and 17 subjects who were incorrectly classified as 
“normally entrained," yielding a specificity of 67%.
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The non-entrained model resulted in 23 of the 37 subjects who were 
previously classified as non-entrained by physiological measures (Chapter 6, 
Figure 7.1) being appropriately classified as non-entrained, with 14 subjects 
who were incorrectly classified as non-entrained for a model sensitivity of 
62%. There were 52 of the 67 subjects correctly classified as “not non- 
entrained” and 15 subjects incorrectly classified as “not non-entrained,” 
yielding a specificity of 78%.
When the non-entrained model was applied to only those subjects with NPL, 
all 16 non-entrained subjects were appropriately classified as non-entrained 
for a model sensitivity of 100%. There were, however, 14 NPL subjects 
classified by the model as non-entrained who were classified by physiological 
measures as “not non-entrained.” Only 9 subjects who were classified using 
physiological measurements as “not non-entrained" were classified correctly 
by the model, resulting in 39% specificity.
Combining the classifications obtained from the normally entrained and non- 
entrained models resulted in 30 subjects who could not be classified in either 
category and three subjects who overlapped categories and were classified 
as both non-entrained and normally entrained.
7.3.2 Application of the model to the survey
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Table 7.3 Application of two circadian classification models to the survey
cohort.__________________________________________________________
Number of subjects
_______________________NPL (% NPL) LP(%LP) Total (% total)
Normally entrained 63 (15) 434 (45) 497 (36)
Non-entrained 259 (62) 279 (29) 538 (39)
Unclassified 90 (22) 243 (25) 333 (24)
Overlapping 
classifications 5(1) 12(1) 17(1)
See text for details
*7 subjects did not provide LP/NPL status and were excluded from the 
model application
LP = light perception, NPL = no perception of light
Table 7.4 Selected mean outcomes by modeled circadian type among
NE Non-E UN OV
Age (y) 57.8(19.5) 55.9(16.1) 56.6(17.2) 58.8 (17.6)
PSQI (score)* 4.9 (2.6) 11.4 (3.4) 7.8 (3.1) 8.1 (3.3)
Latency (min) 21.3 (23.7) 45.6 (42.5) 31.1 (31.1) 27.9 (21.9)
Hours sleep / night 
(h)* 7.2 (1.2) 5.7 (1.4) 62(1.4) 6.5 (1.7)
Age of vision loss 
(age, y) 23.3 (29.5) 16.0 (24.0) 17.9 (26.2) 28.6 (32.2)
Age of loss of light 19.0(19.1; 17.3(18.1; 14.2 (17.7; 24.0 (24.3;
perception (age, y) n = 51) n = 216) n = 75) n := 5)
"These variables were included in the models and are therefore biased towards their
respective categories.
NE = normally entrained; Non-E = non-entrained; UN = unclassified; OV = overlapping 
classification; PSQI = Pittsburgh sleep quality index
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Both models were simultaneously applied to the survey cohort. Results of this 
application are presented in Table 7.3. The majority of NPL subjects (n = 259) 
were classified as non-entrained using this method (62%), while a high 
proportion of subjects with LP (n = 434) were classified as normally entrained 
(45%). There were 24% of all subjects who could not be classified in either 
group (n = 333) and 1% of subjects had overlapping classification in both 
groups (n = 17).
Mean data from selected outcomes are presented in Table 7.4. The mean age 
of normally entrained subjects (57.8 ±19.5 y) was older than non-entrained 
subjects (53.9 ±16.1 y). Non-entrained subjects also reported an earlier onset 
of blindness (23.3 ±29.5 y) and non-entrained NPL subjects reported an 
earlier loss of light perception (17.3 ±18.1) than normally entrained NPL 
subjects (19.0 ±19.1 y).
7.3.3 Comparison of circadian type to cause of vision loss
The distribution of circadian type predicted by the model is tabulated with 
respect to eye condition in Table 7.5. The survey cohort included subjects 
with primary eye conditions that fell into 29 categories. There were higher 
proportions of subjects in the normally entrained category among those 
subjects who reported vision loss due to any form of macular degeneration 
(49%), retinitis pigmentosa (47%) and anterior segment disease (44%). The 
eye conditions that resulted in a higher proportion of subjects categorised as 
non-entrained included those who
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Table 7.5 Circadian type predicted by the model by eye condition among
subjects in the entire survey cohort.
NE 
(% eye 
condition)
Number of subjects 
Non-E UN 
(% eye (% eye 
condition) condition)
OV 
(% eye 
condition)
Amblyopia 1 (100) 0(0) 0(0) 0(0)
Retinal disease-misc 13(57) 4(17) 5(22) 1 (4)
Brain tumour^ 11 (55) 7(35) 2(10) 0(0)
Macular degeneration 25 (52) 15(31) 6(13) 2 (4)
Wet macular degeneration 29 (48) 19(31) 13(21) 0(0)
Dry macular degeneration 29 (47) 15(24) 16(26) 2 (3)
Leber's congenital amaurosis 18(51) 12(34) 5(14) 0 (0)
Visual cortex disease 1 (50) 1 (50) 0(0) 0 (0)
Stickler's syndrome 2(50) 2(50) 0(0) 0(0)
Retinal dystrophies^ 15(50) 10(33) 4(13) 1 (3)
Retinitis pigmentosa 67 (47) 42 (29) 33 (23) 2 (1)
Anterior segment disease 27 (44) 16(26) 16(26) 2 (3)
Albinism 6(27) 7(32) 8(36) 1 (5)
Microphthalmia 3(27) 2(18) 6(55) 0 (0)
Coloboma 2(25) 2(25) 4(50) 0 (0)
Aniridia 3(43) 2(29) 2(29) 0(0)
Unknown 75 (41) 64 (35) 44 (24) 1 (1)
Retinoblastoma 2(40) 1 (20) 2(40) 0(0)
Retinal detachment 7(39) 8(44) 3(17) 0(0)
Glaucoma 29 (39) 25 (33) 21 (28) 0(0)
Optic atrophy 30 (33) 36 (40) 24 (27) 0(0)
Congenital defects-misc 8(23) 15(43) 12(34) 0(0)
Uveitis 7(30) 11 (48) 4(17) 1 (4)
Diabetic retinopathy 10(29) 17(50) 7(21) 0 (0)
ROP/RLF 56 (24) 115(49) 63 (27) 2 (1)
Ocular trauma 4(16) 12(48) 8(32) 1 (4)
Anophthalmia 0(0) 2(50) 2(50) 0(0)
Enucleation of any cause 17(14) 75 (61) 30 (24) 1 (1)
Endophthalmitis
."—"iZ____________2^x1-'xZ'"__
0(0) 1 (100) 0(0) 0(0)
mise = miscellaneous; ROP/RLF = retinopathy of prematurity/retrolentral fibroplasia; NE = 
normally entrained; Non-E = non-entrained; UN = unclassified; OV = overlapping classification
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reported vision loss due to uveitis (48%), diabetic retinopathy (50%),
retinopathy of prematurity (49%) and enucleation of any cause (61%).
The distribution of LP status for selected eye conditions among those who 
were categorised as normally entrained by the model is presented in Figure
7.2. The majority (87%) of the subjects classified as normally entrained 
reported having LP.
The distribution of LP status for selected eye conditions among those who 
were categorised as non-entrained by the model is presented in Figure 7.3. A 
high proportion (48%) of the subjects classified as non-entrained reported 
having NPL.
7.3.4 Duration of eye disease and relation to circadian type
The lag-time between onset of blindness and age at survey was examined for 
subjects who reported enucleation of any cause, glaucoma or ROP as their 
primary cause of vision loss. The mean lag time for enucleated subjects was 
not significantly different between those classified as entrained (n = 17) and 
those classified as non-entrained (n = 75; 48.6 years versus. 48.5 years, 
respectively; p = 0.99). The mean lag time for glaucoma afflicted subjects 
classified as non-entrained (n = 25) was 44.3 years, which was significantly 
different from the mean lag-time for glaucoma afflicted subjects classified as 
normally entrained (n = 29), which was 33.0 years (p = 0.04). The mean lag
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time for ROP subjects classified as non-entrained (n = 115) was 49.9 years 
which was not statistically different from those classified as normally entrained 
(n = 56), who had a mean lag time of 45.6 years (p = 0.07).
7.4 Discussion
This chapter presents a model that may be a useful first step in developing 
clinical questionnaire-based screening tools for determining circadian rhythm 
type in blind people. The model yielded a reasonable sensitivity (62%) and 
specificity (78%) for classification of physiologically confirmed non-entrained 
subjects, but was less reliable for classification of confirmed entrained 
subjects (sensitivity = 51%; specificity = 67%). The model was then applied to 
the entire survey cohort and predicted circadian type was compared by eye 
condition. Subjects with diseases affecting areas such as the blood supply to 
the retina and those affecting the optic nerve were more likely to be classified 
as non-entrained, suggesting eye disease may be an important factor in 
determining circadian type. In addition, subjects with glaucoma who were 
classified as non-entrained had a longer duration since the onset of disease, 
suggesting that disease progression may also be important. Notably, the 
model predicted that 61% of enucleated subjects were non-entrained, which is 
an important confirmation of the model as a very high proportion of 
enucleated subjects would likely be non-entrained.
The classification of subjects using the calculated period between two aMT6s 
peaks over time and changes in sleep disruption was considered the standard
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for the classification of the field study cohort despite the challenges in 
distinguishing light-induced phase from true internally generated non- 
entrained rhythms. Definitive classification of circadian type using extensive 
physiological measures, such as collection of three or more aMT6s peaks, 
may improve the efficacy of this model. Currently there is no clinical standard 
for screening blind people for circadian rhythm disorders thus questions from 
the survey were assessed to determine whether a model could be generated 
from the questionnaire to appropriately classify subjects. Abnormal 
entrainment was not considered in the model, because advanced and delayed 
phases would need to be considered separately and there were too few field 
study subjects available in these categories for validation of such a model.
When applied to the field study cohort, the model yielded relatively good 
sensitivity and specificity for non-entrained subjects, but the model was less 
accurate in predicting normal entrainment. The problems with predicting 
normal entrainment are likely due to the fact that all categories of blind 
subjects, regardless of circadian type or eye condition, are associated with 
significant sleep disruption. Prior studies have found that nap patterns and 
incidence of napping are well correlated with non-entrained circadian type 
(Lockley et a i 1995, Lockley et a i 1999), however, based on the survey 
questions it was not possible to determine whether a subject’s nap pattern 
changed over time in a way that would be consistent with non-entrained type. 
Incidence of napping was included in the normal entrainment model, but was 
not a significant predictor of non-entrained type in this cohort. Sleep 
disturbance has been reported to be associated with non-entrained circadian
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type, but there does not appear to be a good correlation between any other 
single sleep metric and circadian rhythm type (Lockley et a/. 1999, Tabandeh
et al. 1998). As a result, sleep outcomes that were associated with either 
normal entrainment or non-entrained rhythms were included in the model 
despite the assumption that a large proportion of entrained poor-sleepers 
would likely remain unclassified.
The sensitivity and specificity results using the model questions may be 
reasonable for use in current clinical practice given that there are no other 
screening tools available for predicting non-entrained rhythms in the blind. 
Other screening tools have been adopted with similar reliability based on such 
a rationale. For example, the sensitivity and specificity first reported for the 
prostate specific antigen test to screen for prostate cancer was only 46% and 
88%, respectively, and it has been used as the clinical standard for prostate 
cancer screening for 20 years (Deleare et at. 1988).
The model was ultimately applied to the entire survey cohort and yielded 
prevalence numbers that were very similar to prior reports for NPL subjects. 
Among NPL subjects, 62% were classified as non-entrained, while only 15% 
were classified as normally entrained. In addition, 61% of subjects reporting 
bilateral enucleation were classified as non-entrained, compared to only 14% 
of bilaterally enucleated subjects who were classified as normally entrained. 
These numbers are comparable to prior studies that used physiological 
outcomes for classification (Sack et ai. 1992, Tabandeh et al. 1998, Skene et
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a/. 1999) and suggest that this may be an appropriate model to use clinically
with NPL subjects.
In contrast to the NPL subjects, subjects with LP were likely over classified in 
the non-entrained category due to the high prevalence of poor sleepers due to 
non-circadian sleep disorders among the blind. This is also evidenced in the 
lower sensitivity and specificity for the normally entrained model. It might be 
prudent to use such a survey-based model with NPL subjects only and to use 
traditional screening and treatment methods for LP subjects until further 
investigation about why so many blind people with LP experience poor sleep 
can be determined.
Interestingly, when survey outcomes were compared using the model 
classification (for all subjects) it was apparent that those classified as non- 
entrained experienced an earlier age of vision loss than those classified as 
normally entrained. In addition, those subjects with eye conditions affecting 
areas such as the rods and cones (e.g. macular degeneration, Leber’s 
congenital amaurosis) were more likely to be classified as normally entrained 
compared to those who reported eye conditions known to damage blood 
vessels in the retina and presumably the retinal ganglion cell layer (e.g. 
retinopathy of prematurity, diabetic retinopathy), who were more likely to be 
classified as non-entrained (Figure 7.3 and Table 7.4).
The current ophthalmologic classification of eye disorders may not be 
sufficient for using eye conditions to predict circadian rhythm type. For
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example, uveitis is a condition that involves inflammation of the eye. This 
inflammation may be caused by an autoimmune disease which damages the 
uvea (the middle layer of the eye comprised of the choroid, cilliary body and 
iris) or it may be caused by localised inflammation in these areas. 
Autoimmune uveitis is also related to an autoimmune attack on the pineal in 
horses (Kalsow ef a/. 1999) and has therefore been hypothesised to be 
related to circadian sleep disorders (Touitou ef a/. 1986, Tabandeh ef a/. 
1998). Uveitis due to other causes, however, is not known to have 
associations with specific organs related to circadian rhythmicity. Damage to 
the eye due to uveitis would be unlikely to be a primary cause of circadian 
sleep disorders, because such damage does not involve the retinal ganglion 
cells or the optic nerve. As a large proportion of subjects with uveitis were 
classified with non-entrained rhythms, it may be that those with autoimmune 
uveitis experience circadian rhythm disorders, while those with other types of 
uveitis remain normally entrained. Unfortunately that level of detail was not 
collected in the survey. The same concern may be true when considering the 
pathology of all eye diseases reported in the survey.
The duration of time since vision loss may also be an important factor in 
whether an eye condition will be associated with a specific circadian type, for 
example, glaucoma is associated with degradation of the optic nerve and in 
animal studies has been shown to alter adaptation to new circadian phases 
(Drouyer et al. 2009). In the survey cohort, subjects with glaucoma who were 
classified as non-entrained had their eye disease an average of 11 years 
longer than those who were classified as normally entrained. This suggests
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that the progressive degeneration of some eye conditions may ultimately lead
to loss of the ability to entrain to light or an impaired ability to entrain to light.
In summary, there is evidence that a questionnaire-based screening tool may 
be helpful in detecting non-entrained circadian rhythms in blind women. The 
sensitivity and specificity for detecting this circadian rhythm type was fair 
compared to physiological based classification. As there is currently no 
screening tool for identifying non-entrained rhythms in the blind, this model 
may provide a first step towards clinical application. This chapter also 
provides evidence that some eye diseases may predispose a person to a non- 
entrained circadian rhythm type. In addition, the duration of time elapsed 
since diagnosis for conditions such as glaucoma may predict the loss of 
circadian photoreception due to progressive degeneration of the retinal 
ganglion cells and/or optic nerve. Future work in this area should include 
questions identified by the model to predict circadian rhythm type along with 
physiological measurements to definitively classify subjects by circadian type. 
In addition, a detailed examination of circadian type in people with eye 
conditions such as uveitis and glaucoma may reveal how different parts of the 
eye contribute to circadian signal transduction from the human eye to the 
SCN.
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CHAPTER 8
TWENTY-FOUR HOUR OUTPUT OF 6 
SULPHATOXYMELATONIN AND 
OESTRONE-3-GLUCURONIDE
CHAPTER 8 -  TWENTY-FOUR HOUR OUTPUT OF 6- 
SULPHATOXYIVIELATONIN AND OESTRONE-3-GLUCURONIDE
8.1 Introduction
One of the primary hypotheses postulated to explain the differences in breast
cancer risk observed in shift workers compared with the blind is that their 
respective levels of melatonin are different, with higher melatonin levels in the 
blind providing protection against breast cancer. The hypothesis suggests that 
the light-induced melatonin suppression experienced by shift workers at night 
removes the protective effect of melatonin by decreasing its circulating levels. 
In turn, this hypothesis assumes that the lower risk of breast cancer among 
totally blind women is due to their higher circulating melatonin levels given the 
supposed ‘protection’ of the melatonin rhythm from light-induced suppression 
that their blindness confers.
To date, the data comparing melatonin levels and cancer risk are inconsistent 
and are based on different methodologies. Several case-control studies 
comparing breast cancer patients to cancer-free controls have found lower 
plasma melatonin (Tamarkin etal. 1982, Danforth et al. 1985) and urinary 
aMT6s (Bartsch et al. 1981) concentrations in breast cancer patients. These 
data, however, were based on small sample sizes (of 37 cases, 10 cases and 
20 cases, respectively) and the largest case-control comparison of melatonin 
concentration (as measured using urinary aMT6s) among breast cancer 
cases and controls found that such differences are not apparent when large
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sample sizes and appropriate age-matched controls are used for comparison 
(Skene eta/. 1990).
There have been three studies to date that have collected melatonin 
information in a prospective manner, although these studies also differ in their
methodology and findings. One study examined total 24 h levels of urinary 
aMT6s and found no differences between breast cancer cases and controls 
(Travis et al. 2004). Two examinations arising from the Nurses’ Health Study 
reported a lower risk of breast cancer among women with higher levels of 
urinary aMT6s in first morning void samples (Schernhammer et al. 2005; 
Schernhammer et al. 2009). Findings from another cohort, which used 12 h 
overnight urinary aMT6s samples, corroborated these findings and reported 
that women with the highest levels of melatonin at baseline (before cancer 
diagnosis) had a lower risk of breast cancer (Schernhammer et al. 2008). The 
methodological differences in these studies may account for the observed 
differences in aMT6s concentrations. For example, first morning void samples 
do not account for individual differences in circadian phase, which may 
contribute to the differences in results. In addition, shift workers were included 
in the Nurses’ Health Study samples. Inclusion of shift workers is problematic, 
because shift workers have been reported to have an increased risk of breast 
cancer, but they likely experience light-induced melatonin suppression and 
phase shifting which would not be apparent in a first morning void sample. 
Therefore it is not clear that a first morning void sample is appropriate for 
comparison in these groups.
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There have been two cross-sectional assessments of the urinary 24 h aMT6s 
rhythm output in shift workers that support the suggestion that there are
differences in melatonin output among female shift workers. The first of these 
studies reported that permanent night workers and rotating shift workers have 
lower aMT6s production on work days compared to days off in contrast to day 
and evening workers who do not have such rhythm variability (Hansen et al. 
2006). A follow up study by the same group found that all nurses, regardless 
of shift type, slept longer on days off (Garde et ai. 2009). Together these 
findings suggest that there may be differences in 24 h aMT6s output among 
shift workers that may be explained in part through light-induced melatonin 
suppression on work days when exposure to light is presumably longer due to 
shortened sleep episodes.
An extension of the hypothesis that melatonin protects against breast cancer 
suggests that totally blind women might have higher levels of melatonin, 
because they experience less light-induced melatonin suppression. 
Differences in melatonin amount and amplitude among relatively small 
numbers of blind subjects have been investigated previously and all reports 
concur that there are no differences in the 24 h melatonin or aMT6s level or in 
amplitude of the melatonin or aMT6s rhythm in blind people with NPL (n = 30) 
compared to blind people with LP (n = 19; Lockley et al. 1997a) or in blind 
people with NPL (n = 17; Klerman etal. 2001) compared to sighted 
individuals. A further confound of this hypothesis is the inability to confirm 
circadian blindness in estimating whether melatonin suppression is impaired 
in NPL subjects. For example, a small proportion of blind people with total
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Visual blindness retain the cells necessary for circadian photoreception and 
therefore melatonin suppression (Czeisler eta/. 1995, Klerman ef a/. 2002, 
Zaidi ef a/. 2007). As a result of this phenomenon it is important to classify
blind subjects according to the integrity of their retinohypothalamic tract in 
order to qualify their melatonin levels relative to possible light-induced 
suppression.
Additional confounding factors, such as those described in Section 1.4.4, may 
also affect determination of melatonin or aMT6s levels in relation to cancer 
risk. For example, menopausal status has been stated to affect melatonin 
levels (Okatani et al. 2000), although not in all cases (Skene et al. 1990). The 
general effect of aging on melatonin/aMT6s production also has the potential 
to confound melatonin assessments. Numerous cross-sectional studies in the 
sighted (Sack et al. 1986, Bojkowski et al. 1990) and blind (Lockley 1997c) 
have found an association between melatonin/aMT6s and age with lower 
melatonin/aMT6s in older subjects. One study, however, found no differences 
in melatonin levels among very healthy medication-free older and younger 
people except in a small subset (15%) of subjects (Zeitzer et al. 1999). While 
the current consensus is that melatonin production reduces with age, possibly 
due to calcification of the pineal (Kunz et al. 1999), there are no prospective 
studies that would confirm a decline in melatonin production with aging.
The evidence for a direct role of melatonin on breast cancer risk is unclear. It 
has been suggested that there is an interplay between the hormones 
melatonin and oestrogen or modulation of oestrogen receptors by melatonin.
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with lower melatonin profiles in oestrogen receptor positive patients than 
oestrogen receptor negative patients (Tamarkin eta/. 1982). Factors that 
increase a woman’s exposure to oestrogens throughout life (such as early 
menarche and late menopause) are known risk factors for breast cancer, as 
are increased levels of circulating oestrogens (Key ef a/. 2002). Currently it is 
unknown whether oestrogen production is coordinated in any way by the 
circadian clock or if oestrogens are influenced by light exposure. In addition, it 
is unclear whether there is a relationship between melatonin and oestrogen 
production that may account for some of the observed differences in breast 
cancer risk among shift workers and the blind.
The goals of the present chapter are to determine whether there are 
differences in 24 h levels of aMT6s among women with and without light 
perception or by circadian rhythm type. In addition, this chapter attempts to 
compare the methods of collecting aMT6s (in first morning void versus 24 h 
production) to validate its use as a biomarker for breast cancer risk. Finally, 
this chapter examines the levels and time course of oestrogen production as 
measured by a urinary metabolite of oestrogen, e l g and to determine whether 
light perception, circadian status or melatonin relate to any changes observed 
in oestrogen production.
8.2 Methods
8.2.1 Data collection
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Details of data collection for the field study and survey are presented in detail 
in Section 2.6. In brief, subjects were given a 120 question survey and asked
if they would be willing to participate in an 8-week field study. Subjects were 
selected for the field study if they were not taking hypnotics or medications 
known to affect melatonin (e.g. beta-blockers, anti-depressants, melatonin 
supplements) or oestrogen production (e.g. oral contraceptives, hormone 
replacement therapy). Subjects who met these criteria were asked to 
complete a sleep diary (Appendix A) for eight weeks and collect sequential 
urine samples over 48 h on two or three occasions two to four weeks apart. 
Pre-menopausal subjects were instructed to indicate the dates of menses 
prior to beginning the sleep diary, while completing the sleep diary and after 
completing the sleep diary. Urine samples were not collected in a particular 
menstrual phase, but rather were collected based on convenience to the 
subjects.
8.2.2 Assay
8.2.2.1 6-sulphatoxymelatonin
The melatonin metabolite aMT6s was measured in each sample by 
radioimmunoassay (RIA) by Stockgrand Ltd as described in detail in section 
2.6.32.
8.2.2.2 Oestrone-3-glucuronide
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The oestrone metabolite e1g was measured in 920 samples provided by 46 
subjects using an ELISA by Stockgrand Ltd as described in detail in Section
2.6.3.2.
8.2.3 6-sulphatoxymelatonin 24 h output
All 24 h output analyses were calculated in pg/24 h per collection period. Only 
subjects who had complete records (including weight and time of collection) 
were included in these comparisons (n = 114; NPL n = 35, LP n = 79). 
Pearson correlations were used to compare the 24 h output of aMT6s for 
collection one to collection two, mean 24 h output to age and mean 24 h 
output to overnight aMT6s output.
Mean 24 h output was compared using Student’s two-sample t-tests between 
NPL versus LP, bilaterally enucleated versus non-enucleated and pre­
menopausal versus post-menopausal subjects. Each of these comparisons 
was age-adjusted using a linear multivariable regression and further adjusted 
for factors known to influence melatonin production (consumption of more 
than one alcoholic beverage per day versus consumption of one or fewer 
drinks per day (Ekman et al. 1993, Murphy et al. 1996), consumption of 3 or 
more caffeinated beverages per day versus two or fewer drinks per day 
(Ursing et al. 2003), history of smoking [ever/never] (Tarquini et al. 1994) and 
BMI (continuously: Ostroska et al. 1996). Mean 24 h output was also 
calculated by circadian type (normally entrained, abnormally phased, non­
entrained, unclassifiable) and was subjected to a one-way ANOVA to assess 
differences.
8.2.4 6-sulphatoxymelatonin 24 h output versus aMT6s measured in overnight 
collections
The overnight collection of urine included all urine produced during the night 
time collection window and the first morning void. Subjects were instructed to 
void before going to bed as part of the last collection of the day, and then to 
collect all urine voids during the night time hours when they woke 
spontaneously from sleep. They were told that this window could vary based 
on their activities, and sleep time and they were told not to alter their natural 
sleep and wake times in order to complete the collection. This meant that if a 
subject went to bed at 23:00 h, but spontaneously woke at 5:00 h finally and 
got up for the day, their collection would be 6 h in duration. If a subject went to 
bed at 23:00 h, but spontaneously woke at 8:00 h, then the collection window 
would be 9 h. The collection period considered the “overnight” collection was 
the collection window that fell within the night time hours with a wake time 
between 4:00 h and 12:00 h.
The 24 h urine output in pg/h was compared to the overnight sample 
collection window by Pearson correlation. The data were stratified and 
compared using a Pearson correlation for normally entrained subjects, non- 
entrained subjects, abnormally phased advanced and abnormally phased 
delayed subjects.
The overnight collection means were compared to the 24 h means by 
circadian type using one-way ANOVA.
8.2.5 Oestrone-3-glucuronide 24 h output
The 24 h output of e1g was calculated in pg/24 h. The 24 h output of e1g was
calculated for each sample period for 46 subjects, which ultimately included 
92 48 h collection periods available for analysis. The 24 h e1 g output was 
compared for collection one versus collection two in post-menopausal 
subjects using a Pearson correlation.
Due to normal fluctuations in e1g throughout the menstrual cycle it was 
necessary to consider each 24 h sample individually in sub-analyses. 
Therefore, the 24 h outputs of e1g and aMT6s were compared using a 
repeated measures ANOVA using subject code as a repeated factor. The 
mean 24 h e1g production for each collection block was compared between 
subjects with and without light perception, bilaterally enucleated versus not 
enucleated and pre- versus post menopausal as well as by circadian type. All 
comparisons were further adjusted for age.
8.2.6 Oestrone-3-glucuronide rhythmicity
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The amount of e1g per sample was plotted in pg/h and subjected to cosinor 
analysis (Section 6.2.2) to determine whether or not there was a detectable 
rhythm in e1g production for each collection period.
8.3 Results
8.3.1 24 h aMT6s production
The 24 h output of aMT6s (pg/24 h) from sample collection one compared to 
sample collection two was well correlated (p < 0.0001) among all field study 
subjects (n = 114; Figure 8.1). There was a significant negative association 
between the mean 24 h urine output with age among all subjects (p = 0.006; 
Figure 8.2). There were no differences in 24 h aMT6s production when 
stratified by light perception status (p = 0.24; Figure 8.3A) nor when stratified 
by light perception status after age-adjustment (p = 0.28). There were also no 
differences in aMT6s production by light perception status when adjusted for 
potential confounders (p = 0.42, adjusted for age, >1 alcoholic drink/day, >2 
caffeinated beverages/day ever smokers, and BMI). In addition, there were no 
differences in 24 h production of aMT6s in pre- (n = 45) compared to post­
menopausal (n = 55) subjects (p = 0.76; Figure 8.3B; age-adjusted p = 0.75; 
confounder adjusted p = 0.86; peri-menopausal subjects excluded n = 14).
There were no differences in 24 h mean aMT6s production when subjects 
with bilateral enucleation (n = 9, mean ± SEM, 19.68 ± 4.18 pg/24 h), and 
therefore no potential for light affecting melatonin levels, were compared to
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subjects with at least one eye (n = 105, 25.13 ± 1.75 pg/24 h; p = 0.37; age- 
adjusted p = 0.36; Figure 8.4A) or when bilaterally enucleated subjects (n = 9, 
19.68 ±4.18 pg/24 h) were compared to subjects with light perception (n = 79,
25.85 ± 2.15 pg/24 h; p = 0.35; age-adjusted p = 0.33; Figure 8.4B). In 
addition, there was no significant difference in 24 h melatonin production 
between NPL subjects with bilateral enucleation (n = 9, 19.68 ±4.18 pg/24 h) 
and NPL subjects with at least one eye (n = 26, 22.94 ± 2.77 pg/24 h; p = 
0.77).
There were no significant differences in 24 h aMT6s production by circadian 
type (using the circadian type for the 111 subjects with sleep diaries available 
for classification (as classified in Chapter 6) including, NE, 23.16 ± 2.20 pg/24 
h; AP, 24.78 ± 3.64 pg/24 h; Non-E, 28.97 ± 3.66 pg/24 h; UN, 19.83 ± 5.16 
pg/24 h; p = 0.43; Figure 8.5A; age-adjusted p = 0.41 ; adjusted for 
confounders p = 0.34; with unclassified subjects excluded p = 0.34). In 
addition there were no significant differences when stratified by subjects with 
LP (p = 0.64; Figure 8.5B; age-adjusted p = 0.05), by subjects with NPL (p = 
0.78; Figure 8.50; age-adjusted p = 0.57) or when unclassified subjects were 
excluded from comparisons (p = 0.60 and p =0.27, respectively).
8.3.2 Comparison of aMT6s production in 24 h versus the overnight collection
The 24 h production of aMT6s was well correlated (p < 0.001) with the aMT6s 
level in the overnight urine collection of the same collection block (Figure 8.6). 
This correlation remained when the data were stratified by normal (Figure
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Figure 8.1 Correlation between mean 24 h aMT6s output for collection 1 vs. 
collection 2 (n = 114, pg aMT6s/24 h). Lines represent the correlation ± 95% 
confidence intervals.
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Figure 8.2 Correlation between age and mean 24 h aMT6s output for all 
available urine sample collection periods (2 or 3 collection periods) by subject 
(n = 114, pg aMT6s/24 h). Lines represent the correlation ± 95% confidence 
intervals.
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Figure 8.3 Mean 24 h aMT6s output (± SEM) over all collection periods for 
NPL (n = 35) and LP (n = 79) subjects (lag aMT6s/24 h; A) and for pre- (n = 
45) and post-menopausal (n = 55) subjects (pg aMT6s/24 h; B). Peri- 
menopausal subjects (n = 14) were not included in comparisons. There was 
no significant difference in 24 h aMT6s production between NPL and LP 
subjects or between pre- and post-menopausal subjects (Student’s two 
sample t-test).
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Figure 8.4A Mean 24 h aMT6s output (± SEM) over all collection periods for 
subjects whose eyes were enucleated (n = 9) and subjects who retained at 
least one eye (n = 105; irrespective of light perception status). Panel B 
compares subjects with LP (n = 79) to bilaterally enucleated subjects (n = 9) 
There was no significant difference in 24 h melatonin production between 
subjects with bilateral enucleation and those with at least one eye (p = 0.37) 
or between LP and bilaterally enucleated subjects (p = 0.35).
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Figure 8.4C shows the mean 24 h aMT6s output (± SEM) over all collection 
periods for subjects whose eyes were enucleated (n = 9) and subjects with 
NPL who retained at least one eye (n = 26). There was no significant 
difference in 24 h aMTSs production between NPL subjects with bilateral 
enucleation and those with at least one eye (p = 0.77).
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Figure 8.5A Mean 24 h aMT6s output (± SEM) over all available collection 
periods for field study subjects by circadian type (n is shown below each 
category, pg aMT6s/24 h). There was no significant difference in 24 h 
melatonin production by circadian type (p = 0.43; age-adjusted p = 0.41). NE 
= normally entrained; AP = abnormally phased; Non-E = non-entrained; UN = 
unclassified.
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Figure 8.5B shows the mean 24 h aMT6s output (± SEM) over all available 
collection periods for field study subjects with LP (B) or with NPL (C) by 
circadian type (n is shown below each category, pg aMT6s/24 h). There was 
no significant difference in 24 h melatonin production by circadian type for 
subjects with LP (n = 76, p = 0.64; age-adjusted p = 0.05) or for subjects with 
NPL (n = 35, p = 0.78; age-adjusted p = 0.57).
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8.7A) or non-entrained (Figure 8.7B) circadian type and by advanced (Figure 
8.8A), but not delayed phase (Figure 8.8B). The single overnight alVITGs urine 
measurement showed significant differences when compared by circadian 
type (p = 0.01 : Figure 8.9), but there was no significant difference in 24 h 
aMT6s production by circadian type (p = 0.43; Figure 8.9).
8.3.3 Production of el g
As expected, post-menopausal women produced significantly less e l g over 
24 h than pre-menopausal women (post-menopausal mean ± SEM = 7.86 ± 
0.78 pg/24 h; pre-menopausal mean = 29.67 ± 2.56 pg/24 h; p < 0.001 ; Figure 
8.10). The 24 h e l g production was well correlated in collection one versus 
collection two among post-menopausal subjects (p < 0.05; Figure 8.11). A 
correlation between sample collections in pre-menopausal women was not 
attempted, because fluctuation in the production of e l g would be expected 
due to possible differences in menstrual phase from the first to the second 
sample collection. There was a non-significant elevation in e l g among LP (n = 
46 collections) compared to NPL (n = 46 collections) subjects (LP mean = 
21.11 ± 2.59 pg/24 h; NPL mean = 15.63 ± 2.14 pg/24 h; p = 0.10; Figure 
8.12A ; age-adjusted p = 0.11). There was no significant difference in 24 h 
e l g production when subjects with bilateral enucleation (n = 16 collections) 
were compared to subjects with at least one eye (n = 76 collections; p = 0.42; 
Figure 8.12B ; age-adjusted p = 0.43) or when bilaterally enucleated subjects 
were compared to subjects with light perception (p = 0.22; age-adjusted p =
8-19
140 -
120
100
aMT6s output 
morning collection 
(micrograms / 60 
overnight window)
40 -
20 -
r = 0.64 
r^  = 0.41
p< 0.001
20 40 60 80 100
24 h aMT6s output 
(micrograms / 24 h)
120 140
Figure 8.6 Correlation between 24 h aMT6s output for each collection and 
aMT6s output for the overnight collection, which included the urine produced 
in a 6-12 h window overnight (n = 230 collection periods)
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Figure 8.7 Correlation between 24 h aMT6s output for each collection and 
aMTSs output for the first sample collected in the morning, which included the 
urine produced in a 6-12 h window overnight among normally entrained (n = 
98 collection periods) (A) and non-entrained subjects (n = 70 collection 
periods)(B).
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Figure 8.8 Correlation between 24 h aMTSs output for each collection and 
aMTSs output for the overnight collection, which included the urine produced 
in a 6-12 h window overnight among subjects abnormally entrained at an 
advanced phase (n = 30 collection periods; A) and subjects abnormally 
entrained at a delayed phase (n = 14 collection periods; B).
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Figure 8.9 Mean 24 h aMT6s output (black bars) and aMT6s output for the 
overnight collection, which included the urine produced in a 6-12 h window 
overnight (gray bars). The number of collections included in each comparison 
is shown below each circadian type. There was no significant difference in 24 
h aMTSs production by circadian type, but there was a significant difference in 
the overnight collection (p = 0.01, one-way AN OVA). NE = normally entrained; 
AP = abnormally phased; Non-E = non-entrained; UN = unclassified.
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Figure 8.10 Mean 24 h e l g (± SEM) from each collection period for pre­
menopausal subjects (n = 42 collections) compared to post-menopausal 
subjects (n = 45 collections). Pre-menopausal subjects produced significantly 
more of the oestrogen metabolite compared to post menopausal subjects (p < 
0 .0001).
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Figure 8.11 Correlation between mean 24 h e l g output for collection 1 vs. 
collection 2 in post-menopausal subjects (n = 21, pg e1g/24 h). Lines 
represent regression and 95% confidence intervals.
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Figure 8.12 Mean 24 h e l g (± SEM) from each collection period for subjects 
with no perception of light (NPL; n = 46 collections) and with light perception 
(LP; n = 46 collections; A) and for subjects with two eyes removed (n = 16 
collections) compared to subjects with at least one eye (n = 76 collections; B). 
There was no significant difference in 24 h e l g production between subjects 
with and without light perception (p = 0.10; age-adjusted p = 0.11) or between 
subjects with at least one eye compared to those with no eyes (p = 0.42; age- 
adjusted p = 0.43).
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0.22). Finally, there were no significant differences in 24 h e1g production by 
circadian type (p = 0.28 Figure 8.13A; age-adjusted p = 0.38) or when 
stratified by those with LP (n = 19 collections; Figure 8.13B; p = 0.48; age-
adjusted p = 0.70) and those with NPL (n = 22 collections; Figure 8.13C; p = 
0.08; age-adjusted p = 0.09). There were also no differences in 24 h el g
production by circadian type when subjects with an unclassified circadian 
rhythm type were removed from the analysis (p = 0.37, age-adjusted p = 
0.40).
8.3.4 Rhythmicity of e l g
The time course of e l g over the 48 h collection period was assessed in 46 
subjects over 92 collection periods. Of these, only 13 collection periods (14%) 
showed a significant rhythm as assessed by the cosinor fit at the p < 0.05 
significance level. Four subjects had significant rhythms for both collection 
periods. Examples of the time course of e l g in a normally entrained, 
abnormally phased and non-entrained subject are shown in Figure 8.14A, B 
and C, respectively.
8.3.5 Comparison of 24 h aMT6s output with 24 h e l g output
The 24 h urinary metabolites aMT6s and e l g were compared for each 
available urine collection block (n = 92 collections). There was no relationship 
between aMT6s or e l g production among all subjects combined (n = 46 
collections; p = 0.64, Figure 8.15; age-adjusted p = 0.35) or when stratified by
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Figure 8.13 A Mean 24 h e l g output (± SEM) for each collection period for 
field study subjects by circadian type (pg e1g/24 h). There was no significant 
difference in 24 h e l g production by circadian type (p = 0.28; age-adjusted p 
= 0.38). NE = normally entrained; AP = abnormally phased; Non-E = non- 
entrained; UN = unclassified.
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Figure 8.13 B Mean 24 h e lg  output (± SEM) for each collection period for 
field study subjects with LP (n = 19) by circadian type (n is shown below each 
category, pg e1g/24 h). Panel C shows the mean 24 h e lg  output (± SEM) for 
each collection period for field study subjects with NPL (n = 22) by circadian 
type (n is shown below each category, pg e1g/24 h).There was no significant 
difference in 24 h e lg  production by circadian type for LP (p = 0.48; age- 
adjusted p = 0.70) or NPL subjects (p = 0.08; age-adjusted p = 0.09). NE = 
normally entrained; AP = abnormally phased; Non-E = non-entrained. Note 
there was only one subject in each unclassified group, so these subjects were 
excluded from these comparisons.
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Figure 8.14 Profiles of elg (ng/h) over two 48 h collection blocks for a normally 
entrained post-menopausal subject (26BC1489; A), a phase advanced post­
menopausal subject (25BC373; B) and a non-entrained post-menopausal subject 
(25BC539; C). The p-value insets indicate the significance of fit for each collection 
using cosinor analysis (see text for details).
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Figure 8.15 Mean 24 h aMT6s output for each collection vs. 24 h e lg  output 
for the same collection (n = 46 subjects, n = 92 collections, pg /24 h; repeated 
measures A NOVA p = 0.64).
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menopausal status (pre-menopausal p = 0.50; age-adjusted p = 0.39, Figure 
8.16A; post-menopausal p = 0.64; age-adjusted p = 0.91, Figure 8.16B) or 
light perception status (LP p = 0.79; age-adjusted p = 0.61, Figure 8.17A; NPL
p = 0.26; age-adjusted p = 0.26, Figure 8.17B). There were also no significant 
differences observed when further stratified by pre-menopausal subjects with 
LP (p = 0.79; age-adjusted p = 0.83, Figure 8.1 BA), by pre-menopausal 
subjects with NPL (p = 0.84; age-adjusted p = 0.69, Figure 8.1 SB) or by post­
menopausal subjects with LP (p = 0.88; age-adjusted p = 0.93, Figure 8.19A) 
nor by post-menopausal subjects with NPL (p = 0.69; age-adjusted p = 0.92, 
Figure 8.198). There was, however, a relationship between 24 h aMT6s 
production and 24 h e lg  production among normally entrained subjects prior 
to adjustment for age (n = 39 collections; p = 0.04, age-adjusted p = 0.16) and 
a trend towards an association between aMT6s and e lg  among non- 
entrained subjects (n = 29 collections; p = 0.18, age-adjusted p = 0.07; Figure 
8 .20).
8.4 Discussion
This chapter shows that 24 h aMT6s levels do not vary by light perception, 
circadian or menopausal status among blind women. These data also show a 
weak association between higher age and lower aMT6s. Further, these data 
demonstrate that 24 h collection of aMT6s should be considered the gold- 
standard collection for total aMT6s production, because overnight collections, 
though well correlated with 24 h levels in normally phased subjects, are
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Figure 8.16 Mean 24 h aMT6s output for each collection vs. 24 h e lg  output 
for the same collection in pre (n = 21 subjects, n = 42 collections, pg /24 h; A; 
repeated measures AN OVA p = 0.50) and post-menopausal women (n = 25 
subjects, n = 50 collections; repeated measures ANOVA B; p = 0.64).
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Figure 8.17 Mean 24 h aMT6s output for each collection vs. 24 h e lg  output 
for the same collection in LP (n = 23 subjects, n = 46 collections, pg /24 h; A; 
repeated measures ANOVA p = 0.79) and NPL women (n = 23 subjects, n = 
46 collections; B; repeated measures ANOVA p = 0.26).
8 -3 4
micrograms/24 h
40 
35 - 
30 - 
25 - 
20 -  
15 - 
10 -  
5 - 
0
A
T
T
■
micrograms/24 h
40 
35 - 
30 - 
25 - 
20 -  
15 - 
10 -  
5 - 
0
B
aMT6s
aMT6s
e1g
...........
Figure 8.18 Mean 24 h aMT6s output for each collection vs. 24 h e lg  output 
for the same collection in pre-menopausal subjects with LP (n = 12 subjects, n 
= 24 collections, pg 124 h; A; repeated measures ANOVA p = 0.79) and NPL 
(n = 9 subjects, n = 18 collections; B; repeated measures ANOVA p = 0.84).
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Figure 8.19 Mean 24 h aMT6s output for each collection vs. 24 h e lg  output 
for the same collection in post-menopausal subjects v/ith LP (n = 12 subjects, 
n = 24 collections, pg /24 h; A; repeated measures ANOVA p = 0.88) and NPL 
(n = 12 subjects, n = 24 collections; B; repeated measures ANOVA p = 0.69).
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Figure 8.20 Mean 24 h e1g output for each collection vs. 24 h aMT6s output 
for the same collection in normally entrained (n = 19 subjects, n = 39 
collections, pg 124 h; A; p = 0.04) and non-entrained subjects (n = 15 subjects, 
n = 29 collections; B; p = 0.18).
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standard collection for total aMT6s production, because overnight collections, 
though well correlated with 24 h levels in normally phased subjects, are 
confounded by circadian phase differences between individuals. 6-
sulphatoxymelatonin production in 24 h showed a positive association with 24 
h e1g output for normally entrained subjects prior to age-adjustment and a 
trend for an association among non-entrained subjects. 6- 
sulphatoxymelatonin production was not well correlated with e1g production in 
any other stratification. As expected, pre-menopausal subjects produced 
significantly more e1g than post-menopausal subjects. Finally, there was little 
objective evidence to suggest that e1g production is strongly rhythmic, 
although visual inspection of the time course of e1g production suggested that 
there may be a circadian component to e1g output, at least in a number of 
subjects, that cannot be fully established in the present cohort.
The finding that 24 h production of aMTSs is not different in women with and 
without light perception is consistent with earlier reports of smaller groups 
(Lockley et al. 1997c, Klerman at ai. 2001 ). This finding suggests that if 
aMTSs plays a role in the protection against breast cancer in totally blind 
women (Verkasalo et al. 1999, Pukkala et al. 200S, Flynn-Evans et al. 2009) it 
is not via an overall elevation in melatonin as measured in aMTSs among 
those with NPL.
The comparison between overnight aMTSs levels and circadian rhythm type 
varied depending on the method used to estimate aMTSs output; overnight 
urinary aMTSs output by circadian type yielded different results than the same
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comparison made using 24 h aMTSs output. These differences are likely due
to differences in when the overnight collection samples melatonin with respect 
to circadian phase among different subjects. Figure 8.21 shows the 24 h 
aMTSs profiles for three subjects with aMTSs peaks at different times. The 
shaded areas of the figure represent the duration of time when urine was 
collected as part of the overnight collection window. This figure demonstrates 
how in a normally entrained subject (A), an overnight collection may be able 
to capture the peak of the aMTSs rhythm, however, when a subject is out of 
phase as in the non-entrained subject (B) or the abnormally phase delayed 
subject (C) the peak of the aMTSs rhythm can be completely missed or only 
partially captured in an overnight collection. This suggests that an overnight 
urine collection is not sufficient for comparing aMTSs levels in subjects who 
are out of phase, like shift workers, following transmeridian travel and in other 
circadian rhythm sleep disorders. Further, it is probable that even when a 
subject is assumed to be normally phased, the aMTSs peak may not be 
appropriately captured unless the phase angle from aMTSs peak to wake time 
is constant among all subjects as there is a wide range of phase associated 
with normal entrainment (Lockley et a i 1997, Wright et al. 2005, Section 
1.2.5). Determining the phase angle requires measurement of the aMTSs 
profile, which if collected, would obviate the need to make comparisons using 
an overnight sample.
The finding that an overnight urine sample collection is less accurate for 
estimating total circulating aMTSs levels than 24 h output suggests that 
studies that have relied on first morning void or overnight collections to
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Figure 8.21 shows aMT6s profiles for the first urine collection in a normally 
entrained (A), non-entrained (B), and abnormally entrained phase delayed 
subject (C). The gray bars show the duration of time when urine was collected 
for the overnight sample for each subject. Note; the y axis differs for each.
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establish total aMT6s production are potentially confounded by missing phase 
information, if the subjects had phase shifts of more than a few hours from the 
norm. For example, the inclusion of shift-workers in such analyses may have 
driven the observed results. In the Nurses’ Health Study cohort 
(Schernhammer ef a/. 2005, Schernhammer ef a/. 2009), participants were not 
asked whether they had performed a night shift the night prior to first morning 
void collection, but were asked if they had worked at least one night shift 
within the two weeks prior to sample collection. When those who had worked 
at least one night shift in the past two weeks were excluded from analysis, the 
observed differences in melatonin levels in relation to breast cancer risk 
became non-significant (Schernhammer et al. 2005). This makes sense when 
considering that shift-workers have an increased risk of breast cancer and 
shift-workers may also have low levels of aMT6s in first morning void samples 
due to either light-induced melatonin suppression or abnormal entrainment 
resulting from shift-work. Therefore, the results from these studies are likely 
an artefact of the methodology. Differences in phase cannot be assessed in a 
first morning void sample. In addition to the confound presented by including 
shift workers in the analysis, these reports may be also confounded by the 
methods used in collecting the first morning void sample. The urine sample 
was not collected specifically for the purpose of measuring aMT6s and 
therefore the subjects were not given instructions about the timing of the 
collection and therefore even if it could be assumed that all subjects were 
entrained at the same phase angle, it is not clear that all subjects collected 
their urine sample at the same relative clock or circadian time. Despite these 
methodological challenges, reports using 24 h urinary aMT6s measurements
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have found lower aMT6s levels on work days (Hansen et al. 2006), though 
this study did not examine breast cancer risk.
Another similar report also found lower breast cancer risk among those with 
higher levels of alVITGs (Schernhammer ef a/. 2008). This study is likely
confounded by the same factors as the Nurses’ Health Study reports (as 
discussed above). In that study 12 h overnight urine collections were 
assessed for differences in aMTBs, however, as evidenced in Figure 8.21 , it 
is unlikely that even a 12 h urine collection is sufficient for such comparisons 
when subjects may be at an adverse circadian phase.
The only study that has used complete 24 h aMTBs outputs to examine risk of 
breast cancer in a prospective manner, found no differences in aMTBs levels 
(Travis et al. 2004). The results provided in this chapter provide support for 
these findings and suggest that appropriate methodology is extremely 
important when examining any output that is under circadian control.
The finding that aMTBs levels do not predict differences in breast cancer risk 
does not necessarily mean that melatonin is not involved in modulating a 
woman’s risk of breast cancer. The bulk of animal model studies investigating 
this topic suggest that melatonin does have anti-tumour properties (Cos et al. 
1994, Blask eta/. 1999, Blask ef a/. 2003, Blask ef a/. 2005, Cini ef a/. 2005). 
In humans, some studies have shown that breast cancer patients have lower 
24 h plasma melatonin production (Tamarkin et a i 1982, Danforth et al. 1985) 
and urinary aMTBs rhythms that are desynchronised from the solar day
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compared to healthy controls (Bartsch ef a/. 1981). A separate study that 
controlled for factors influencing melatonin production (e.g. age) did not find 
such differences between control and breast cancer sufferers in 24 h urinary 
aMTBs output (Skene ef a/. 1990). Despite the inconsistency in these results,
the potential interplay between melatonin and reproductive hormones and 
receptors deserves further investigation as it relates to breast cancer risk. The 
study by Tamarkin and colleagues (1982) found that lower 24 h plasma 
melatonin production was correlated with oestrogen receptor positive tumours 
and increased oestrogen receptor concentration. This finding is consistent 
with animal research that suggests that melatonin interferes with the ability of 
oestrogen to bind to its receptor (Roy & Wilson 1981, Hill et al. 2000, Kiefer et 
al. 2002) and conversely that melatonin receptor overexpression in tumours 
slows proliferation (Yuan etal. 2002, Gonzalez etal. 2007). Together these 
findings suggest that melatonin may interact with oestrogen or oestrogen 
receptors, though it is unclear how or why such a relationship may exist.
In order to determine how oestrogen might be influenced by light perception 
and circadian type, 24 h production of a urinary metabolite of oestrone was 
measured in the present cohort. There is currently no standard oestrogen that 
is used as a biomarker with respect to breast cancer risk, though several 
studies have examined the feasibility of using a variety of oestrogens with 
varying results (Section 1.7.4). The oestrone metabolite e l g was ultimately 
chosen for this analysis because of its good correlation with total urinary 
oestradiol and urinary oestrone (Elder et al. 1990).
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As expected, there was a correlation in 24 h e1g production between the first 
and second collection periods for post-menopausal women. There was also
lower 24 h e1g production among post-menopausal compared to pre­
menopausal women, which validates the use of this metabolite as a reliable 
measure of oestrogen in this cohort. There were no differences in e1g 
production when subjects were compared by circadian status.
There were no significant correlations between aMTBs and e l g 24 h outputs 
when compared by light perception or menopausal status. Interestingly, there 
was a significant positive correlation between e1g and aMTBs among 
normally entrained subjects. It is unclear if these findings are meaningful, 
though it might be hypothesised that light exposure, which suppresses 
melatonin at night, may also stimulate oestrogen production. This hypothesis 
may explain the lower e1g levels observed among NPL subjects and the 
differences in the observed relationship in aMTBs and e l g in normally 
entrained and non-entrained subjects. It may also help explain the time 
course of e1g production in this cohort. Several subjects had what visually 
appeared to be rhythmic production of e1g, though these observations were 
not confirmed by cosinor analysis. It is still unclear what factors other than the 
menstrual cycle may contribute to changes in e1g production over the course 
of the day, although there is evidence for a peripheral circadian oscillator in 
the ovaries in mammals (Fahrenkrug et al. 200B), which could underlie 
circadian rhythmicity in release of sex steroids. The current data are not 
sufficient to assess these questions and they should be explored in future 
studies.
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There are several possible limitations \with the data presented in this chapter. 
Firstly, all data used to classify subjects by light perception and menopausal 
status were based on self-reports. It is possible that some subjects mis- 
reported their status. For example, one subject (25BC207) reported being pre­
menopausal at age 51, which was confirmed by a second self-report, but as 
the majority of women in the US are at least peri-menopausal by age 51 it 
seems unlikely that her reproductive hormones would be the same as a pre­
menopausal woman at age 30. In addition, subjects collected all urine 
samples at home and it is possible that mistakes were made in sample 
collection that were not reported. Furthermore, subjects were selected for 
study if they were not taking medications known to affect melatonin or 
oestrogen production (Sections 1.4.4 and 1.6), but they were not controlled in 
any way during the field study. Subjects were allowed to go about their usual 
activities and eat and sleep ad libitum. There are potential dietary factors that 
influence both melatonin and oestrogen production and metabolism (Sections 
1.4.4 and 1.6), but as data on daily diet were not collected, these factors could 
not be controlled for in analysis. Similarly, if light or sleep affects oestrogen 
production, the present results would not be able to fully account for these 
influences. Despite the potential issues with these results, efforts were made 
to minimize the influence of error at each step by including controlling factors 
in the analysis and by following up with subjects when survey answers were in 
question. In addition, there is no reason to suspect that any group would 
systematically mis-report information.
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In summary, the data presented in this chapter provide support for the notion 
that aMTBs production is not different among women with and without light
perception, but that levels are lower in older women. These data suggest that 
the methodology used to estimate aMTBs production should include 24 hours 
of sample collection. In addition, this chapter reports that light perception is 
associated with increased oestrogen levels and that there is a positive 
relationship between e1g and aMTBs production among those normally 
entrained. This study cannot conclusively determine how aMTBs and 
oestrogen may be related, but leads to many new hypotheses that should be 
considered in future studies.
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CHAPTER 9
GENERAL DISCUSSION
CHAPTER 9 -  GENERAL DISCUSSION
9.1 Rationale
The primary rationale of this thesis was to examine the prevalence of breast 
cancer in blind women with LP compared to blind women with NPL. Prior 
studies reported a lower risk of breast cancer among blind women (Hahn 
1991, Feychting ef a/. 1998, Pukkala ef a/. 1999, Kliukiene ef a/. 2001), 
however, all prior studies in the blind were based on historical records with 
minimal information available on reproductive or lifestyle characteristics that 
might account for the observed lower risk in the blind. In addition, there have 
been reports suggesting that reproductive outcomes such as age at menarche 
and fertility are different in blind women with NPL compared to those with LP 
(Section 1.5.2); factors which could independently modify the risk of breast 
cancer among women with NPL.
One of the primary hypotheses postulated to explain the differences in breast 
cancer risk observed in shift workers and the blind is that their respective 
levels of melatonin are different, with higher melatonin providing protection 
against breast cancer. Some studies in shift workers have reported lower 
levels of aMTBs in breast cancer patients prior to diagnosis (Schernhammer 
ef a/ 2005, Schernhammer ef a/. 2008, Schernhammer ef a/ 2009) as well as 
in cross-sectional studies of shift workers (Hansen et al 200B, Garde et al.
2009). However, there have also been reports that melatonin levels in breast 
cancer patients prior to diagnosis are not different from controls (Skene et al.
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1991, Travis et al .2004). No such comparisons have been made in blind 
women in relation to breast cancer, although two separate studies have 
reported that there is no difference in total melatonin production or amplitude 
among blind men and women combined (Lockley ef a/ 1997a, Klerman ef a/
2001). Therefore a secondary aim of this thesis was to examine 24 h aMTBs 
production in blind women by light perception status and circadian rhythm 
type in order to determine whether such stratification might reveal differences 
that could relate to breast cancer risk.
As oestrogens are central to the development of breast cancer (Section 
1.7.2), it has been hypothesised that oestrogen production may also be 
different in blind women. Therefore oestrogen production as measured by the 
urinary metabolite elg, was also examined as an outcome of this thesis.
A separate aim of this thesis was to create objective criteria to define 
circadian rhythm disorders among women with LP and NPL using eight weeks 
of sleep and nap logs and two aMTBs acrophases, from urine samples 
collected over 48 h in four or eight-hourly bins, separated by at least two 
weeks. While the prevalence of circadian rhythm disturbance has been 
previously reported (Section 1.5.3), it is unclear whether questionnaire-based 
tools may be used to identify reliably those with non-entrained rhythms. The 
only questionnaire-based study to attempt circadian classification reported a 
prevalence that was much lower than what has been reported in field-based 
studies using physiological measures (Leger etal. 1999). In addition, tools for 
clinical assessment of circadian rhythm sleep disturbance in the blind are
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virtually non-existent. Therefore an additional aim of this thesis was to create 
model to determine which survey questions might best predict circadian 
rhythm type and to determine the sensitivity and specificity of the model. 
Ultimately, the development of a reliable tool will be helpful in diagnosing and
treating circadian rhythm disorders in the blind.
There have been some reports that suggest that the aetiology of blindness 
may predict circadian rhythm disturbance (Drouyer et a/. 2009), however, a
large scale examination of type of blindness compared to circadian rhythm 
disturbance has not been attempted. Therefore a final aim of this thesis was 
to compare circadian rhythm type to the aetiology of blindness.
9.2 Breast cancer risk and reproductive outcomes
This study confirmed that NPL women have a lower risk of breast cancer 
compared LP women (Chapter 5). The finding that NPL women experience 
approximately half the risk of breast cancer compared to LP women is 
consistent with prior reports (Hahn 1991, Feychting et al. 1998, Pukkala et al. 
1999, Kliukiene et al. 2001). The present results differ from all prior results in 
that this was a cross-sectional study and all study participants were asked 
questions about their reproductive history and lifestyle habits. As a result, it 
was possible to adjust for potential confounders, which was not entirely 
possible in the prior studies that examined historical records and did not have 
direct contact with the subjects.
9-3
In contrast to prior reports, there was no evidence of a dose response 
relationship with degree of visual impairment and breast cancer risk 
(Verkasalo et a/. 1999, Pukkala et at. 2006). In the present study, there was a
significantly increased risk of breast cancer among women with low vision 
when LP women were categorised by level of visual acuity. Women who could 
only perceive light or see shadows and hand movement had a significantly 
increased risk of breast cancer when compared to women with NPL, while 
women with better vision (able to count fingers and able to see the top letter 
on the vision chart) had a higher, but not statistically significant increase in 
breast cancer risk compared to NPL women. This study, however, cannot rule 
out the possibility that a dose response exists. There are several possible 
methodological reasons for the differences in results. It is possible that the 
observed differences are simply due to differences in definition. For example, 
the category with the highest visual acuity in the prior reports (moderate low 
vision) was defined using the World Health Organisation classification system 
as 20/70 to 20/160 on the Snellen Scale. This category of "moderate low 
vision” would be considered “sighted with impaired vision" in the United 
States; and in the present study women with a visual acuity better than 20/200 
were excluded from study participation. This difference may be a primary 
reason for the differences in the results. Based on the present results, it is 
unclear whether visual acuity relates to breast cancer risk in a dose response 
manner, but it is clear that women with any level of conscious light have a 
higher risk of breast cancer compared to NPL women.
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There were several outcomes of interest that were examined as potential 
modifiers of breast cancer risk. Specifically, the reproductive outcomes, early
menarche, late menopause, fewer children and later age at first birth are all 
associated with increased breast cancer risk, while late menarche, early 
menopause, greater number of children and earlier age at first birth all reduce 
a woman’s risk of breast cancer (Section 1.7.7). It was important to ensure 
that the modifiable risk factors were not responsible for the lower risk reported 
in the prior studies. For example, it might have been hypothesised that NPL 
women would have more children at an earlier age and that such a 
reproductive lifestyle difference common to NPL was responsible for the lower 
risk of breast cancer, as opposed to an effect of blindness itself. The 
comparison of reproductive outcomes in NPL and LP women revealed that 
this was not the case and that in many cases NPL women tended to have 
reproductive outcomes that would normally be associated with an increased 
risk of breast cancer, despite exhibiting reduced risk.
The differences in reproductive outcomes among LP and NPL women varied 
with respect to breast cancer risk. In contrast to reports in sighted women 
(Section 1.7.7), there was no effect of age at menopause, or HRT use on 
breast cancer risk when comparing LP to NPL blind women. There was a 
modest increased risk associated with older age at first full term pregnancy, 
higher BMI, any use of oral contraceptives and history of benign breast 
disease, whilst later age at menarche and a greater number of pregnancies 
were modestly associated with a decreased risk. Similar to prior reports, a 
positive family history of breast cancer was associated with an increased risk
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(Kelsey et al. 1993). The observation that breast cancer risk factors are 
different in blind women compared to the general population is not 
unexpected given that the hypothesis of this study was that blindness itself
reduces breast cancer risk. Therefore, it is plausible that blindness may also 
influence reproductive outcomes.
Some of the observed differences in reproductive outcomes among NPL 
compared to LP women may relate lifestyle differences, for example the lower
proportion of parous NPL women may relate to lifestyle factors. While the 
proportion of women who reported being currently married was the same 
among NPL and LP women (Section 3.3), it is possible that lifestyle choices 
still accounted for the differences in parity. For example, some women 
reported anecdotally that they chose not to have children in order to avoid 
passing on genetic causes of blindness. This would not, of course, be the 
case for all NPL subjects, but it may account for some of the observed 
differences. Alternatively, it is possible that blindness itself may lead to 
impaired fertility. There was no question on the survey which asked about 
desire versus ability to have children or about the prevalence of fertility 
treatment among NPL and so it was not possible to assess this outcome.
This work does show that the timing of menarche may be influenced directly 
by light and/or blindness. Age at menarche differed between NPL and LP 
subjects with NPL subjects having an earlier menarche. In multivariate 
analyses, adjusted for current age, current BMI and BMI at age 18, menarche 
remained approximately four months earlier in NPL women, compared to LP
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women. Further examinations revealed that age of menarche was even earlier 
in those women NPL from birth compared to the all other women in the 
cohort. In addition, a significant positive association between early loss of LP 
and early onset of menarche was observed. It is also possible that differences 
in melatonin production among NPL subjects prior to puberty relates to these 
differences as has been previously reported (Section 1.4.5.1). In order to 
examine that hypothesis, it would be necessary to conduct a study in blind 
girls prior to and throughout puberty as there are no differences in 24 h 
aMT6s production in this adult cohort (Section 8.3.1).
9.3 Melatonin and oestrogen production
One possible explanation for the differences in breast cancer risk observed in 
shift workers and the blind is that their respective levels of melatonin are 
different, with higher melatonin providing protection against breast cancer.
The hypothesis suggests that the light-induced melatonin suppression 
experienced by shift workers at night removes the protective effect of 
melatonin by decreasing its circulating levels. In turn, this hypothesis assumes 
that the lower risk of breast cancer among totally blind women is due to their 
higher circulating melatonin levels given the proposed protection' of the 
melatonin rhythm from light-induced suppression that their blindness confers.
Prior studies examining melatonin output in the blind did not find differences in 
total daily output, duration or amplitude in blind compared to sighted people
(Lockley et al. 1997a, Klerman et al. 2001). The results of the present study
9-7
confirm these findings and suggest that 24 h production of aMT6s is not 
different in LP compared to NPL women. In addition, 24 h aMT6s levels did 
not vary by light perception, circadian or menopausal status among the LP 
and NPL women in the present cohort. Similar to prior reports (Sack ef a/
1986, Bojkowski et al 1990, Lockley 1997c), there was evidence for an 
association between older age and lower aMT6s. Collectively, these findings 
suggest that if aMT6s plays a role in the protection against breast cancer in 
totally blind women (Chapter 5) it is not via an overall daily elevation in the 
production of aMT6s among those with NPL.
These findings do not mean that melatonin is not involved in modulating a 
woman's risk of breast cancer. The present study involved measurement of 
urinary aMT6s and while this metabolite faithfully reflects plasma production 
of melatonin (Arendt 1995), it is possible that melatonin acts to modulate 
breast cancer through a mechanism that cannot be assessed through aMT6s 
production. For example, some animal studies suggest that melatonin may act 
at the receptor level, though the mechanism for such an action is presently 
unknown. There have been some studies that report that melatonin interferes 
with the ability of oestrogen to bind to its receptor (Roy and Wilson 1981, Hill 
etal. 2000, Kiefer et al. 2002), thus providing protection against breast 
cancer. Other studies have found that melatonin receptor overexpression in 
tumours slows proliferation (Yuan et al. 2002, Gonzalez et al. 2007). In these 
cases, measurement of aMT6s may not be an appropriate measure of action 
at the receptor level.
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It is possible that the observed results are confounded by the lack of 
restrictions in the study protocol. During this study subjects were screened out 
if they were taking medications known to affect oestrogen or melatonin, 
however, they were not asked to change any lifestyle habits once enrolled in 
the study. It is possible that the metabolism of urinary alVITGs was affected by 
individual lifestyle choices among the subjects. For example, caffeine intake 
varied widely among the study population. As caffeine intake may delay the 
clearance of melatonin (Ursing et al., 2003) and is metabolised via the same 
pathway as melatonin (Facciola et al., 2001, Skene et al., 2001), it is possible 
that caffeine intake may have confounded the observed results. The 
comparison of aMT6s was adjusted for self-reported habitual caffeine use, 
using a single question from the survey, however, subjects were not asked to 
keep records of actual caffeine use throughout the study. Similarly, other 
factors that have an unclear relationship with melatonin production (Section 
1.4.4), such as PCOS, menstrual phase, smoking and dietary factors, may 
have influenced the observed results. Given the fact that the results are 
consistent with prior studies that found no changes in melatonin production in 
the blind, such explanations seem unlikely to account for the results.
It has also been suggested that the protection conferred by melatonin may act 
through modulation of oestrogens (Section 8.1). Such an interaction suggests 
that there might be a reciprocal relationship between melatonin and 
oestrogen, such that higher melatonin levels result in lower oestrogen levels.
In order to evaluate these hypotheses, the urinary metabolites aMT6s and
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e1g were measured and the total 24 h production was compared between
NPL and LP subjects.
In order to determine how oestrogen might be influenced by light perception 
and circadian type, e1g was measured in 46 field study subjects (NPL n = 23, 
LP n = 23). As expected, post-menopausal women produced less e1g over 24 
h compared to pre-menopausal women. There was a non-significant elevation 
in e1g in LP compared to NPL subjects, but no differences in e1g production 
when subjects were compared by number of eyes present or by circadian 
status.
There were no significant correlations between aMT6s and e1g 24 h outputs 
when compared by light perception or menopausal status. There was, 
however, a significant positive correlation between e1g and aMT6s among 
normally entrained subjects. It is unclear whether or not these findings are 
clinically meaningful. It is possible that oestrogen is independently influenced 
by light or blindness, though there are little data on whether the circadian 
pacemaker has any influence on oestrogen production in humans. There is 
evidence for a peripheral circadian oscillator in the ovaries in mammals 
(Fahrenkrug et al. 2006), which could underlie circadian rhythmicity in release 
of sex steroids which was observed in a small number of cases. However, a 
recent report suggests that the expression of oestrogens throughout the 
oestrus cycle influences clock gene rhythms in the ovaries (Nakamura et al.
2010). These findings suggest that there may be a relationship between the 
circadian and reproductive systems, but it may be that oestrogens influence
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peripheral circadian clocks as opposed to a role for peripheral clocks driving
circadian regulation of oestrogen. If this is the case in humans, it is possible 
that the positive correlation between aMT6s and elg observed among 
normally entrained subjects is driven by internal synchronisation. Such a 
phenomenon may or may not relate to future development of breast cancer. 
Prospective examinations in this cohort would be required to determine 
whether the relationship between aMT6s and e1g differs in those women who 
are ultimately diagnosed with breast cancer.
If oestrogen production is controlled in part by the circadian system, it would 
be expected that a circadian rhythm in oestrogen production would be 
apparent. Visual inspection of the time course of e1 g suggests that e1 g 
production may be rhythmic in some women, though very few subjects had 
such visual observations confirmed by cosinor analysis. It is still unclear what 
factors other than the menstrual cycle may contribute to changes in e1g 
production over the course of the day. It is possible that the circadian system 
does influence oestrogen production, but as with production of other 
hormones, such as growth hormone or thyroid stimulating hormone (for 
review Czeisler and Klerman 1999), it is possible that such control is masked 
by sleep or other external phenomena. The current data are not sufficient to 
assess these questions and they should be explored further in cohorts of 
sighted individuals under controlled laboratory conditions.
9.4 Circadian rhythm disorders and sleep disturbance among the blind
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A secondary aim of this thesis was to assess the prevalence of circadian 
rhythm disturbance in 118 women through assessment of sleep diaries,
urinary aMT6s phase and answers to survey questions. The prevalence of 
circadian rhythm disturbance in the blind has been assessed in several prior 
smaller studies (Section 1.5.3). It was not possible, however, to classify 
subjects in the present cohort using the same procedures as in prior studies 
due to methodological differences. In the present cohort, subjects were only 
asked to complete two 48 h sequential urine sample collection periods. In 
contrast, prior studies asked subjects to collect sequential urine samples 
weekly or bi-weekly for several weeks or months allowing circadian period 
assessment through regression analysis. In order to classify subjects in the 
present cohort by circadian rhythm type, it was necessary to develop new 
criteria to account for the different methodological differences (Section 6.2).
Using the aforementioned objective criteria, the distribution of circadian 
rhythm disturbance in this cohort was similar to what has been previously 
reported for those with NPL. Using aMT6s peak timing, calculated period and 
sleep disturbance as methods for classification, 65% of subjects with NPL 
were classified as having an abnormal circadian rhythm type, including 40% 
who were classified as having non-entrained rhythms. Prior reports have 
suggested that the prevalence of abnormal circadian rhythm type is somewhat 
higher, with 76% of subjects having an abnormal circadian rhythm type 
(Skene et al. 1999). The present findings that approximately 40% of NPL 
subjects have non-entrained rhythms is also lower than prior reports that
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reported prevalence estimates for non-entrained rhythms in 62% (Skene ef a/. 
1999) and 56% (Sack ef a/. 1992) among NPL blind subjects.
In contrast to prior reports, only 49% of subjects with LP were classified as
having normally entrained rhythms, compared to 77% as reported in prior 
studies (Skene et al. 1999). In addition, 28% of field study subjects in the 
present analysis were classified as non-entrained, while prior studies estimate 
the prevalence of non-entrained rhythms among those with LP to range from 
3% (Skene ef a/. 1999) to 13% (Leger ef a/. 1999).
The differences between the present classification of LP and NPL subjects 
and prior reports may be explained by several methodological differences. 
There are large geographical, methodological and possibly generational 
differences between the prior cohorts and the present cohort. For example, 
one of the prior studies was completed in the United Kingdom (Skene et al. 
1999), another was conducted in a cohort living on the west coast of the 
United States (Sack etal. 1992), and the third was a study in France (Leger et 
al. 1999), whereas the present cohort was conducted throughout North 
America. It is, of course, unlikely that geography itself would influence 
circadian rhythm type, however, the cultural perception of these types of 
studies may have led to selection bias in any of the cohorts. For example, it is 
possible that the prior cohorts were perceived as sleep studies and therefore 
it is possible that the prior studies suffer from some selection bias, whereby 
those with sleep problems chose to participate and those without sleep 
problems did not. The present cohort could have also been perceived as a
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sleep study, however, the majority of study advertising described it as a 
breast cancer study. Such differences may account for some of the 
differences in results. Similarly, some differences between the studies may 
relate to access to accessible technology. Data comprising the prior studies 
were collected 15 to 20 years ago. Since that time internet use has exploded 
worldwide and accessible technology and computer training for the blind has 
improved. This means that those who live alone now have access to social 
networks without leaving their homes. In many cases subjects reported 
anecdotally that such internet groups were a primary forum for their social 
interaction. This means that it is possible that some of the subjects with light 
perception may be unintentionally self-selecting light exposure that might lead 
to self-induced non-entrained rhythms. In the current study this cannot be 
confirmed as questions on internet use were not part of the questionnaire, 
however, it might explain why there is such a high number of LP subjects 
classified as non-entrained. Of those with LP classified as non-entrained, 23% 
reported living alone (Section 3.3.1). Subjects who live alone may not use 
indoor lighting at all and therefore may never receive sufficient light exposure 
to achieve entrainment. Similarly, 64% of the LP subjects classified as non- 
entrained were not employed and an additional 18% were only employed part- 
time.
Another potential reason for the differences between prior studies and the 
present study may simply relate to the method of classification used to assign 
circadian rhythm type. Both the Lockley and Sack cohorts collected multiple 
melatonin and/or aMT6s rhythms across many weeks and used regression
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analysis to determine circadian rhythm type. Using regression analysis 
provides estimates of the error around the rhythm peaks through the 
collections. Using only two sample periods as in the present study, it is not
possible to estimate error and a straight line relationship is assumed. It is 
possible that in some cases subjects did not collect one or both of the 48 h 
urine collection periods correctly. In these cases it would not be possible to 
uncover such error and the circadian period estimates for those subjects 
would not be correct. In addition, this methodology used strict application of 
rules. It could have been assumed that subjects who self-reported having light 
perception would not be capable of having non-entrained rhythms due to the 
presence of light cues, however, such an assumption was not made for 
several reasons. First, it is unclear how the aetiology of blindness may affect 
the non-visual pathway from the eye to the SCN. It may be possible that some 
of the LP subjects have non-entrained rhythms due to damage to the 
melanopsin-containing, photosensitive retinal ganglion cells or the retino- 
hypothalamic tract (Section 1.3.2.1). Some blind people with NPL retain the 
cells necessary for circadian entrainment (Czeisler etal. 1995, Klerman et al. 
2002, Zaidi et al. 2007), however, it has not been shown that blind people with 
LP lack circadian photoreception. If such a scenario is possible, it is likely that 
such a condition would be extremely rare. Given the high proportion of 
subjects with LP who were classified as non-entrained in the present study, it 
is unlikely that such an explanation would be responsible for the classification 
of all of these subjects. A more likely explanation is that some of the non- 
entrained LP subjects have self-induced free-running rhythms for the social 
reasons described above.
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Among the entire survey cohort, there was evidence of sleep disturbance as 
measured by the PSQI in NPL and LP subjects, with both groups having
mean PSQI scores indicative of sleep disorders (> 5, Buysse et al. 1989). The 
prevalence of sleep disturbance among all subjects in the present cohort was 
69%, including 76% of NPL and 66% of LP subjects reporting sleep 
disturbance. This sleep disturbance did not appear to be related to eye 
condition, as group PSQI means for all but two eye conditions were > 5 
(Section 6.3.3). The prevalence of sleep disorders among the blind 
(regardless of light perception status) has been reported to be as high as 82% 
(Leger et al. 1999). It may be assumed that the prevalence of sleep disorders 
among those with NPL is high due to circadian rhythm disturbance, though it 
is unclear why blind people with LP also report disturbed sleep. There are 
several possible hypotheses to explain the disturbed sleep among the blind. 
First, as previously described, some lifestyle factors, such as self-selected 
light exposure may account for disturbed sleep among LP subjects. In 
addition, the elevated BMI among this cohort may relate to increased co­
morbidity with sleep apnea (Waller et al. 2008). Depression related to older 
age onset of blindness may also contribute to sleep disturbance among LP 
blind people (Ip et al. 2000). It is also possible that progressive degeneration 
of retinal ganglion cells ultimately leads to loss of or impaired light input to the 
circadian pacemaker, leading to circadian rhythm sleep disturbance. It is also 
possible that the prevalence of sleep disorders relates to selection bias. This 
study was primarily advertised as a breast cancer study, but due to the 
extensive sleep measures involved in the study procedures, it is possible that
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some subjects viewed it as a sleep study and therefore those with pre-existing 
sleep disorders may have been more likely to participate.
9.5 Questionnaire based classification of circadian rhythm type
There are currently no validated clinical screening tools available for 
predicting circadian rhythm disorders among the blind. Therefore a secondary 
aim of this thesis was to use the physiological classification of circadian 
rhythm type from the field study to develop a model to predict circadian 
rhythm disturbance using only questionnaire based methods. Questions from 
the survey were selected based on their association with circadian rhythm 
types. These questions were then scored and weighted based on the strength 
of the predictive association and a model score was calculated for each 
subject for entrained or non-entrained circadian type. The entrained and non- 
entrained models were simultaneously applied to the field study cohort to 
measure their predictive strength. The model yielded a reasonable sensitivity 
(62%) and specificity (78%) for classification of non-entrained subjects, but 
was less reliable for classification of entrained subjects (sensitivity = 51%; 
specificity = 69%).
The model was ultimately applied to the entire survey cohort and yielded 
prevalence estimates comparable to prior studies (Sack et al. 1992,
Tabandeh et al. 1998, Skene et al. 1999). Among NPL subjects, 62% were 
classified as non-entrained, while only 15% were classified as normally 
entrained. In comparison, prior estimates for non-entrained rhythms in NPL
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subjects were reported to be 62% (Skene et a/. 1999) and 56% (Sack et a/. 
1992) with classification based on physiological measures. In addition, 
application of the model to the present cohort resulted in 60% of subjects with 
bilateral enucleation being classified as non-entrained, compared to only 15% 
of bilaterally enucleated subjects who were classified as normally entrained. A 
finding that is similar to a prior report that found 92% of bilaterally enucleated 
subjects to be non-entrained (Skene ef a/. 1999).
In contrast to the classification of NPL subjects, subjects with LP were likely 
over classified in the model in the non-entrained category due to non- 
circadian causes of sleep disturbance and lifestyle choices among LP 
subjects. Among LP subjects, 45% were classified as normally entrained, 
while 29% were classified as non-entrained. This is in contrast to prior 
estimates in LP subjects that report entrained status to be as high as 77% and 
non-entrained status to be as low as 3%. These estimates are, however, 
comparable to the physiological assessment of circadian disorders in the 
present cohort which were estimated to be 49% for entrained classification 
and 28% for non-entrained classification. This finding suggests that the 
problems associated with classification of LP type among field study subjects 
are also present in the model. Therefore it might be advisable to use the 
questionnaire based method only of classification only for those with NPL and 
to use traditional methods of sleep disorder screening for those with LP.
When demographic outcomes were compared using the model classification it 
was apparent that those classified as non-entrained experienced an earlier
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age of vision loss than those classified as normally entrained. There also 
appeared to be logical trends in the proportions of subjects classified as 
entrained or non-entrained by eye condition. For example, those subjects with 
eye conditions affecting rods and cones in the outer retina (e.g. macular 
degeneration, Leber's congenital amaurosis) were more likely to be classified 
as normally entrained compared to those who reported eye conditions known 
to damage blood vessels in the retina, and presumably increase ganglion cell 
death (e.g. retinopathy of prematurity, diabetic retinopathy, glaucoma), who 
were more likely to be classified as non-entrained (Section 7.3.3).
The duration of time since vision loss may also be an important factor in 
whether an eye condition will be associated with a specific circadian type, for 
example, glaucoma is associated with degradation of the optic nerve and in 
animal studies has been shown to alter adaptation to new circadian phases 
(Drouyer etal. 2009). In the survey cohort, subjects with glaucoma who were 
classified as non-entrained had their eye disease an average of 11 years 
longer than those who were classified as normally entrained. Similarly, optic 
atrophy, which affects the optic nerve, and retinitis pigmentosa, which affects 
the rods and cones, both result in progressive degeneration of the eye. Each 
of these eye conditions had large numbers of subjects classified in the 
entrained and non-entrained categories. Together, these findings suggest that 
the progressive degeneration of some eye conditions may eventually lead to 
loss of the ability to entrain to light or an impaired ability to entrain to light.
9.6 Final remarks
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The data presented in this thesis represent the largest cross-sectional survey 
and field study ever conducted in the blind. The majority of findings were 
consistent with a priori hypotheses. The finding that blind women with NPL 
experience approximately half the risk of breast cancer compared to LP 
women confirms and extends prior research and suggests that the differences 
in risk are not due to obvious differences in reproductive outcomes. The 
finding that menarche is approximately four months earlier in NPL women 
also confirms prior reports and the finding that menarche is earlier with earlier 
age at NPL suggests that light and/or blindness is involved in human 
reproductive outcomes. There was little evidence to support the commonly- 
held view that 24 h aMT6s production is elevated in NPL compared to LP 
women, although this is also in line with prior research. In addition, the 24 h 
production of the urinary oestrogen metabolite e1g did not vary by light 
perception status or circadian rhythm type suggesting that the differences in 
breast cancer risk among NPL and LP women are not driven by differences in 
the overall production of this oestrogen, although the complex biochemistry of 
sex steroids does not rule out other associations. There was no evidence to 
suggest a relationship between aMT6s and e1g except in those women who 
were normally entrained, where there was a positive relationship and 
therefore the data do not support a reciprocal relationship for melatonin and 
oestrogen. It is unclear how such a finding might relate to breast cancer risk 
and further research is needed in this area.
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The distribution of circadian rhythm types among field study subjects was 
similar to prior reports for NPL subjects, but the prevalence of LP subjects 
classified as non-entrained was higher than previously reported. The present 
data are insufficient to determine the cause of this higher prevalence and 
further research in this area is needed. Similarly, use of a new model to 
determine the prevalence of circadian rhythm types across the entire survey 
cohort was in line with prior reports for NPL subjects, but the classification of 
non-entrained type was higher than expected among LP subjects. Together 
these findings suggest that the model may be useful for initial screening and 
classification of NPL, but not LP subjects. In addition, the relationship 
between the aetiology of blindness and circadian rhythm type suggests that 
some eye conditions relate to specific circadian type and that eye conditions 
that involve progressive degeneration of photoreceptor cells or the retino- 
hypothalamic tract may result in eventual loss of circadian photoreception. 
Larger targeted studies of specific eye disorders are needed to characterise 
fully the role of visual disorders on circadian photoreception.
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Appendix B
Sl66p
You need to keep a daily sleep diary throughout the study. Please answer the 
questions in the diary once per day. Any sleep outside bedtime needs to be 
recorded in the Nap diary. Please complete this diary each morning and
describe the last 24 hours.
SLEEP DIARY
Please try to complete this diary at the same time each morning.
1. What is the date? (Please give the date that you wake up on)
2. What time did you go to bed last night?
3. What time did you start trying to sleep?
4. How long do you think it took you to fall asleep?
5. How many times did you wake up in the night?
(Please try and give the exact times and duration you wake up for, for each wake 
period).
6. How many minutes sleep did you lose?
7. What time did you wake up?
8. What time did you get up?
9. Please rate your sleep quality on a 1 to 9 scale where 1 = the best
sleep ever, 5 = neither the best nor worst sleep and 9 = the worst sleep ever.
NAP DIARY
Please record any sleep that was not part of your main sleep episode.
If possible, please also try and record when you would nap if you were able but 
are unable to do so because you are busy etc.
1. What is the date and time?
2. What time did the nap start?
3. What time did the nap end?
4. How long was the nap?
Menstrual Cycle
The hormones we are measuring fluctuate throughout the menstrual cycle. If you 
are pre-menopausal, please note the start and end dates of your periods during 
the study. Please also include the date of the last period you had before starting 
the study.
Activity monitor
You need to wear the activity and light monitor 24 hours a day. Please put it on 
your non-dominant wrist and try and keep it uncovered at all times as the light 
recorder is on the outside of the monitor. It is not waterproof and you will need to 
remove it if it could get wet. Please record all the times you take it off each day 
including the date and the times (especially the time you first put it on).
Time O ff______
Time On
1 6 -
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18-7
Normally entrained, pre-menopausal subjects with light perception
#— Urine collection 1 Days 29-31 
— O -  Urine collection 2 Days 57-59 
O Acrophase 1 
❖ Acrophase 2
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC516 aMT6s 
Mnset scaled to a maximum value of 1.0 ng/h for rhythm observation.
#— Urine collection 1
Late Luteal/Early Follicular
-  O -  Urine collection 2
Late Luteal/Early Follicular
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time 
25BC516 e1g
18-8
Normally entrained, pre-menopausal subjects with light perception
• - Urine collection 1 Days 29-31
- o - Urine collection 2 Days 57-59o Acrophase 1
Acrophase 2
m m
.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24,00 6.00
Time
26BC602 aMT6s
#— Urine collection 1 
Late Follicular 
O -  Urine collection 2 
Late Follicular
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time 
26BC602 e1g
18-9
Normally entrained, pre-menopausal subjects with light perception
Unne collection 1 days 28-30
-  O— Urine collection 2 days 56-58 
O Acrophase 1
^  Acrophase 2
mm
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
26BC753 aMT6s
10
—#— Urine collection 1
Menstrual phase unreported 
— O— Urine collection 2
Menstrual phase unreported
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time 
26BC753 e lg
18-10
Normally entrained, pre-menopausal subjects with light perception
E
2O)2o
E
10
—#— Urine collection 1 days 15-17 
— O— Urine collection 2 days 46-48 
❖ Acrophase 1 
<$> Acrophase 2
9
8
7
6
5
4
3
2
1
0 ■ "  ^ f, ' ' I '#T ' ' ' I  ^ ' I ' ' I ....   1
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
26BC855 aMT6s
■
—#— Urine collection 1
Menstrual phase unknown 
-  O- Urine collection 2
Menstrual phase unknown
6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
26BC855 e1g
18-11
Normally entrained, pre-menopausal subjects with light perception
9 - 
8 - 
7 - 
6 - 
5 - 
4 - 
3 - 
2 - 
1 -
—#— Urine collection 1 days 22-24
-  O -  Urine collection 2 days 36-38
O Acrophase 1
^  Acrophase 2
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
26BC906 aMT6s
10
9 - -#— Urine collection 1Menstrual phase unknown 
■ O— Urine collection 2
Menstrual phase unknown
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
26BC906 e1g
18-12
Normally entrained, pre-menopausal subjects with no light perception
E 2O)2o
E
10
—#— Urine collection 1 days 24-zü 
— O— Urine collection 2 days 51-53 
O Acrophase 1 
<$> Acrophase 2
6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
25BC121 aMT6s
—#— Urine collection 1
Menstrual phase unknown 
-  O— Urine collection 2
Menstrual phase unknown
10 
9 H 
8 
7 
6 
5 
4
3 - 
2 -  
1
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC121 e1g
18-13
Normally entrained, pre-menopausal subjects with no light perception
10
9 - —#— Urine collection 1 days 18-20— O— Urine collection 2 days 53-55
^  Acrophase 1
^  Acrophase 2
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18,00 24.00 6.00
Time
25BC239 aMT6s
10
—#— Urine collection 1 
Late luteal 
-  O— Urine collection 2 
Follicular
r--«v.
^o~— o---
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time 
25BC239 e1g 
'Inset scaled to a maximum value of 1.0 fig/h for rhythm observation.
18-14
Normally entrained, pre-menopausal subjects with no light perception
10
9 %
.L... _
Urine collection 1 days 21-23
- o - Urine collection 2 days 39-4i
o Urine collection 3 day 53-55
♦ Acrophase 1
o Acrophase 2
e Acrophase 3
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
26BC1424 aMT6s 
Inset scaled to a maximum value of 1.0 pg/h for rhythm observation.
10 
9 - 
8 -  
7 - 
6 -  
5
4 - 
3 - 
2 -  
1 -
—#— Urine collection 1
Menstrual phase unknown 
— O -  Urine collection 2
Menstrual phase unknown
------------------------- "TT
6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
26BC1424 e1g 
'Inset scaled to a maximum value of 1.0 pg/h for rhythm observation.
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18-23
Norm ally entra ined , post-m enopausal subjects w ith  light perception
10
9
8
7
6
5
4
3
2
1
0
— # —  Urine collection 1 days 17-19  
— O — Urine collection 2 days 39-41 
O  Acrophase 1 
<$> Acrophase 2
# 0 #
24.00 6 .00  12.00 18.00 24 .00  6.00 12.00 18.00 24 .00  6.00
Time
25BC475 aMT6s
10
— # —  Urine collection 1 
— O — Urine collection 2
9
8
7
6
5
4
3
2
1
0
24 .0 0  6 .00  12.00 18.00 24 .00  6.00 12.00 18.00 24 .00  6 .00
Time
25BC475 e1g
18-24
Norm ally entra ined , post m enopausal subjects w ith  light perception
10
p - Urine collection 2 days 41 43 I
Urine collection 3 days 61 63
8 ■ o Acrophase 1 I
Acrophase 2 |
6 
5 
4 
3 
2 
1 
0
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
ex
26BC707 aMT6s
Urine collection 2 
Urine collection 3
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
26BC707 e1g
'Inset scaled to a maximum value of 3.0 pg/h for rhythm observation.
18-25
N orm ally entra ined , post-m enopausal subjects w ith light perception
Urine collection 1 days 36 
O -  Urine collection 2 days 50 
O Acrophase 1
^  Acrophase 2
12.00 18,0018.00 24.0012.00
Time
24.00 6.00
26BC1226 aMT6s
Urine collection 1
— O — Urine collection 2
24.00 6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
26BC1226 e1g
Inset scaled to a maximum value of 1.0 pg/h for rhythm observation.
18-26
N orm ally entra ined , post-m enopausal subjects w ith light perception
10 
9 4 Wm- - Urine collection 1 days 36-38 O -  Urine collection 2 days 50-52 
O  Acrophase 1 
Acrophase 2
12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
26BC1237 aMT6s
Unne collection 1 days J6-38
-  O -  Urine collection 2 days 50-52
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
26BC1237 e1g
'Inset scaled to a maximum value of 0.5 |ug/h for rhythm observation.
18-27
N orm ally entra ined , post-m enopausal subjects w ith light perception
10
— # —  Urine collection 1 days 16-18 
-  O -  Urine collection 2 days 44-46 
O Acrophase 1 
^  Acrophase 2
9
8
7
6
5
4
3
2
1
0 -I 1  1---1---,---'---~ ' I ---'---1---'I'""" '------------- '---1---'---'---'---1 ' 1 —
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
26BC1245 aMT6s
10
— # —  Urine collection 1 
-  O — Urine collection 2
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time 
26BC1245 e1g 
'Inset scaled to a maximum value of 0.3 jig/h for rhythm observation.
18-28
N orm ally  entra ined, post-m enopausal subjects w ith light perception
# —  Urine collection 1 day ^2 z4
O — Urine collection 2 days 50-52
O Acroptiase 1
0  Acroptiase 2
m&'mi
.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
26BC1266 aMT6s
Urine collection 1 
O — Urine collection 2
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time 
26BC1266 e1g 
Inset scaled to a maximum value of 1 pg/h for rhythm observation.
18-29
N orm ally  entra ined , post-m enopausal subjects w ith  light perception
Urine collection 1 days 22-24 
- O -  Urine collection 2 days 51-53 
O Acrophase 1
<$> Acrophase 2
,00 6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
26BC1427 aMT6s 
'Inset scaled to a maximum value of 1 |.ig/h for rhythm observation.
E
5O)2o
E
10
7
6
5
4
3
2 H 
1 
0
24
g
— # —  Urine collection 1 
- O -  Urine collection 2
00 6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
26BC1427 e1g
Inset scaled to a maximum value of 1 ng/h for rhythm observation.
18-30
N orm ally  entra ined , post-m enopausal subjects  w ith light perception
10
9
8
7
6
5
4
3
2
1
— # —  Urine collection 1 days 36-38 
- O — Urine collection 2 days 50-52 
O  Acrophase 1 
<3> Acrophase 2
a *
am
# 0 #
- # —  Urine collection 1 
-O — Urine collection 2
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
26BC1427 aMT6s
10 
9 - 
8 
7 
6 
5 
4 
3 
2 
1
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
26BC1427 e1g
'Inset scaled to a maximum value of 1 ).ig/h for rhythm observation.
18-31
N orm ally entra ined , post-m enopausal subjects w ith light perception
10
9 - Urine collection 1 days 14-16
— O — Urine collection 2 days 42-44 
❖  Acrophase 1
<§> Acrophase 2
24.00 6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
27BC1528 aMT6s
- # —  Urine collection 1 
- O -  Urine collection 2
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
27BC1528 e1g
Mnset scaled to a maximum value of 2 pg/h for rhythm observation.
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18-33
N orm ally  entra ined, post-m enopausal subjects w ith no light perception
10
-#—  Urine collection 1 days 16-19
O -  Urine collection 2 days 37-39
O  Acrophase 1
<& Acrophase 2
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC105 aMT6s
# —  Urine collection 1 
O — Urine collection 2
.00 6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
25BC105 e1g
Inset scaled to a maximum value of 1 pig/h for rhythm observation.
18-34
Norm ally entra ined, post-m enopausal subjects w ith no light perception
10
— # —  Urine collection 1 days o6-59
— O -  Urine collection 2 days 88-90
O  Acrophase 1
^  Acrophase 2
9
8
7
6
5
4
3
2
1
0 -I—   '1"'—'—'—I— I—'—'—'—I— ------1-"^ ' •'—'—1—'—'—'—I—'—'—'—I—
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC373 aMT6s
# —  Urine collection 1 
O — Urine collection 2
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time 
25BC373 e1g 
'Inset scaled to a maximum value of 1.5 j.ig/h for rhythm observation.
18-35
N orm ally  entra ined, post m enopausal subjects w ith  no light perception
a
— # —  Urine collection 1 days 27 29
— O -  Urine collection 2 days 54 56
O Acrophase 1
"3> Acrophase 2%'
g a
. . .
.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
26BC562 aMT6s
10
— # —  Urine collection 1 
— O — Urine collection 2
9
8
7
6
5
4
3
2
1
12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
0   ' ..
24.00 6.00
Time
26BC562 e1g
Inset scaled to a maximum value of 1 pg/h for rhythm observation.
18-36
N orm ally  entrained, post-m enopausal subjects w ith no light perception
10 1 
9 - 
8 - 
7 - 
6 - 
5 - 
4 - 
3 - 
2 - 
1 -
— Uri ne collection 1 days 31-33 
— O — Urine collection 2 days 59-61 
O  Acrophase 1
^  Acrophase 2
6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
26BC620 aMT6s 
'Inset scaled to a maximum value of 1 pg/h for rhythm observation.
— # —  Urine collection 1 
-  O -  Urine collection 2
10 
9 - 
8 - 
7 - 
6 - 
5 - 
4 - 
3 - 
2 - 
1 -
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
26BC620 e1g
'Inset scaled to a maximum value of 1 pg/h for rhythm observation.
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18-39
A bnorm ally  phased - A dvanced, p re -m encpausal subjects w ith light
perception
10
9 n m .
A, — # —  Urine collection 1 days 21-23
-  O -  Urine collection 2 days 58-60
W
O  Acroptiase 1
Acroptiase 2
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC293 aMT6s 
'Inset scaled to a maximum value of 1 p,g/h for rhythm observation.
Urine collection 1 
Early Follicular 
O — Urine collection 2 
Late Follicular
12.0012.00 18.00 24.0024.00 18.00 24.00 6.00
25BC293 e1g
Inset scaled to a maximum value of 1 pg/h for rhythm observation.
18-40
c0
1<Ü
2Q
a
ZO)
oc
5
o
0)
IS*
3(/)
15(/)
3
(0a
oc0)
E
£a
%3ouc
ns>
T3
<
TJ0)tfi(QXa
E
o
cX
<
0 o  <$>
X
ro
CO ^
CD o
CO o
s io
Cû
CD
CM
JLj/SLUBjSOJOjLU
>
E
3
E
ro
E
CD
2
■O d Q o
t o  c  
m %
(O X
c  o
18-41
A bnorm ally  phased - A dvanced, pre-m encpausal subjects w ith no light
perception
10 
9 - 
8 - 
7 - 
6
5 H 
4
3 - 
2 - 
1 -
— # —  Urine collection 1 days 15-17 
— O — Urine collection 2 days 55-57 
❖  Acrophase 1 
Acrophase 2 
-Tw;-------------------------- ^—
24.00 6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
25BC119 aMT6s
# —  Urine colleclion 1 
-  O -  Urine collection 2
«
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC119 e1g
18-42
A bnorm ally  phased - A dvanced, pre m enopausal subjects w ith no light
perception
Urine collection 1 days 28-30
-  O -  Urine collection 2 days 49-51 
O  Acrophase 1
<$> Acrophase 2
6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
25BC333 aMT6s 
Inset scaled to a maximum value of 1 |ig/h for rhythm observation.
# —  Urine collection 1 
Late Follicular 
-  O — Urine collection 2 
Follicular
.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC333 e1g
18-43
Abnorm ally phased - A dvanced, pre-m encpausal sub jects  with no light
perception
Urine collection 1 days 29-31 
-  O -  Urine collection 2 days 57-59 
O Acrophase 1
<$» Acrophase 2
' I t
6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
25BC431 aMT6s 
Inset scaled to a maximum value of 1 ^ig/h for rhythm observation.
10
9
8
7
6
5
4
3
2
1
A #  #
Ml
— # —  Urine collection 1 
Ovulation 
-  O — Urine collection 2 
Ovulation
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC431 e1g
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18-46
A bnorm ally  phased - A dvanced, post-m enopausal subjects w ith  light
perception
# —  Urine collection 1 days 19-21 
-  O — Urine collection 2 days 26-28  
O Acrophiase 1 
<S> Acrophase 2
.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC167 aMT6s
Unne collection 1 days
O -  Unne collection 2 days
6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
25BC167 e1g
Inset scaled to a maximum value of 1 pg/h for rhythm observation.
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A bnorm ally  phased - A dvanced, post-m enopausal subjects w ith  no light
perception
Unne collection 1 days 15-17
57-59O — Unne collection 2 days 
O Acrophase 1
❖  Acrophase 2
12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
25BC141 aMT6s
10 
9 - 
8 -  
7 - 
6 - 
5 - 
4 - 
3 - 
2 - 
1
Urine collection 1
- o - Urine collection 2
o Acrophase 1
e Acrophase 2
9
M / '
-o- I"-Ô
\\\
6 - - - C X .
:zo#
00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00
Time
6.00
25BC141 e1g
18-49
A bnorm ally  phased - A dvanced, post-m enopausal subjects w ith no light
perception
Unne collection 1 days 22-24 
O -  Urine collection 2 days 36-38 
O Acrophase 1
^  Acrophase 2
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
26BC1154 aMT6s
10
9 - 
8 -  
7 - 
6 -  
5 - 
4 - 
3 - 
2 -  
1 -
- # —  Urine collection 1 
■ O — Urine collection 2
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time 
26BC1154 e1g 
Inset scaled to a maximum value of 1 pg/h for rhythm observation.
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18-51
A bnorm ally  phased - delayed, pre-m enopausal subjects  w ith light
perception
10
9
8
7 -j 
6
5 - 
4 - 
3
00
#
— # —  Urine collection 1 days 32-34 
— O -  Urine collection 2 days 60-62 
O  Acrophase 1 
<S> Acrophase 2
6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
25BC584 aMT6s
10
— * —  Urine collection l 
Luteal
-  O -  Urine collection 2 
Luteal
Eg
cn
2o
E
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time 
25BC584 e1g
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18-59
N on-entra ined - p re-m enopausal subjects with light perception
Unne collection 1 days 18-20
-  O -  Urine collection 2 days 67-69 
O  Acrophase 1
^  Acrophase 2
12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
25BC396 aMT6s
10 
9 4
Urine collection 1
Follicular
- o - Urine collection 2
Late Luteal
M m
6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
25BC396 e1g
18-60
N on-entra ined - pre-m enopausal subjects with light perception
10
— # —  Urine collection 1 days 29-31 
— O -  Urine collection 2 days 57-59 
O  Acrophase 1 
<$> Acrophase 2
9
8
7
6
5
4
3
2
1
- - 0-0--0
24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC576 aMT6s
12.00 18.00 24.00 6.00
10
— # —  Urine collection 1 
Luteal
— O — Urine collection 2
Late Luteal/Early Follicular
9
8
7
6
5
4
3
2
1
0 4-^
24.00 12.00 18.00 24.00 6.0012.00 18.00 24.00 6.006.00
Time 
25BC576 e1g
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18-62
N on-entra ined - pre-m enopausal subjects w ith no light perception
Unne collection 1 days 27-29
- O — Urine collection 2 days 5b-57 
O Acrophase 1
<$> Acrophase 2
12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
25BC485 aMT6s
- # —  Urine collection 1 
Follicular 
• O — Urine collection 2 
Follicular
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC485 e1g
18-63
N on-entrained - pre-m enopausal subjects  w ith no light perception
Urine collection 1 days 35-37
-  O -  Urine collection 2 days 5 /-59  
❖ Acrophase 1
^  Acrophase 2
A
12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
25BC544 aMT6s
• Urine collection 1
Late Follicular
- o - Urine collection 2
Follicular
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC544 e1g
18-64
Non-entra ined - pre-m enopausal subjects  with no light perception
2
cn
§
E
Urine collection 1 days 34-36 
— O — Urine collection 2 days 62-64 
O Acrophase 1
<S> Acrophase 2
6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
26BC765 aMT6s
Urine collection 1
-  o — Unne collection 2
6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
26BC765 e1g
Inset scaled to a maximum value of 1.0 |ig/h for rhythm observation.
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18-67
N on-entra ined - peri-m enopausal sub jects  w ith no light perception
Unne collection 1 days 17-19
— O — Urine collection 2 days 38-40 
O Acrophase 1
€> Acrophase 2
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC539 aMT6s
10 
9 - 
8 - 
7 - 
6 - 
5 - 
4 - 
3 - 
2 
1
..
— # —  Urine collection 1 
— O -  Urine collection 2
0
24.00 6.00
, ,r'„.
12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
25BC539 e1g
18-68
0 o  <s>
«memam:
(/)
CO
o
CD
O
en
CD
CM
jLi/suiBj6 ojO!ai
o
Q.
Z
G)
O0)
!d
3tf)
(Q
(0
3raao
c0)
E
V,(/)001
TJ0)
C
s
c
Q ) O o  <N
C O
g
LO
CM
O
en
L O
CM
JLj/SLUBjSOJOILU
18-69
O )
m
00
O
□ü
CD
CM
E3
E
CO
E
CO
o
■D C 0) O
S'I (/) 2
0) % CO _ o
c o
jl| /s u j b j 6 o jo !LU
0>
20)
Q .
O )
ü
0)
S'3
(/)
< <
O <$>
re
(03(0
Q.O
CO
E
tn
o
Q .
T30>_C
(Ô
CO
CD
CD
00N
CD
ü  
Cû
CD
CM
Jy/SLUBJGOJOILU
18-70
en
CO
CO
00o
CD
ü00
CO
CNJ
Q.oo
oQ.
O)
Üo
'S
3(0
rou>
3WQ.
O
c
0)
E
V ,
(A
OQ.
T3OC
2
O <N
(A  O )I?
CO (U CO 3
Ü ro
CO
CO
CNJ
>
E
3
E
Xm
E
cc
-2
73(Ü
s
cn
ji^ /SLuejGojoiLu
CO 
0) W
cn  _ Q  
c o
18-71
Q O ^
CO
CO1-
m
00N
CM
Üm
CO
CM
jl| / s l u b j 6 o jo !UJ
(D (U (D 0)
Q  O  <S>
iHWiUt v ' SJS ,
CO
CO
00
o00
CO
CM
JLj/SLUBj60J3ILU
18-72
o <$>
U)
CD
LO
C D00
OCÛ
C D
C N
O)zL
O
(DD
CO>
E
zs
E
X
C O
E
CD
2
T3 C  
CD O
8 |  en ^
0 %
en _ a  
c o
JLj/SLUBjGOJOILU
Q.(U
2
o
Q .
O )
i
u
0
!q
3
en
(Den
3
CD
Q .
0  
C 
0
1 
0  
O  
Q .
T30
C
2
c
Q ) O
cOz
0
CD
S
00
o
Dû
C D
C M
JLI/SLUBjBoJOjLU
18-73
o  <s> o /
</) 
CO I—
m
CNJ
I
o00
CO
CNJ
co
to
2d>a
O)
$
42oo
in'
3
(/)
15tn
3MQ.OCQ)
E
jl| /s l u b j 6 o j o !UI
ii
^ 0) Û)
t t
= ) = ) < <  
f  c? ❖ <s>
O '
c/J
CO
CO
TT
CO
Ü
CD
CO
CM
jLi/stuejBojojUJ
18-74
N on-entra ined - post-m enopausal subjects w ith light perception
# —  Urine collection 1 days 14-i6
O — Urine collection 2 days 41-43
O Acrophase 1
0  Acrophase 2
24.00 6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
10
9 -
7 -
6 -
5 -
4 -
25BC153 aMT6s
— # —  Urine collection 1 
Luteal
— O — Urine collection 2 
Luteal
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC153 e1g
18-75
N on-entrained - post-m enopausal subjects w ith light perception
9
8
7
6
5
4 - 
3 - 
2 
1
— # —  Urine collection 1 days 21-23 
— O — Urine collection 2 days 49-51 
O Acrophase 1 
Acrophase 2
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC189 aMT6s
10
9
8
7
6
5
4
3
2
0
24
— # —  Urine collection 1 
-  O -  Urine collection 2
00 6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
25BC189 e1g 
Inset scaled to a maximum value of 1.0 pg/h for rhythm observation.
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18-77
N on-entrained - post-m enopausal subjects  w ith no light perception
-#—  Urine collection 1 days 15-17
O — Urine collection 2 days 43-45
❖  Acrophase 1
A  Acrophase 2
o - ^
.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC236 aMT6s
10 
9 
8 
7 
6 - 
5 - 
4
3 H 
2
1 H
— # —  Urine collection 1 days 15-17 
-  O — Urine collection 2 days 43-45
mm
0 ■
24.00 6.00 12.00 18.00 24.00 6.00
Time
12,00 18.00 24.00 6.00
25BC236 e1g
18-78
N on-entra ined - post-m enopausal subjects w ith no light perception
10
— # —  Urine collection 1 days 41-43 
-  O -  Urine collection 2 days 61-63 
O Acrophase 1 
<$> Acrophase 2
9
8
7
6
5
4
3
- Q2
1
0 ■■■■» -  .
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC256 aMT6s
10 
9 - 
8 - 
7 - 
6 -  
5 
4 
3 
2
1 H
- # —  Urine collection 1 
■O— Urine collection 2
:
.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC256 e1g 
Inset scaled to a maximum value of 1.0 |ig/h for rhythm observation.
18-79
N on-entra ined - post-m enopausal subjects w ith no light perception
.................................................. ....  ’
Urine collection 1 days 15-17
- o - Urine collection 2 days 40-43
Acrophase 1
Acrophase 2
6.00 12.00 18.00 24.00 6.00
Time
12.00 18.00 24.00 6.00
25BC320 aMT6s
Unne collection 1
-  O — Unne collection 2
.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
25BC320 e1g 
'Inset scaled to a maximum value of 1.0 i^g/h for rhythm observation.
18-80
N on-entrained - post-m enopausal subjects w ith no light perception
ETO
O)
i
E
Unne collection 1 days 21-23
-  O -  Unne collection 2 days 50-52 
O Acrophase 1 
Acrophase 2
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
26BC828 aMT6s
10
9
— » —  Urine collection 1 
— O — Urine collection 2
.00 6.00 12.00 18.00 24.00 6.00 12.00
Time
-o— o
18.00 24.00 6.00
26BC828 e1g 
Inset scaled to a maximum value of 1.0 )ig/h for rhythm observation.
18-81
N on-entra ined - post-m enopausal subjects w ith  no light perception
- O -  Urine collection 1 days 50-52
O Urine collection 2 days 57-59
O Acrophase 1
^  Acrophase 2
0-A-wx~>-r-r(n^'";‘P
.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
Time
26BC1085 aMT6s 
Inset scaled to a maximum value of 1.0 pg/h for rhythm observation.
10
— # —  Urine collection 1 
— O -  Urine collection 29
8
7
6
5
4
3
2
1
24.00 6.00 12.00 18.00 24.00 6.00 12.00 18.00 24.00 6.00
0
Time
26BC1085 e1g 
Inset scaled to a maximum value of 1.0 |.ig/h for rhythm observation.
18-82
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